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ABSTRACT 
Medical implants delivering drugs are used to ensure efficient medication at body sites, 
at which the conventional administration of drugs is insufficient. The application of drug-
delivery coatings is a beneficial concept for implants exposed to mechanical loads, such as 
orthopedic implants or cardiovascular stents. Many of the commercially available coated 
stent-implants are designed to release a drug locally and at a predefined rate out of a polymer 
matrix in order to prevent the re-blocking of the artery. The polymer matrices of such so-
called drug-eluting stents (DES) can either be bio-degradable or inert. In spite of their 
successful drug-release capability, they often fail with regard to biocompatibility and long-
term chemical and mechanical stability. The aim of the project is to create a novel, 
nanostructured, ceramic drug-delivering coating for stents, which exhibits an improved 
performance as compared to the one of conventional DES-implants. The present work 
addresses the processing and characterization of a nanoporous coating, its drug-loading and 
release behavior as well as its cytocompatibility. 
 
A nanostructured titania (TiO2) coating was deposited on either 316L stainless steel or 
silicon wafer supports by a multi-step dip coating process involving TiO2-nanoparticle and 
polymer template suspensions. A subsequent sintering step burned the polymer template 
particles to create drug reservoirs in the thin coating, which has a thickness of 1.2 μm. These 
drug reservoirs have a diameter of 1 μm and are surrounded by a porous ceramic structure. 
This surrounding ceramic structure exhibits a mean pore width of 76 nm and has an open 
porosity of 50 % as was determined by small angle neutron scattering and mercury intrusion 
porosimetry. The presence of the drug reservoirs further increases the porosity and hence the 
drug-load capability of the coating. In addition, the coating was characterized with regard to 
the specific surface area by the Brunauer-Emmett-Teller (BET)-method, the crystal phases of 
TiO2 by X-ray diffraction (XRD) and the elemental composition by X-ray photoelectron 
spectroscopy (XPS). 
 
From cardiovascular DESs, therapeutical agents, which either reduce the activation of 
the immune system or inhibit cell growth, are released into the coronary artery tissue to 
prevent the local re-blocking of the artery. In the present study, the cell growth inhibiting 
drug paclitaxel (PTX) was successfully loaded into the highly porous titania coatings by a 
low-pressure, solvent evaporation technique. The pharmaceutical was accumulated in the 
drug reservoirs, in the pores of the surrounding ceramic structure and on top of the coating. 
The total quantity of loaded drug could be varied by changing the coating’s structure or the 
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parameters of the drug-loading process. The maximum quantity of PTX incorporated into the 
coatings was comparable with the amount of PTX in the commercially available TaxusTM 
DES of 1 µg/mm2. The in vitro release tests of PTX from the coatings into ultra pure water 
revealed a slow, continuous liberation of the therapeutical agent. After one month of testing, 
only 11 % of initially incorporated drug were released. The obtained release profile is similar 
to the one of a PTX-eluting stent. Further release tests of PTX from the titania coatings into 
bovine plasma were performed and the findings compared to a release profile of the TaxusTM 
stent. 
 
In vitro cytotoxicity tests were accomplished, in which isolated, primary, bovine 
endothelial cells were brought in direct contact to the non-PTX-loaded titania coatings. First 
results indicate that the nanostructured TiO2-coatings on wafer and 316L stainless steel 
supports are cytocompatible.  
 
A technology platform has been established, which comprises the characterization of 
the titania coatings, the loading and quantification of PTX as well as the cytotoxicity 
evaluation. Factors affecting each of these issues were identified. The findings of the present 
study will contribute to optimize the nanostructured, ceramic drug-eluting coating for its 
implementation in DESs and to adapt it to various biomedical applications. 
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ZUSAMMENFASSUNG 
Wirkstofffreisetzende Implantate werden angewandt, um die Medikation an den 
Körperstellen sicherzustellen, in denen die Dosis des herkömmlich verabreichten 
Medikamentes nicht ausreicht. Die Anwendung wirkstofffreisetzender Beschichtungen ist 
vorteilhaft für Implantate, die mechanischen Beanspruchungen unterliegen. Solche sind zum 
Beispiel orthopädische Implantate oder kardiovaskuläre Gefässprothesen, so genannte 
„Stents“. Viele der kommerziell erhältlichen, beschichteten Stents sind so konstruiert, dass 
sie kontrolliert einen Wirkstoff aus einer Polymerbeschichtung freisetzen. Diese Wirkstoffe 
verhindern eine Wiederverschliessung der Arterie nach der Implantation. Die 
Polymermatrizes der wirkstofffreisetzenden Stents (WFS) können bio-degradabel oder inert 
sein. Trotz ihrer erfolgreichen Anwendung als Wirkstofffreisetzungssysteme versagen sie 
häufig wegen ungenügender Biokompatibilität, sowie ihrer chemischen und mechanischen 
Langzeitstabilität. Ziel war es, eine neue nanostrukturierte, wirkstofffreisetzende 
Keramikbeschichtung für Stents zu entwickeln, die eine bessere Leistungsfähigkeit als 
herkömmliche WFS aufweist. Die vorliegende Arbeit befasst sich vornehmlich mit der 
Herstellung und Charakterisierung einer nanoporösen Keramikbeschichtung, deren Beladung 
mit einem Wirkstoff und dessen Freisetzung, sowie ihrer Zytokompatibilität. 
 
Eine nanostrukturierte Titanoxidschicht (TiO2) wurde durch eine mehrstufige 
Tauchbeschichtung auf rostfreiem Stahl der Spezifikation 316L oder Siliziumwafer 
aufgebracht. Dabei wurden Suspensionen aus TiO2-Nanopartikeln und strukturgebenden 
Polymerpartikeln verwendet. Im darauf folgenden Sinterschritt wurden die strukturgebenden 
Polymerpartikel ausgebrannt, um Wirkstoffreservoirs in der 1.2 μm dicken Schicht zu 
bilden. Diese Wirkstoffreservoirs haben einen Durchmesser von 1 μm und werden von einer 
porösen Keramikstruktur umgeben. Die umgebende Keramikstruktur hat eine offene 
Porosität von 50 % und einen mittleren Porendurchmesser von 76 nm, der mit 
Kleinwinkelneutronenstreuungs- und Quecksilberporosimetrie bestimmt wurde. Die Präsenz 
der Wirkstoffreservoirs erhöht die Porosität und somit die Beladungskapazität der 
Beschichtung mit dem Wirkstoff. Weitere Eigenschaften der Beschichtung wurden 
bestimmt, wie zum Beispiel die spezifische Oberfläche mit der Brunauer-Emmett-Teller 
(BET)-Methode, die kristallinen Phasen des TiO2 mit Röntgenbeugung und die chemische 
Zusammensetzung mit Photoelektronenspektroskopie.  
 
Von kardiovaskulären WFS werden Medikamente in das Gewebe der Koronararterie 
freigesetzt, um eine lokale Wiederverschliessung der Arterie zu verhindern. Ihre 
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Wirkungsweise besteht darin, entweder die Aktivierung des Immunsystems zu verringern 
oder das Zellwachstum zu hemmen. In der vorliegenden Studie wurde die poröse 
Titanoxidschicht erfolgreich mit dem zellwachstumshemmenden Wirkstoff Paclitaxel (PTX) 
durch eine Lösungsmittel-Verdunstungs-Methode beladen. PTX war in den 
Wirkstoffreservoirs, in den Poren der umgebenden Keramikstruktur und auf der Oberfläche 
der Beschichtung angereichert. Die Wirkstoffquantität in der Keramikschicht konnte durch 
die Struktur der Beschichtung und durch die Methode der Wirkstoffbeladung variiert 
werden. Die maximale Beladung von PTX in der Schicht ist vergleichbar mit dem Anteil 
PTX in dem kommerziell erhältlichen TaxusTM WFS von 1 µg/mm2. Die Versuche zur 
Wirkstofffreisetzung von PTX aus der Beschichtung in Reinstwasser zeigten eine langsame, 
kontinuierliche Liberation des Medikamentes. Nach einem Monat waren nur 11 % des 
anfänglich eingebrachten Wirkstoffs abgegeben. Das gemessene Freisetzungsprofil war dem 
eines PTX-beladenen Stents ähnlich. Weitere Wirkstofffreisetzungsversuche von PTX aus 
der porösen Schicht in Rindsplasma wurden durchgeführt und die Ergebnisse mit dem 
Freisetzungsprofil des TaxusTM WFSs verglichen.  
 
Getestet wurde ausserdem die in vitro Zytotoxizität der Beschichtung. Dabei wurden 
isolierte, primäre Rinderendothelialzellen in direkten Kontakt mit nicht-PTX-beladenen 
Titanoxidbeschichtungen gebracht. Erste Ergebnisse wiesen darauf hin, dass die 
nanostrukturierten Schichten auf dem Siliziumwafer und den Stahlsubstraten zytokompatibel 
sind.  
 
Es konnte eine Technologieplattform entwickelt werden, die die Charakterisierung der 
Titanoxidschichten, die Wirkstoffbeladung, Freisetzung und auch die Überprüfung der 
Zytotoxizität umfasst. Faktoren, die diese Sachverhalte beeinflussen, konnten identifiziert 
werden. Die Ergebnisse der vorliegenden Arbeit werden in Zukunft dazu beitragen, die 
nanostrukturierte, wirkstofffreisetzende Keramikbeschichtung für die Anwendung in einem 
WFS zu optimieren und an weitere biomedizinische Anwendungen anzupassen. 
 
Schlagwörter: nanostrukturierte Beschichtung, wirkstofffreisetzender Stent, Zytotoxizität
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LABELING OF SAMPLES 
 
The samples used in the present study hold the following systematic labeling. The 
modification of the solvent used in the drug-loading procedure (highlighted in blue) is only 
added to the sample label in Chapter 5: “Drug-Loading of The Thin Titania Films and Drug-
Release”. Special heat treatments (labeled in red), which are deviating from the conventional 
one, are only applied in the names of the samples in Chapter 6: “Preliminary In Vitro 
Cytotoxicity Tests”. 
 
EA_w730NRL(HT1)
support material
w: silicon wafer
ss: flat stainless
steel
ssWire: wire shaped ss
maximum sintering
temperature
700; 720; 730; 
750; …
structure
of the coating
NRL: non-reservoir
layer
RL: reservoir layer
solvent for
drug loading
EA: ethyl acetate
DCM: dichloromethane
ACET: acetone
DMSO: dimethyl sulfoxide
WEA: EA, water
WDCM: DCM, water
WACET: ACET, water
WDMSO: DMSO, water
special
heat treatment
HT1: hydrogen/argon/
oxygen
HT2: encapsulated
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CHAPTER I 
1 INTRODUCTION  
1.1 Coronary artery disease and the application of stents 
Coronary Artery Disease (CAD) is the most common type of heart disease and the 
leading cause of death in the developed countries. Today CAD affects more than 10 million 
people in the US every year [1, 2]. It originates from unhealthy lifestyles, like living on a 
noxious diet, getting insufficient exercise or being exposed to stress situations. This can abet 
atherosclerosis, which is the formation of plaque at the inner walls of the arteries, like 
illustrated in Figure 1-1 (a) [2, 3].  
 
(a) (b) (c)
 
Figure 1-1 (a) Atherosclerosis, (b) balloon angioplasty (PTCA), where a catheter with a small balloon is 
inserted into the blocked section of the artery and inflated, in order to compress the plaque and to open the 
artery, (c) stenting, in which a stent is inserted into the coronary artery by PTCA [4]. 
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The coronary arteries, which supply oxygen-rich blood to the heart muscle, become 
hardened and narrowed. Hence the blood flow to the heart is reduced and less oxygen 
delivered to the heart muscle. This can generate angina, heart attack and in the worst case 
death. Angina is chest pain or discomfort, which arises when insufficient blood is delivered 
to the heart muscle [5]. A heart attack evolves, when a blood clot formed at the site of 
atherosclerosis blocks the blood flow to a section of the heart’s muscle. This can cause its 
permanent damage or die off [6]. Persisting CAD with time can weaken the heart muscle and 
contribute to heart failure and arrhythmias. In heart failure, the heart is not able to pump 
blood to the rest of the body effectively. Arrhythmias are changes in the normal rhythm of 
the heartbeats. Treatment options include medication, coronary artery bypass surgery or 
catheter-based procedures. 
 
Several types of catheter-based technologies are available. During Percutaneous 
Transluminal Coronary Angioplasty (PTCA), the physician passes a special balloon catheter 
into the narrowed segment of the artery. The balloon is then expanded, which opens the 
artery and compresses the blockage against the artery’s wall, Figure 1-1 (b), [7]. This 
technique has become one of the most well-studied and most frequently performed 
procedures in modern medicine. In 2006, 1.3 million patients were treated with percutaneous 
coronary interventions in the US [8]. But about 30-40 % of patients, who undergo balloon 
angioplasty, may experience restenosis (re-narrowing) of the diseased artery segment within 
6 months of the procedure [9, 10]. Restenosis is a complex inflammatory healing response 
after injury of the blood vessel [11]. Other incidents recorded after PTCA are acute recoil of 
the artery and abrupt vessel closure [12].  
 
Hence researchers developed coronary stent-implants, which were launched on the 
market in 1987. Coronary stents are small, metal mesh-like tubes, like depicted in Figure 
1-2, with typical sizes ranging from 8 to 38 mm in length and 2.5 to 4 mm outer diameter 
[12, 13].  
 
 
Figure 1-2 Bare metal coronary artery stent [14]. 
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They are inserted into the narrowed segment of the artery via PTCA. The procedure is 
also known as stenting. Therefore the implants are cramped on the balloon of the catheter 
during placing them at the site of atherosclerosis in the artery, Figure 1-1 (c). Afterwards the 
balloon is inflated with pressures of 12-18 atm [15]. The stent expands to increase its 
diameter of a factor of 2 or 3, which can cause deformations on some parts of the stent up to 
10 % [12, 16, 17]. The implant is thus embedded into the vessel-wall and keeps the 
previously narrowed section of it open. The balloon is deflated and removed along with the 
catheter. The stent is left behind to serve as a metal support for the artery and to main the 
blood flow to the heart.  
 
While stents virtually eliminated many of the complications of abrupt artery closure, 
problems like acute thrombosis and restenosis persisted, Figure 1-3. Thrombosis is the 
formation of a thrombus, composed of platelets and fibrin, which originates in the stents or 
around them [18]. This body response appears typically in a time up to 14, maximal 30 d  
after intervention. Restenosis includes inflammation responses of the body, such as 
neointimal hyperplasia and extracellular matrix production, Figure 1-3, and results in a 
blockage of the stented artery section. Neointimal hyperplasia is the overproliferation of the 
smooth muscle cells (SMCs), which are present in the middle layer of the artery  
(Figure 1-4). They are surrounded by a layer of endothelial cells (ECs) facing the lumen of 
the artery and by connective tissue in the external layer of the vessel. Although restenosis 
rates were lower when implanting bare metal stents (BMS) compared to performing only 
PTCA, 20-30 % of patients still experienced an in-stent restenosis [1, 10, 12]. Repeated 
interventions to re-open the obstructed artery were hence necessary.  
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Figure 1-3 Blood vessel healing response to the implantation of bare metal stents [12]. 
 
Today the solution has moved away from purely mechanical devices. Several drugs, 
which were known to interrupt the biological processes that cause restenosis, have been 
tested. Stents coated with these drugs imbedded in a thin, permanent polymer for time-
release, the so-called drug-eluting stents (DES), are on the market. 
 
Introduction  Chapter I 
 
4 
tunica intima
(endothelial cells)
tunica media
(smooth muscles)
tunica externa
(loose fibrous connective tissue)
serosa
(epithelial cells)
elastin
blood flow through lumen
 
Figure 1-4 Structure of an artery, modified from [19]. 
 
The DES market is the largest market in revenues for a single type of medical device. 
In 2006, the US-market for coronary stents was estimated to be 5 billion US$, whereas 90 % 
were attributed to DES [20]. Commercially available DESs comprise a metal support, 
typically made of 316L stainless steel or CoCr alloys, on which a durable polymer coating is 
fabricated. The drug is dispersed in it. After implantation, the pharmacological agent is 
dissolved and released by diffusion through the polymer. The implantation of DESs reduced 
the restenosis rates to below 10 % and limited the incidents for acute (0-24 h) and subacute 
(24 h-30 d) thrombosis. The events of very late stent thrombosis, defined as occurring more 
than 1 year after implantation, recorded in the last two years in various studies were higher 
for DESs compared to BMSs [7, 18, 21, 22]. The incorporated drugs delay healing and hence 
decelerate re-endothelialization, resulting in the lack of neointimal strut coverage by 
endothelial cells. The commercially available DESs were coated with a permanent polymer, 
which persisted after drug elution. The presence of such a polymer resulted in 
hypersensitivity reactions in some cases [12]. The polymer detachment during expansion of 
the stent and the release of polymer debris created additionally adverse reactions [7]. 
Another problem facing the polymer approach is related to their fabrication. The need to 
dissolve the drugs and polymers in a common solvent for coating the stents can restrict the 
number of drugs available for the polymer-based drug-delivery. Because some solvents can 
alter the performance of the drugs. These certainties give motivation to work on new 
concepts for DESs. In this project the application of a well structured, titanium oxide (TiO2) 
coating for stents will be explored. 
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1.2 Objectives of the study 
Despite the successful application of drug-eluting stents (DESs) to prevent restenosis, 
the commercially available ones exhibit deficits in terms of their mechanical, chemical 
stability and their performance in the body. This project focuses on creating a 
nanostructured, drug-eluting, thin ceramic coating for stents. The work was conducted in the 
frame of a CTI-project and in collaboration with Debiotech SA, who owns patents to this 
technology [23, 24, 25]. 
 
The structured ceramic films, made of a biocompatible material like titania (TiO2), are 
to be prepared on metal substrates typically used in stents. These are for instance 316L 
stainless steel (SS) or cobalt chromium alloys (CoCr). Ceramic coatings made of TiO2 are 
commonly used in biomedicine to prevent the corrosion of the underlying metal or to trigger 
certain cell responses [13, 26, 27, 28]. In the present study it should furthermore serve as a 
drug carrier. Because TiO2 is inert to many solvents, any solvent can be used for the drug-
loading of the coating. For the formation of drug-eluting polymer coatings on the contrary, 
one has to be selective. One possible design of the ceramic coating is illustrated in Figure 
1-5. It comprises a monolayer of large pores with diameters of 500-1000 nm, called 
reservoirs, embedded in a ceramic layer with smaller pores. The reservoirs increase the 
overall pore volume of the coating and serve as storage rooms for the drug. The surrounding 
porous ceramic structure, and especially the nanoporous layer on top, will be used to control 
the drug-release from the reservoirs by diffusion, Figure 1-6. Other designs of the coating 
might use a nanoporous layer with different properties to the ones of the surrounding porous 
ceramic structure. The special nanoporous layer can then modify the drug-release or mediate 
a certain cell response when it is implanted. In the following, a layer containing drug 
reservoirs will be abbreviated by “RL”, a coating without reservoirs will be named “NRL”. 
 
nanoporous layer
support
base layer
reservoir
porous TiO2-layer
x
y
z
 
Figure 1-5 Scheme of the reservoir layer of the nanostructured, drug-delivering ceramic coating for medical 
implants. 
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Figure 1-6 Scheme of a reservoir layer of the nanostructured, drug-delivering ceramic coating. The drug 
reservoirs are filled with the pharmaceutical agent and the drug molecules are released through the surrounding 
porous bulk structure into the body tissue.  
 
Various parameters have to be taken into account when designing such nanostructured, 
ceramic coatings with respect to the final applications: the type of substrate, the structure of 
the coating, the chosen pharmaceutical, the desired drug-release for an efficient medication 
and more generally the materials involved in the processing. The nanostructured ceramic 
coating in a DES has to meet the following requirements: 
? Mechanical stability during implantation and after stenting. A coronary stent has to 
withstand a certain deformation during implantation and the dynamic strain in the 
artery due to the permanent blood flow [13]. The metal support should prevent the 
recoil of the artery. The coating should exhibit no delamination from the support and 
no crack formation.  
? A high porosity, achieved by the incorporation of the drug reservoirs, needs to ensure 
storage room for a sufficient quantity of the pharmaceutical agent.  
? The pore density, pore size and their arrangement in the nanoporous layer should 
control the drug-release. The release mechanisms need to be understood to adapt the 
coating, to make it effective against restenosis and neointimal hyperplasia. 
? The coating should possess a high biocompatibility. Biocompatibility is the ability of 
a material to perform with an appropriate host response in a specific application 
(Williams 1987) [13]. This term combines several aspects. An appropriate host 
response for instance includes the normal, uncomplicated healing. Applying to the 
stent, it should particularly trigger a fast re-endothelialization and hence prevent 
thrombus formation, besides being active against restenosis.  
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? Methods to prepare the drug-eluting coating should be adjustable, to apply it to 
various medical implants.  
 
1.3 Thesis structure 
The proof to apply the nanostructured ceramic coatings on stent-implants is complex 
and only some aspects will be covered in the present work. Emphases are given on first 
introducing the reader to the state of the art of the stent technology. The production and 
characterization of the nanostructured coatings made of titania will be pointed out further. In 
the last two chapters the drug-load and release capabilities of the coating will be evaluated, 
and its performance in an in vitro biological environment will be exploited in preliminary 
tests.  
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CHAPTER II 
2 STATE OF THE ART 
This chapter summarizes the state of the art of drug-eluting stents (DESs), including 
support materials, coatings and pharmaceutical agents. The methods to fabricate highly 
porous, structured ceramic coatings will be envisaged. 
 
2.1 Drug-eluting stents 
2.1.1 Commercially available systems 
The first DES commercialized was the CypherTM by Cordis Corp., whose approval by 
the US Food and Drug Administration (FDA) was obtained in 2003 [1]. The CypherTM stent 
contains a stainless steel (SS) support, on which a thin durable polymer coating made of 
polyethylene-co-vinyl acetate and poly-n-butyl methacrylate is attached. The pharmaceutical 
agent sirolimus, also known as rapamycin, is embedded in it in a concentration of 140 
µg/cm2 [2, 3, 4]. Sirolimus is an immunosuppressive agent, which prevents restenosis by 
inhibiting vascular smooth muscle cell (SMC) migration, proliferation and growth [3, 4, 5]. 
It binds to an intracellular receptor protein and ultimatively induces cell arrest. Two 
formulations of these polymer coatings are available, generating either a fast or a slow 
release of the drug. In the fast release modification, the coating comprises a bi-layered 
structure: a parylene coating on top of the steel, which is covered by a drug-containing 
polymer. For the slow release formulation, three layers are applied: parylene, drug-
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containing polymer and a pure polymer outermost, which limits the drug diffusion. While 
the fast release is characterized by a total drug-liberation in 15 d, the slow release lasts 
continuously up to 90 d [4]. 
 
Barely one year after the CypherTM stent was launched on the market, the TaxusTM 
stent by Boston Scientific Corp. was FDA-approved [1]. It is made of a 316L SS platform, 
on which a thin, permanent polystyrene-b-isobutylene-b-styrene (SIBS) coating is present. It 
contains paclitaxel (PTX) in a concentration of 1 µg/mm2. PTX was licensed by the FDA in 
1992 as an antineoplastic agent to treat metastatic ovarian cancer. It is an anti-proliferative 
therapeutical agent promoting the microtubule assembly in cells by facilitating the 
polymerization of tubulin to stable microtubules. This stabilization can interrupt many 
cellular processes. For instance it inhibits the cell division by keeping the mitotic spindle. It 
stops the migration, activation and maintenance of the cytoskeletal support, as well as the 
intracellular and transmembrane protein transport. Referring to restenosis, it affects the 
development of neointimal hyperplasia by disrupting SMC migration and proliferation [6]. 
Because the drug is dispersed homogeneously in the polymer matrix, modulating the drug 
concentrations in the polymer can create three different release profiles: the fast, moderate 
and slow release. For the fast and moderate formulations, an initial burst-liberation of PTX 
up to 48 h is recorded. 55 % and 8 % of totally incorporated PTX is then released under in 
vitro conditions, respectively. The slow release modification is characterized by a continuous 
release up to two weeks. 90 % of PTX remains then still trapped in the polymer [3, 4]. The 
slow release configuration is applied in the commercialized TaxusTM stent. 
 
Beneficial clinical outcomes of the implantation of DESs compared to BMSs were 
observed. The restenosis rates for DESs dropped significantly below 10 % [3, 7, 8, 9]. 
Events of acute (0-24 h) and subacute (24 h-30 d) thrombosis decreased. But a higher 
incidence of very late stent thrombosis, which occurs more than 1 year after implantation, for 
DESs compared to BMSs was recorded lately in different studies [10, 11]. Sirolimus and 
PTX delay healing and hence can hinder a complete re-endothelialization of the implant. The 
presence of the permanent polymer coating may contribute to stent thrombosis as a result of 
hypersensitivity reactions in some cases [3]. The removal of some parts of the coating during 
stenting can influence local drug concentrations in the artery-tissue [2, 12]. Intensive 
research to overcome these problems has directed the development of the second generation 
of DESs, which are now available on the European and US markets: the XienceVTM by 
Abbott Vascular Inc., the PromusTM by Boston Scientific Corp. and the EndeavorTM stent by 
Medtronic Vascular [1], Table 2-1.  
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Table 2-1 Drug-eluting stents in clinical use or under investigation. Copied from [3] and updated. 
drug stent support coating  stent name company approval status 
Sirolimus SS DP Cypher select Cordis FDA/CE 
 SS BP Supralimus Sahajanand CE 
 SS BP CURA Orbus Neich  
 SS BP Exel JW Medical  
 SS None Yukon Translumina CE 
 CoCr BP Supralimus-
Core 
Sahajanand  
Everolimus CoCr DP Xience V Abbott FDA/CE 
 CoCr DP Promus* Boston 
Scientific 
FDA/CE 
 PLLA BP Absorb Abbott Trial 
Zotarolimus CoCr DP Endeavour Medtronic FDA/CE 
 CoCr DP Endeavour 
resolute 
Medtronic Trial 
Biolimus A9 SS BP Biomatrix Biosensors CE 
 SS BP Nobori Terumo CE 
 CoCr BP Xtent Xtent Trial 
Tacrolimus SS None Janus Sorin CE 
 CoCr BP Maharoba Kaneka Trial 
Pimecrolimus CoCr BP Corio Conor  
 CoCr BP Prolimus Biotronik Trial 
 Magnesium BP Dreams Biotronik Trial 
Paclitaxel SS DP Taxus Liberte Boston 
Scientific 
FDA/CE 
 SS BP Infinnium Sahajanand CE 
 CoCr BP CoStar Conor CE 
 SS None Axxion Biosensors CE 
 Tyrosine 
polycarbonate 
BP REVA REVA Trial 
 
Anti-CD34 SS DP Genous Orbus Neich CE 
SS: stainless steel, CoCr: cobalt chromium, DP: durable polymer, BP: biodegradable polymer, PLLA: poly-L-
lactic acid, CE: Conformité Européenne, FDA: Food and Drug Administration, *: PROMUSTM Stent is a 
private-labeled XIENCE V™ everolimus-eluting coronary stent system manufactured by Abbott and 
distributed by Boston Scientific. XIENCE is a trademark of Abbott Laboratories group of companies [13]. 
 
PromusTM is a copy of XienceVTM licensed from Abbott and sold by Boston Scientific. 
They all contain CoCr support materials and the drug is present in durable polymer coatings. 
The XienceVTM contains 100 µg/cm2 everolimus in a poly(vinylidene) fluoride-co-
hexafluoropropylene polymer matrix [14]. Everolimus is an analogue of rapamycin with the 
same mode of action as an antiproliferative agent [15]. The EndeavorTM stent elutes 
zotarolimus from a phosphorylcholine polymer coating. Phosphorylcholine is a synthetic 
mimic of the outer wall of red blood cells and as such considered to be bioinert [2]. 
Zotarolimus is again a sirolimus analogue and effective against cell proliferation. The 
EndeavorTM stent releases 70 % of the pharmaceutical within 30 d in vitro, and acts in the 
inflammatory response after stenting, like is depicted in Figure 1-3 [3].  
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First studies have shown a tendency that they are more effective against very late stent 
thrombosis than the first generation of DESs. But further evidence has to be adduced [13]. 
The companies, which sell the stents introduced so far, hold at the moment most of the US-
stent market [16]. An overview of more licensed DESs, as well as stent systems in an 
advanced stage of development, were summarized by Kukreja et al. in 2008 and are 
displayed in Table 2-1 [3].  
 
2.1.2 Support materials 
Different types of support materials for stents are of current interest. They can be non-
degradable or degradable. Their properties affect the mechanical stabilities and designs of 
stents, as is pointed out in Figure 2-1. The arrangement of the struts and the strut’s 
geometries greatly vary in the displayed models.  
 
(a) (b)
(c)
(e)
(d)
(f)
 
Figure 2-1 Examples of different stents used in humans: (a) balloon expandable 316L coil stent (Gianturco 
Roubin IITM by Cook Inc.), welded to an axial spine [2]; (b) balloon expanding 316L laser-cut steel tube stent 
(BxVelocityTM) [2]; (c) balloon expanding stainless steel stent, laser-cut and segments welded together (S7TM, 
Medtronic) [2]; (d) CoStarTM Stent from Conor Medsystems showing ductile regions and passive elements in 
which drug reservoirs are fabricated [3]; (e) self expanding nitinol coil stent CordiocoilTM (Medtronic) [2]; (f) 
totally biodegradable everolimus-eluting poly-l-lactic acid stent from Abbott Laboratories [3]. 
 
Non-degradable SS or CoCr are the supports of many different balloon expandable 
stent systems. SS is radiopaque with an adequate radial strength for stents and it is employed 
in many BMSs and in DESs. Besides using compact SS, a stent made of microporous SS was 
developed by Translumina [3, 17], which can serve as a matrix for drugs. It offers the 
potential to customize drug doses and drug-combinations, and it is therapeutically active 
with rapamycin. The tendency however is towards the use of CoCr. This alloy has a higher 
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radial strength and improved radiopacity than SS and allows for smaller stent struts. They 
can improve the biocompatibility of stents. The concept of the CoStarTM DES from Conor 
Medsystems in Figure 2-1 (d), is based on CoCr. It has a special design, which promotes that 
sections of the stent experience higher deformations during stent deployment, whereas others 
stay passive elements. The passive sections are provided with drug reservoirs [3]. Other 
stents are based on the shape memory alloy nitinol (nickel-titanium, NiTi) and are self 
expandable, like the CordiocoilTM from Medtronic depicted in Figure 2-1 (e). A less 
frequently applied support for stents is tantalum. Besides its excellent corrosion resistance 
and biocompatibility, it is more brittle than SS. Hence these stents have a higher possibility 
for breaking during stenting. The pressure applied during the balloon deployment in PTCA 
needs to be accordingly lower and this often results in stent recoil. Stent recoil is the 
contraction of the stent’s diameter from short after deployment to the end of the procedure. 
Commercially available tantalum stents are the StreckerTM stent from Medi-Tech and the 
Tantalum CrossflexTM from Cordis [2].  
 
Fully degradable stents composed of poly-L-lactic acid (PLLA), such as the AbsorbTM 
stent from Abbot including Everolimus (Figure 2-1 (f)), showed promising results in clinical 
studies. Their safety has already been accomplished [3] and their mechanical properties seem 
to be favorable. The acute recoil after stenting was similar to the one of a CoCr based stent. 
The PLLA-stent is radiolucent and contains two platinum markers at each end to allow its 
identification by angiography. Angiography is a X-ray based technique to visualize the 
inside of blood vessels [3]. PLLA is fully metabolized into water and carbon dioxide after a 
certain time in the body. Hence PLLA stents are no permanent implants like the stents based 
on SS on CoCr. Another fully degradable stent made of tyrosine-derived polycarbonate, the 
REVATM stent, is currently under clinical evaluation [3]. Apart from the polymer based fully 
degradable stents, magnesium is in the focus of interest by Biotronik, Switzerland. It consists 
of a bioabsorbable magnesium (Mg) alloy, which corrodes in physiological environment into 
soluble Mg hydroxide, Mg chloride and hydrogen gas [5]. First clinical results regarding re-
endothelialization and neointimal hyperplasia were contradictory when implanted in 
children. Reasons might be associated to the degradation products, whose formation is not 
well controllable. A drug-eluting version is under exploration [5, 18, 19]. A biodegradable 
stent composed of iron (Fe) was also tested. Its biodegradation involves the oxidation of Fe 
into ferrous ions, which dissolve in the biological media. It has been shown that the ferrous 
ions reduced the proliferation of SMCs in in vitro conditions. The presence of the ferrous 
ions thus might inhibit neointimal hyperplasia and might reduce thrombogenicity when 
implanted. Further testing is still required [5, 20].  
 
State of the Art  Chapter II 
 
16 
2.1.3 Coatings 
To improve the performance of stents, the mechanically stable supports are often 
coated. The coatings for coronary stents can be categorized into passive and active ones. 
Passive coatings do not change or contain drugs and focus on triggering a certain cell 
response. Active coatings change after implantation and/or elute pharmaceuticals.  
 
A gold passive coating was produced on SS stent supports to increase the strut’s 
visibility when having thin struts and to enhance their biocompatibility. The performance of 
the coating however depended strongly on its fabrication and the presence of impurities. In 
human tests the coating did not deliver satisfying results: a higher tendency for restenosis 
and an increased neointimal proliferation [5]. Another stent concept consists of an iridium 
oxide coating on a metal support. Iridium oxide is a biocompatible inert ceramic. The 
rationale behind applying this material is the following. Hydrogen peroxide is formed at a 
metal surface when it is corroding. This can cause inflammatory reactions in the artery. A 
metal coated with iridium oxide should promote the immediate conversion of hydrogen 
peroxide into water and oxygen, hence reducing inflammatory reactions and promoting re-
endothelialization. Iridium oxide, on top of a gold coating on a stainless steel stent, was 
produced by Inflow Dynamics in the LunarTM stent. It was demonstrated that it triggered the 
fast re-endothelialization in humans because of its capability to prevent the production of 
free oxygen radicals, which can affect the adhesion and proliferation of endothelial cells. 
Restenosis rates of 13.8 % were recorded. The surface of SS produced little hydrogen 
peroxide and hence more investigations have to be made for evaluating the influence of this 
chemical reaction on restenosis [5, 21, 22, 23]. An amorphous hydrogenated semiconducting 
silicon-carbide (SiC) layer on top of a SS supporting stent showed promising results in in 
vitro tests: a reduction in platelet deposition with possibly reducing thrombosis and 
restenosis. However, clinical outcomes of the SiC-coated stents produced by Biotronik up to 
6 month showed contradictory results in two studies. They were not significantly superior to 
BMSs [24, 25, 26, 27]. Despite that diamond-like carbon coatings on stents have shown 
improved biocompatibility [28, 29], the clinical tests have revealed incoherent results. In one 
study a significant reduction in stent thrombosis and restenosis was reported, while others 
recorded the coating to be inactive and not influencing the inflammatory response [30, 31]. 
Other researchers applied a titanium-nitric oxide coating to stainless steel stents. A decreased 
platelet adhesion and less neointimal hyperplasia compared to BMS was observed [3, 32]. 
 
As active stent coatings durable polymers were applied in the first and second 
generation of DESs. The focus has now been given to degradable polymers. PLLA coatings, 
containing drugs, are applied on SS supports in combination with different drugs. Examples 
are the ExcelTM stent from JW Medical and the CE-approved Supralimus-CoreTM from 
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Sahajanand Medical Technologies, both eluting sirolimus. A poly-lactic-glycolic acid 
(PLGA) coating, which contains PTX, is used in the CoStarTM stent by Conor Medsystems, 
cf. Table 2-1. DES-concepts, which include inert inorganic coating materials for drug-
release, have also become attractive [33]. A passive nanoporous hydroxyapatite coating 
under investigation by MIV Therapeutics Inc. showed good biocompatibility in animal 
studies, when compared to the performance of BMS. No significant difference in neointima 
formation was found after four weeks of implantation in rabbits. Next steps include the 
impregnation of the layer with anti-restenoic drugs and their evaluation [34, 35]. A SS stent 
coated with nanoporous aluminum oxide, in which tacrolimus was incorporated, exhibited 
disappointing results in terms of biocompatibility. The surface modification by the ceramic 
coating did not significantly affect the reduction of the neointima in a rabbit model. The 
release of tacrolimus resulted in a reduced neointima thickness. However, it was reported 
that this coating may liberate ceramic particle debris, which affect the antiproliferative effect 
of the drug and increase the neointima thickness [5, 36, 37]. 
 
2.1.4 Pharmaceutical agents 
Besides the successful application of PTX and sirolimus in the first generation of DESs 
to reduce restenosis, attention has been given on employing various drug analogues in the 
new stent systems. Sirolimus analogues like everolimus, zotarolimus and biolimus A9, are 
now applied in different coatings, Table 2-1. They have the same mode of action like 
sirolimus, being immunosuppressive, but they might differ in their aqueous solubilities. 
Biolimus A9 was combined in a PLLA coating on a SS support creating the BiomatrixTM 
stent (Biosensors International). After approximately 70 % of the drug were eluted over 30 d, 
a sustained release of the residual drug was governed by the polymer degradation over 
several months. The stent is effective and approved for the commercialization in Europe [38, 
39, 40]. Another immunosuppressive drug employed is Tacrolimus. A CoCr stent coated 
with PLGA incorporating this drug is under exploration by Kaneka [3]. In other concepts, 
CoCr and Mg stents are coated with biodegradable polymers, in which pimecrolimus is 
dispersed. Pimecrolimus is a tacrolimus analogue and causes fewer side effects. An 
alternative approach focuses more on healing than on SMC-growth inhibition. In the 
GenousTM stent from Orbus Neich, the SS support is coated with antibodies, which attract 
circulating endothelial progenitor cells. This encourages rapid endothelialization and lowers 
hence the risk of thrombosis [41, 42].  
 
2.1.5 Future of drug-eluting stents 
From the above discussed development trends of DESs, design criteria for an ideal 
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stent can be derived. The stent should provide a scaffold to prevent the recoil of the artery. 
Furthermore it needs to be deliverable and visible with appropriate radiopacity to enable its 
positioning. A stent should exhibit good fatigue properties during stenting as well as 
afterwards, when it is exposed to the cyclic stresses caused by the blood flow. A fast and 
total re-endothelialization is recommended, which helps to prevent stent thrombosis and 
limits neointimal hyperplasia [3, 43]. The drug-delivery should help to prevent restenosis 
and should not limit a fast re-endothelialization of the implant. 
 
The commercially available DESs CypherTM and TaxusTM have shown that 
inflammatory responses can evolve due to the presence of the durable polymer [4]. The 
drugs can cause a delayed healing of the blood vessel. Various kinds of combinations of 
materials are under investigation to produce the ideal DES. Many of them were listed above. 
Porous TiO2-films have recently also gathered interest for the application in stents.  
 
2.2 Titania for the application in stents 
TiO2 is a well studied mineral and has found its application in diverse areas. As 
powder it is used as a white pigment in paints, coatings, plastics, papers and cosmetics. On 
account of its ability to be transparent for visible, but absorbing UV-light, it is an essential 
component in sunscreens [44, 45]. In the field of photocatalysis TiO2 is employed for the 
purification of wastewater, in the killing of bacteria and it might be effective against the 
growth of tumor cells [44, 46, 47]. The combination of the photocatalysis reaction and 
photoinduced superhydrophobicity has led to the development of titania coatings and 
cements with self-cleaning properties. Additional applications are as anti-reflective coatings 
by reason of its high refractive index or as oxygen gas sensors on the basis of its 
semiconducting features [44, 46]. TiO2 as a semiconductor is moreover used in 
photovoltaics, in particular in solar cells for the direct production of energy or for splitting 
water to yield hydrogen. Furthermore it is implemented in biomedicine.  
 
Titanium metal and its alloys have been employed in orthopedic and dental medical 
applications, because of their superior biocompatibility. They exhibit a stable, native oxide 
layer providing excellent corrosion resistance and contributing to osseointegration in bone 
implants [48, 49, 50, 51, 52, 53, 54]. However, titanium is not commonly used for making 
stents, because it has a lower tensile strength than CoCr [5, 55]. Hence there is a higher 
probability of tensile failure of the titanium stents when expanded to stresses beyond their 
yield stress. This condition can potentially occur during stenting [5]. However a titanium-
nitride oxide coating was applied on a 316L SS support. It was found that it reduced platelet 
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and fibrinogen adhesion, resulting in a reduced neointimal hyperplasia. This coating 
technique is implemented in the TitanTM stent from Hexacath in France [56, 57]. Reported by 
Liu et al. in 2003, nitinol stents, which were coated with an anatase TiO2 thin film by sol gel 
techniques, were effective in improving the corrosion resistance of the underlying NiTi-
alloy. It exhibited an improved hemocompatibility compared to the bare NiTi [51]. Plant and 
coworkers used NiTi-alloys and performed an oxidizing heat treatment at 600 °C to thicken 
the TiO2-layer on top of the alloy. This resulted in a reduction of the concentration of nickel 
ions on top of the surface. The lower nickel ion concentration influenced the cell attachment 
to the surface. A significant reduction in the oxidative stress on human umbilical vein ECs 
was registered compared to the one caused by the native NiTi [58]. A very recently 
published work from Peng et al. focused on the reaction of ECs and SMCs on porous 
nanotubular titanium oxide surfaces [59]. Highly ordered, vertically oriented, crystalline 
TiO2-nanotube arrays with a diameter of 30 nm were prepared by anodic oxidation and were 
subjected to in vitro tests. The ECs proliferation was significantly enhanced compared to the 
one on flat TiO2-surfaces. Cells had a more elongated morphology than on the flats and were 
assumed to have higher migration speeds. This would be beneficial for a fast re-
endothelialization of the stent [59]. In contrast, the proliferation of the SMCs grown on the 
tubular surface decreased. Cell morphologies were more rounded shaped, cells were 
clustered and they seemed to minimize their contact with the nanotube surface in comparison 
to the flat controls. This effect might contribute to prevent neointimal hyperplasia on a stent 
[59]. No information was given on the mechanical stability of the coatings.  
 
The loading of a nanoporous TiO2-film, characterized by randomly arranged pores of a 
mean width of 5.5 nm, with the drug dexamethasone for the application in stents was 
reported by A.A. Ayon et al. [60]. Drug-loading was performed by immersion of the 
specimens into the drug/solvent solution, whereas the pores were filled by capillary 
permeation. The solvent was subsequently evaporated, leaving the solid drug in the pores. 
The method was optimized to obtain a drug-load comparable to the therapeutic dose. 
However, no photos of the drug’s position in the coating, ensuring that the drug was present 
in the pores and not concentrated on the surface of the coating, were shown in their 
publication. Neither was information given about the drug-release kinetics or the mechanical 
stability of the coating. 
 
2.3 Porous structuring of ceramic films 
The nanostructured drug-eluting TiO2-coating to be investigated in the present study, 
needs to be manufactured on complex stent geometries. The reservoirs arranged in a 
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monolayer are to be created by template particles [61, 62]. Various techniques have been 
employed up to date to achieve structured porous surfaces using colloidal particles and a 
detailed summary of these can be found in the thesis of F. Juillerat [63]. Only a few 
techniques will be mentioned at this point. 
 
In the one-step deposition techniques the coating that needs to be structured and the 
template particles are deposited simultaneously on a substrate. As example, polystyrene (PS) 
sphere particles were mixed with silica sols and dip coated on a flat glass substrate by J.N. 
Wang and co-workers. Subsequent heating at 500 °C to burn the PS-templates created a 
ceramic layer with randomly distributed 500 nm holes in a surrounding finer porous 
structure. These coatings were superhydrophobic and can be used as self cleaning coatings 
[64, 65]. The size, shape and concentration of the templates in the sol direct the structure of 
the coatings. Hierarchically structured materials containing mesopores (diameters between  
2 to 50 nm) and macropores (diameters > 50 nm) due to a combination of different sized, 
shaped templates in the sol, were also fabricated. These types of coatings found various 
applications, such as in heterogeneous catalysis or in separation processes involving large 
macromolecules [64, 66, 67, 68, 69].  
 
Colloidal lithography is another technique that applies colloidal particles, deposited on 
a substrate, as a sacrificial mask for the subsequent deposition of the coating’s material. 
Particles can be deposited either in ordered arrays, like depicted in Figure 2-2 (a) [70, 71,], 
or randomly [63, 72]. The big pores of the coating represented in Figure 2-2 (b), which were 
created by the removal of the mask particles, could represent the drug reservoirs in the 
nanostructured titania coating to be prepared.  
 
In soft lithography particles act as a stamp to be imprinted into a soft substrate, mainly 
polymeric. Choi et al. have used silica 320 nm ordered arrays stamped on polyurethane films 
to form hole arrays [63, 73].  
 
In the case of laser techniques, laser irradiation of PS and silica particles, spin-coated 
onto an aluminum thin film, have been shown to possibly lead to the formation of random 
hole arrays [74]. 
 
Another method employed to structure surfaces is anodic oxidation, which not 
necessarily requires the presence of colloidal particles. Porous alumina coatings with straight 
cylindrical pores were prepared for bone implants [59, 75]. Peng et al. produced in that way 
TiO2-nanotube arrays with controlled straight pores of a certain diameter on titanium foils. 
Their potential to be used in stent-implants is currently under investigation [59]. 
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Figure 2-2 SEM-micrographs of (a) polystyrene colloidal crystal template after dip drawing process and (b) 
TiO2-film structure after burn of the polymer templates [69]. 
 
In the techniques applying sacrificial particles, different methods are applied to remove 
them depending on their nature. These may either be based on chemical, thermal, irradiation 
or mechanical treatments [63]. The focus in the present study was put on using colloidal 
lithography for the production of the coatings, because preliminary work was already 
deduced by F. Juillerat [63]. 
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CHAPTER III 
3 AIMS OF THE THESIS 
The feasibility to use the nanostructured TiO2-coatings, which are introduced in 
Chapter 1.2, as drug-eluting films on stents will be evaluated. Complex testing is required to 
judge if the coatings have the potential to be applied on a stent. In the frame of this thesis, 
the following topics will be in the focus of interest: 
? The characterization of the structural and chemical features of two modifications of 
the titania layers (with and without reservoirs), when produced on 316L stainless 
steel (SS) and on silicon wafer model supports. 
? Finding and controlling the procedures to load the therapeutical agent paclitaxel 
(PTX) into the porous films. They will be optimized to yield a drug concentration of 
1 µg/mm2 in the coating, which corresponds to the dose used in the commercially 
available TaxusTM stent. PTX will be used as a model drug, because it is approved by 
the US Food and Drug Administration (FDA) for its application in drug-eluting 
stents (DESs) and it is a non-patented drug freely available.  
? Performing in vitro PTX-release tests in water and bovine plasma. The release 
kinetics will be deduced and compared with literature findings. The transport 
governing factors during the drug-liberation from the coating will be identified. This 
will help to possibly change the coating’s properties to adapt it to various desired 
release profiles. 
? Preliminary in vitro cytotoxicity tests of the coatings when exposed to a direct 
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contact with primary bovine endothelial cells will be performed. They serve as first 
biocompatibility evaluations of the coatings. 
 
More detailed information regarding the production of the thin TiO2-films on simple 
and complex steel geometries, as well as its mechanical behavior during expansion can be 
found in the doctoral thesis of A. Tourvieille de Labrouhe*. He studied the formation of 
cracks and their propagation in the nanostructured titania coatings, which were exposed to 
deformations greater than 40 %. His findings were acquired in parallel to the ones in the 
present study. Both studies are complementary to each other and were deduced within the 
framework of the project Nanostent, supported by the Innovation Promotion Agency (CTI), 
Switzerland and the industrial partner Debiotech SA, Switzerland. The developed technology 
platforms will provide Debiotech SA a powerful tool to adapt the coatings to various 
applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*A. Tourvieille de Labrouhe, “ Nanostructured ceramic coatings for deformable medical implants such as 
stents”, Thesis, Ecole Polytechnique Fédérale de Lausanne, 2009
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CHAPTER IV 
4 CHARACTERIZATION OF THE STRUCTURED TITANIA 
FILMS 
4.1 Background and Introduction 
Ceramic coatings have proven to be beneficial to increase the performance of the 
underlying bulk material. As insulators, ceramic coatings are applied in electronic devices, 
like in wire and heater elements, or in microelectronic circuits. They can protect their 
support material in high temperature environments or from wear and deformation due to the 
good hardness. Permanent ceramic films and coatings can be used to protect materials from 
reaction and corrosion in harsh environments [1, 2]. Various ceramic coatings are applied in 
medical implants, which are exposed to the biological environment [3, 4, 5, 6, 7], like was 
mentioned previously in Chapter 2.1.3 and Chapter 2.2.  
 
Some common methods to create thin ceramic films are physical vapor deposition 
(PVD), chemical vapor deposition (CVD), thermal spray processing, solution and sol gel 
techniques. Methods like CVD and PVD allow the production of dense films as well as 
porous films when templates are involved. However in some cases, the coverage of complex 
geometries is difficult [1, 2]. In the present study, highly porous films with well ordered 
reservoirs are to be fabricated. The reservoirs are to be created by colloidal lithography, cf. 
Chapter 2.3. The method of choice to create the nanostructured titania coatings was dip 
coating, which allows an easy coverage of the complex shaped stent. The coating’s 
thickness, obtained by dip coating a support into a colloidal particles suspension, is 
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controlled by the concentration of the colloidal particles and binders, the particle size and of 
the surface tension of the support [2]. The viscosity of the suspension and the withdrawal 
speed also have an influence. An equation derived by Landau and Levich relates these 
parameters [8]. The thickness of the deposited film by dip coating, H, can be calculated as 
 
(4-1), 
 
 
with η: dynamic viscosity of the suspension, v: withdrawal speed, γLV liquid/vapor surface 
tension, ρ the density of the suspension and g the acceleration due to gravity. By simply 
varying one of the parameters, e.g. the withdrawal velocity, different coating thicknesses can 
be achieved. The main advantages of dip coating are that complex geometries can be coated 
in a controlled, fast and inexpensive way. The combination of colloidal lithography and dip 
coating is already established for coatings with structured porosities, like was demonstrated 
in Chapter 2.3. This made dip coating an attractive technique to be used in this study to form 
the porous TiO2-coatings on stent implants.  
 
It was important to characterize the structural features of the produced coatings in 
regard to their application in a drug-eluting stent (DES). In the following, a short summary 
of the main definitions and classifications of porous structures is given, which will be used 
further. Regarding the pore sizes, the International Union of Pure and Applied Chemistry 
(IUPAC) has defined a micropore as a pore with an internal width of less than 2 nm, a 
mesopore with an internal width between 2 and 50 nm and a macropore as a pore with a 
width greater than 50 nm. The term nanopore does not yet have a precise definition, but is 
commonly used to describe pore widths in the range of 0.1 to 100 nm [9]. Possible shapes of 
pores in a porous solid are pointed out in Figure 4-1. Pores completely isolated from the 
surrounding are named closed pores, such as in (a). They influence the bulk properties like 
strength, but would not contribute to the drug-load and release. The others are termed open 
pores (b, c, d, e and f), which would be responsible for the drug transport. Some may be 
open at one end (b), they are called blind pores. Others might be open at two ends (e), named 
through pores. Pores can also be classified according to their shape: they may be cylindrical 
(c), (f) or inkbottle shaped (b), funnel (d) or slit-shaped [10]. 
 
An important parameter affecting the diffusion of molecules through a porous solid is 
the tortuosity of the pores. It is defined as the ratio of the effective diffusion length in a pore 
to the distance between its ends [9]. The porosity of a porous bulk is the ratio of the pore 
volume to the overall volume occupied by the solid [9]. 
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Figure 4-1 A schematic cross section of a porous solid representing all possible types of pores. (a): closed pore, 
(b to f): open pores, whereas (b), (f) in particular are blind pores, and (c), (e) through pores [10]. 
 
Another important characteristic of a porous solid is its specific surface area, SBET. It 
represents the ratio of the total surface area available, including the one of the open pores 
and the one of the lateral area of the specimen, to the sample mass. The mean equivalent 
spherical grain diameter from the specific surface area, dBET, can be calculated as 
 
(4-2), 
 
 
with ρtheo: theoretical density of the porous structure excluding all pores. Another density 
describing porous structures is the skeletal density ρs, which represents the density of the 
material including all closed pores and inaccessible voids. The Archimedes density, ρArch, 
denotes the density of the whole porous structure including all pores and voids. 
 
In this chapter, the production of the thin titania coatings in the non-reservoir (NRL) 
and reservoir layer (RL) modifications by dip coating will be presented. Anatase initial 
nanoparticles, with a diameter smaller than 50 nm, were chosen rather than micrometer sized 
particles, because: 
? Nanopores and high porosities can be created in the coating. This is necessary to 
incorporate the drug and to release it in a controlled way. 
? The total contact area between the nanoparticles and the support is higher and thus 
might contribute to a better adhesion of the coating on the steel support. 
? The higher specific surface area of the nanoparticles allows a densification at lower 
sintering temperatures. 
? Anatase is the stable crystalline morphology of TiO2 for particles with a diameter 
smaller than 100 nm [11]. 
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4.2 Materials and methods for the production of the thin films and the 
bulks 
The fabrication of the thin titania films on 316L stainless steel (SS) or silicon wafer 
supports will be explained. Because their structural characterization was difficult, like will 
be pointed out in Chapter 4.5.1, equivalent bulk titania bodies with a cylindrical shape were 
prepared. 
 
4.2.1 Suspensions 
The porous films and bulks were created with initial anatase TiO2-nanoparticles, which 
were purchased from TechPowder SA, Switzerland. This powder had the specifications like 
shown in Table 4-1, with an average particle diameter from the specific surface area, dBET, of 
21.5 nm and an agglomerate factor of 2.9. To form a stable colloidal suspension to be used 
for the sample preparation, the initial powder was dispersed in water with binder to obtain 
suspension “TP1”. It was composed of 6.8 %wt TiO2, 3.8 %wt poly vinyl alcohol (PVA, 
Mowiol 3-96 from Clariant, Germany) and water. The pH was adjusted to 10.5 with 
technical ammonia. A suspension without binder and a solid content of 13 %wt, “TP2”, was 
used to prepare samples for dilatometry. The higher solid content formed bigger bulk bodies 
necessary for this analysis. Before the suspensions were applied, they were sonicated with 
ultrasound (DG-100-36, Telesonic Ultrasonics) for 10 min to disrupt agglomerates. To 
manufacture reservoir containing layers (RLs), a water based template suspension containing 
5 %wt spherical polymer templates (Latex Microsphere Suspension, Duke Scientific 
Corporation), with a mean diameter of 1 µm, was employed. 
 
Table 4-1 Specifications of the initial titania powder used to produce the nanostructured films and bulks. 
characteristics of the titania powder 
crystal phase anatase 
specific surface area, SBET (m2/g) 75.4 
average particle diameter, dBET (nm) 21.5 
median particle diameter, dv50 (nm) 62.0* 
agglomerate factor 2.9 
density (g/cm3) 3.7 
* see for Figure A-1 in Appendix 
 
4.2.2 Supports for the thin films 
The thin TiO2-films were prepared on two different support materials: 316L stainless 
steel (SS) and silicon wafers.  
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The 316L stainless steel supports (Metallica SA, Switzerland) had a rectangular shape 
with a length of 50 mm, a width of 10 mm and a thickness of 1.25 mm. The SS exhibited the 
following composition: carbon (C) < 0.03 %wt, chromium (Cr) = 16-18 %wt, 
nickel (Ni) = 10-14 %wt, molybdenum (Mo) = 2-3 %wt, manganese (Mn) < 2 %wt, 
silicium (Si) < 1 %wt, phosphor (P) < 0.045 %wt, sulfur (S) < 0.03 %wt [12]. Prior to the 
application of the ceramic film, the metal specimens were electrochemically polished. This 
process served for a reduction in roughness of the surface and for a brightening and 
passivation of the stainless steel [13]. The electrolyte, composed of 15 %vol deionized water 
(Christ ministil P-12, 0.5 µS/cm), 35 %vol phosphoric acid (85 %wt, Acros organics) and 
50 %vol glycerol (95 %wt Glycerol synthetic, Acros organics), was heated up to 90 °C in a 
glass beaker. The metal workpiece was used as an anode (+), the cathode (-) corresponded to 
a metal mesh surrounding the interior of the beaker. Both electrodes were covered by the 
electrolyte and attached to the laboratory power supply (EA-PS 2016-100). If a current 
density of 0.75 A/cm2 between the anode and the cathode was applied, metal ions from the 
surface of the specimens were removed. The electrolyte acted as a conductor and allowed the 
metal ions to be drawn to the cathode, where the reduction reaction was taking place and 
hydrogen gas formed. After polishing for 5 min, a mean roughness, Ra, of 100 nm was 
measured by laser profilometry (UBM-microfocus) [14].  
 
Silicon wafers with a 100 nm SiO2 layer (Silicon-Wafer, P/Bor <100>, double sided 
polished and 100 nm SiO2, Si-Mat Silicon Materials) were used as model supports for the 
titania coatings. They were easier to handle in respect of cutting or porosimetry analyses 
than the SS.  
 
Before the coatings were applied to any type of support, they passed through a 3-step 
cleaning procedure to remove grease and dust. Specimens were firstly immersed in a 
water/soap solution and put into an ultrasonic bath for 5 min. After the same procedure was 
performed secondly in acetone and thirdly in ethanol, the specimens were dried under air 
flow and then dip coated. 
 
4.2.3 Films by dip coating 
The thin films were prepared by a multi-step dip coating technique. Depending on the 
desired microstructure-non-reservoir layer (NRL) or reservoir layer (RL)-the process 
parameters were adjusted according to Table 4-2. By dipping the supports multiple times 
into the TiO2-suspension (Precision dip coating system PL 3201, Speedline Technologies) 
and pulling them out with a defined withdrawal speed, a NRL was obtained. The same 
thicknesses of the NRLs were deduced by two methods. One method was to withdraw the 
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specimens with two times 90 mm/min and one time with 250 mm/min from the suspension 
TP1. In the second method, the specimens were withdrawn consecutively 4 times with 
1000 mm/min. Between each dip, the deposited film was dried for 20 min at 37 °C and 10 % 
relative humidity in a climatic test cabinet (RUMED®).  
 
To create RLs, a support was dipped one time into the TP1 suspension and withdrawn 
with 90 mm/min. Subsequently after drying, it was dipped into the template suspension and 
pulled out with a speed of 90 mm/min. The specimens were then once again dipped into the 
TiO2-suspension and withdrawn with a speed of 90 mm/min, before in the last step being 
pulled out of the titania suspension with 250 mm/min, Table 4-2.  
 
Table 4-2 Parameters of the dip coating to produce titania non-reservoir layers (NRL) and reservoir layers (RL) 
on either stainless steel (SS) or wafer (w) supports. 
number of dips / withdrawal speed (mm/min) sample support structure 
TiO2-suspension template-suspension 
ss730NRL steel NRL 2/90; 1/250 - 
ss730RL steel RL 2/90; 1/250 1/90 
w800NRL wafer NRL 2/90; 1/250 or 4/1000 - 
w800RL wafer RL 2/90; 1/250 1/90 
f800NRL wafer NRL 4/1000 - 
w730NRL wafer NRL 2/90; 1/250 or 4/1000 - 
w730RL wafer RL 2/90; 1/250 1/90 
 
The strong adhesion of the thin films on the supports, as well as the small amount of 
porous material available, made it difficult to perform standardized analyses for the pore size 
characterization with the films (cf. Chapter 4.5.1). An alternative way had to be found to get 
access to the structural parameters. Therefore bulk titania samples in the NRL-modification 
were prepared. 
 
4.2.4 Bulks by slip casting 
Bulk samples were prepared by slip casting. The TiO2-suspension was degassed at 
200 mbar for 10 min (Epovac Stuers) to eliminate air, which might have caused a false, 
lower density of the green bodies compared to the one in the films. A cellulose nitrate filter 
(Whatman) with a cutoff diameter of 0.2 µm was placed onto a highly porous gypsum plate, 
which served to take up the liquid coming from the suspension. On top of the filter a rubber 
mould of a height of 20 mm with cylindrical holes exhibiting a diameter of 15 mm was 
mounted. The TiO2-suspension was carefully introduced into the cylindrical voids of the 
mould with a pipette. The set-up was covered by a glass plate to avoid contamination and 
left for drying at room atmosphere for 7 d. The generated green bodies had a shape of a 
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pellet with a diameter of 10 mm and a height of 2 mm. 
 
4.2.5 Sintering of the films and the bulks 
The heat treatments of the films and bulks were carried out in a tubular furnace (Model 
54434, Lindberg) under continuous gas flow with 0.342 l/min. The sintering cycle consisted 
of 3 main stages, like illustrated in Figure 4-2. With a rate of 4.5 °C/min, samples were 
heated in air up to 450 °C. This temperature was maintained for 60 min to remove the 
organic binder by thermolysis. To densify the TiO2-nanoparticles, a second heating step up 
to a maximum sintering temperature, Tmax, in an atmosphere of air and argon (Ar)* followed. 
Ar as an inert gas was employed to protect the steel from oxidation at elevated temperatures. 
The dwell time at Tmax was 80 min before the samples were cooled to room atmosphere.  
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Figure 4-2 Sintering cycles of the films and bulks with representative maximum sintering temperatures, Tmax, 
of 730 and 800 °C. r denotes the heating rate, Ar: argon. 
 
The sintering parameters applied on the various film samples are summarized in Table 
4-3. Sample names contain the information of the applied support material (ss or w), the 
maximum sintering temperature and their modification (NRL or RL). Except of f800NRL, all 
films were sintered while being attached to the support. The coatings of the samples 
f800NRL, hence the letter “f”, were removed from the silicon supports before the heat 
treatment. They were produced to determine the influence of the support material on the 
coating’s structure. The maximum sintering temperatures of the various cylindrical bulks are 
depicted in Table 4-4. The names of the bulks contain “b” for the bulk-modification and the 
value of the maximum sintering temperature. 
 
* The exact concentrations of argon and air were not determined. But it was observed that the TiO2 in the films 
was not reduced, which was expected by applying argon gas. Reasons were that argon was not purified before 
its application and that the oven showed a leakage. The oxygen partial pressure in the oven during sintering was 
not measured. 
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Table 4-3 Conditions used for the sintering of the TiO2-films produced by dip coating. Tmax represents the 
maximum sintering temperature. 
sample ss730NRL ss730RL w800NRL w800RL f800NRL w730NRL w730RL 
Tmax (°C) 730 730 800 800 800 730 730 
substrate (yes/no) yes yes yes yes no yes yes 
 
Table 4-4 Conditions used for the sintering of the TiO2-bulks produced by slip casting. Tmax represents the 
maximum sintering temperature. 
sample b700 b720 b740 b750 b770 b800 b820 
Tmax (°C) 700 720 740 750 770 800 820 
 
4.3 Methods for the characterization of the porous structures 
4.3.1 Microscopy 
The quality of the deposited TiO2-films at different steps of the dip coating were 
examined by an optical microscope (Olympus B071 equipped with an Altra 20 Soft Imaging 
System; Software analySIS getIT, Olympus Soft Imaging Solutions GmbH). In addition, the 
density and dispersion of the deposited template microbeads was observed by optical 
microscopy.  
 
Micrographs of the top views of the coatings and the bulks were taken by a scanning 
electron microscope (SEM, XLS 30, Philips). Photos of the cross sections of the films on 
wafers, which could easily be prepared by cutting with a diamond knife, were taken by a 
high resolution scanning electron microscope (XL-30SFEG, Philips). Focused ion beam 
(FIB) cutting in combination with scanning electron micrography was used to obtain images 
for the grain size analysis of NRLs. Manipulation of the machine and image processing was 
performed by M. Cantoni, Center for Electron Microscopy (CIME), EPF Lausanne. The 
titania coated specimens were therefore mounted on the stage of a FEI Nova 600 Nanolab 
FIB. On a selected area, platinum was deposited to provide a smooth, conducting surface. 
Cross sections were prepared every 10 nm using the FIB at 30 kV and a beam current of  
300 nA. Backscattered electron scanning images were recorded at accelerating voltages of  
4 kV. The set of 2-dimensional images were processed using the software ImageJ. 
 
4.3.2 X-ray diffraction 
Determinations of the crystal phases of TiO2, during and after the sintering, were 
performed with three different X-ray diffraction (XRD) methods. The applied technique 
depended on the existing shape of the ceramic as a powder, as a thin film on wafer or stainless 
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steel, or as a bulk.  
 
The powder in its initial state, the films w800NRL, f800NRL, w730NRL, w730RL and 
the bulks were characterized by powder XRD (X’ Pert Pro, PANalytical), with a  
Cu-Kα-radiation, an operation voltage of 40 kV, a current of 50 mA and a step size of  
0.017 °2Theta. The films were detached from the supports prior to analysis. Thin film XRD 
was performed by A. Neels at the Centre Suisse d'Electronique et de Microtechnique, 
CSEM, in Neuchâtel, Switzerland. Data were acquired on a Panalytical MRD PRO 
instrument with a copper filament at a gazing incident angle of 1° (ω) in the range of 10 to 
100 °2Theta. This technique was employed to measure the phases of the coatings on SS 
supports, ss730NRL and ss730RL. In situ XRD (X’Pert Pro instrument, PANalytical) during 
sintering was performed using a CuKα-radiation, an operation voltage of 40 kV, a current of 
40 mA and a step size of 0.008 °2Theta. The aim was to observe the phase transition of TiO2 
while heating. Hence the conventional heat treatment was modified to collect a statistical 
sufficient amount of intensity counts. X-ray spectra were recorded each before and after a 
heating step, during which the temperature was kept constant for each additional 30 min. The 
Tmax chosen was 800 °C and helium was selected instead of argon, because this gas had 
lower background absorption. Only bulk samples and no films were applied in this 
experiment. The quantitative phase analyses of anatase and rutile of all measurements were 
evaluated using the Rietveld refinement method and the software X’Pert High Score Plus 
(PANalytical) [15].  
 
4.3.3 Densities 
The theoretical densities of the films and bulks were deduced from the XRD 
measurements. The skeletal densities, which include closed pores and inaccessible voids, 
were determined by helium-pycnometry (AccuPyc 1330, Micrometrics). The bulk densities 
of the porous bulk samples were determined by the Archimedes method. The corresponding 
mean values were acquired from three replicas.  
4.3.4 Specific surface area 
The specific surface area, SBET, was measured by nitrogen adsorption on a 
Micrometrics Gemini 2376 using the Brunauer-Emmett-Teller (BET) method. Each type of 
specimen was measured in triplicates.  
 
4.3.5 Grain size analysis 
Common methods, which are usually employed to determine the grain size, were 
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inappropriate for the TiO2-coatings. The epoxy resin, typically infiltrated into the porous 
structure for stabilization, failed to penetrate throughout coating. Subsequent grinding caused 
the breakout of small particles from the coating. One way out was to make perfectly polished 
cross sections of the thin films by FIB and recording SEM-images, cf. Chapter 4.3.1. For 
representative statistical results, a minimum of 400 TiO2-grains was counted in the images, 
using the linear intercept method of the program LINCE (Lince Linear Intercept, Version 
2.4.2., Technical University Darmstadt, Materialwissenschaften, Nichtmetallisch-
Anorganische Werkstoffe).  
 
4.3.6 Porosimetry 
Various methods, which are based on different physical models, were applied to 
determine the porosity of the titania nanostructures. The porosity and pore size distribution 
(PSD) of the films, which were not removed from the support prior to the analysis, were 
measured by the three following techniques: 
? Ellipsometric porosimetry (EP), 
? Small angle neutron scattering (SANS),  
? Stereology.  
 
Two methods were employed to determine the porosity and PSD of the films, which were 
detached from the wafer support before analysis, and of the bulks: 
? Mercury intrusion porosimetry (MIP), 
? Nitrogen sorption porosimetry (NSP). 
 
A summary of the analyses performed on the specimens is presented in Table 4-5.  
 
Table 4-5 Summary of the methods used for pore size determinations of particular samples. 
method sample 
ellipsometric porosimetry (EP) ss730NRL, w730NRL 
small angle neutron scattering porosimetry (SANS) w730NRL, w730RL 
stereology w730NRL 
mercury intrusion porosimetry (MIP) w730NRL, w800NRL, f800NRL, b740 
nitrogen sorption porosimetry (NSP) b740 
 
In the following section methods used, when the films were not detached from the 
supports, are pointed out. More detailed information will be given for EP, because it might 
become in the future a powerful technique for the structural characterization of highly 
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porous, thin films. Also some principles of SANS will be explained, because it is not a 
commonly used method to determine PSDs and porosities. The other techniques will not be 
elucidated in detail, because they are standardized. 
 
4.3.6.1 Ellipsometric porosimetry 
The basic principle of EP is to measure the change in the optical properties of the 
porous film, while performing an adsorption/desorption experiment to obtain an adsorption 
isotherm, Figure 4-3 [16]. Ellipsometric parameters, which characterize the change in 
polarization of an incoming light beam upon reflection on the film, are recorded. This 
behavior is determined by the coating’s properties, such as thickness, refractive index or 
dielectric constant. The emitted radiation E, with a defined wavelength λ, can be 
decomposed into a linearly polarized component, Ep, which is oscillating parallel to the 
plane of incidence. The second component, Es, is perpendicular to the plane of incidence and 
parallel to the sample surface. The polarized light falls onto the specimen. After the specular 
reflection at the sample, the radiation passes a second polarizer and goes into the detector. 
The amplitudes of the s- and p- components of the waves, after reflection and normalized to 
their initial values, are measured and result in the amplitude ratio upon reflection, tan(ψ). 
Also the phase shift, Δ, of the waves is evaluated [17]. 
 
 
Figure 4-3 Schematic of the ellipsometric porosimetry. The sample is placed in a vacuum chamber, in which 
the relative pressure of the adsorptive can be controlled. The incoming beam with a specific wavelength λ 
enters the chamber through the optical window. The optical properties, tan(ψ) and cos (Δ), of the porous 
material on the substrate are monitored by ellipsometry during the whole adsorption/desorption process [18]. 
 
It is obvious that these parameters alter when a solvent adsorbs in the porous film. 
Models are applied to calculate the adsorption isotherms from the change in these optical 
properties. First the alteration of adsorptive volume is determined from the shift in refractive 
index over the relative pressure with the so called Lorentz-Lorentz equation [16, 18]. The 
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dependence of the adsorptive volume on the relative pressure is the adsorption isotherm used 
to calculate the PSD. Based on the Kelvin equation for cylindrical pores [9],  
 
 
(4-3), 
 
with pe: equilibrium vapor pressure, p0: saturation vapor pressure, γlv: liquid/vapor surface 
tension of the adsorbed liquid, Vm: molar volume of the condensate, θc: the wetting angle of 
the adsorptive, R: ideal gas constant of 8.3145 J/(mol·K), T: temperature, rk: the radius of the 
meniscus of the adsorptive or Kelvin radius. From that equation the pore size distribution 
can be deduced [16, 18]. Besides the characterization of the PSD in micro- and mesoporous 
coatings [16], EP can deliver additional data about the film thicknesses, refractive indices, 
extinction coefficients and Young moduli.  
 
The EP-measurements and evaluations of the titania films applied in the present study 
were performed by A. Bourgeois at the company SOPRA SA. A wavelength of the incoming 
beam of 633 nm and an incident angle of 60 ° were applied. First the refractive index and the 
thickness of the coatings were determined by conventional ellipsometric measurements 
under nitrogen flow. The open porosity was ascertained by varying the relative pressure of 
the adsorbent toluene and recording the change in refractive index. Furthermore the volume 
adsorbed isotherms were recorded, from which the PSDs using a cylindrical pore model 
were deduced. 
 
4.3.6.2 Small angle neutron scattering 
Radiation scattering from solids can be used to determine porosities and PSDs. The 
scattering arises from variations in the scattering length densities of different materials and 
occurs over distances exceeding the interatomic spacing. Neutron scattering can give 
structural information on length scales of 1 to 100 nm. This technique is established in the 
characterization of hard matter and soft matter [19, 20, 21]. For instance, the pores in metals 
or the conformation of polymers in solution can be examined. In a SANS experiment, a 
beam of collimated neutrons is directed at the sample. Fractions of the incident beam are 
either transmitted, absorbed or scattered by the sample (Figure 4-4). A detector of the 
dimensions dx and dy is positioned at a certain distance from the sample and at a scattering 
angle θSANS. It records the flux of the scattered radiation into a solid angle element [22].  
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Figure 4-4 (a) Illustrates a schemata of a small angle neutron scattering (SANS) experiment. (b) displays the 
scattering vector: the incoming wave with the wave vector ki gets scattered at an object as ks. QSANS is the 
resulting scattering vector [23]. 
 
The value measured during small angle scattering is the scattering intensity, I(QSANS), 
as a function of the modulus of the scattering vector QSANS, like depicted in Figure 4-5 (a). 
I(QSANS) is described as [9] 
 
(4-4), 
 
with QSANS the modulus of the scattering vector: 
(4-5). 
 
 
The variables in Equation (4-4) are np: the pore number density, Vp: pore volume,  
ρp, ρs: scattering length densities of the pores and the solid. P(QSANS) represents the shape 
factor, which depends on the size and shape of the pores. It describes the decay of scattering 
intensity at low QSANS, a domain of the scattering curve also known as the Guinier region. 
S(QSANS) is the interparticle structure factor, describing the effect of interference of the 
scattering waves from individual pores.  
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Figure 4-5 (a) Represents the interparticle structure factor S(QSANS) of diluted (dashed line) and concentrated 
particles of a small angle neutron scattering (SANS) experiment [24]. (b) illustrates the scattering curves for 
diluted (dashed line) and concentrated particles [24]. The Guinier approximation to determine the pore size by 
SANS is shown in (c). 
 
For spherical and dilute pores, that means the pores scatter independently, S(QSANS) 
equals 1, like is illustrated in Figure 4-5 (b). P(QSANS) simplifies for low QSANS, and 
Equation (4-4) can be re-written as 
 
(4-6), 
 
 
with I0: initial beam intensity and Rg: mean radius of gyration of the pores [9]. The mean 
radius of gyration is related to the pore radius, rp, by 
 
 
(4-7). 
 
Equation (4-6) is an example of Guinier’s law, which is valid for QSANS·Rg < 1. To obtain the 
desired PSD from the scattering data, the Guinier plot as depicted in Figure 4-5 (c) is drawn. 
A linear approximation for small QSANS2 delivers the slope of –Rg2/3 and the intercept ln(I0). 
The pore radius rp can then be derived with Equation (4-7) [9].  
 
The evaluation of PSDs of thin, porous films by SANS was first recorded by Wu and 
co-workers [20]. They used a stack of 6 silica films, each with a thickness of 1 µm, to 
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increase the scattering intensity as compared to one single film. The wafer supports did not 
significantly contribute to the signal. A similar method was applied in the present study. 
SANS measurements were performed by J. Kohlbrecher at the Paul Scherrer Institute (PSI), 
Villigen, Switzerland using the SANSII beamline. Three different types of samples were 
analyzed. Silicon wafers without coating and heat treated at a maximum sintering 
temperature of Tmax of 730 °C served as a reference. The titania coatings on wafers in the 
modification of a NRL (w730NRL) and RL (w730RL) were furthermore applied (Table 4-5). 
Prior to analysis, the samples were cut with a diamond knife to each having a surface area of 
1 cm2. Ten samples of one kind were then stacked and placed into the sample holder. The 
neutron beam was directed normal to the surface of the stack in such a way that the 
illuminated area occupied a diameter of 8 mm. The applied wavelengths, which directed the 
length scales to be analyzed in the films, were 0.4549; 0.6369 and 1.9593 nm. They ensured 
the measurement of pore widths between 0-100 nm. The obtained scattering data were 
mathematically fitted to the Guinier approximation. The PSD was therefore deduced from a 
model, assuming dilute, spherical pores.  
 
4.3.6.3 Stereology 
Stereology is based on the observation of cross sections of the solid, recorded by 
optical or electron microscopy, and deducing the porosities [9, 10]. The cross sections of the 
NRL- coatings obtained by FIB milling were subjected to the porosity evaluation with the 
program LINCE, as was explained in Chapter 4.3.1 and Chapter 4.3.5. Instead of measuring 
the grain sizes, the amount of pores were evaluated from the linear intercepts with the so-
called foreign phase, representing the voids.  
 
4.3.6.4 Mercury intrusion porosimetry 
The porosity of different film and bulk samples was measured by mercury intrusion 
porosimetry (MIP) with the low pressure unit Pascal 140 and the high pressure unit Pascal 
440 series (Thermo Electron Corporation). To fill the samples into the glass capillary for the 
analyses, it was necessary to crush them to form fragments in the size of approximately  
1 mm2. The PSDs were deduced from the data by applying a cylindrical pore model. 
Samples were analyzed each in triplicates.  
 
4.3.6.5 Nitrogen sorption porosimetry 
Only b745 bulk samples were analyzed by nitrogen sorption porosimetry (NSP) with 
an ASAP 2010 from Micrometrics. Prior to analysis, the samples were crushed to form small 
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debris, which were filled into the analysis capillary. Subsequent drying for 1 h at 200 °C was 
followed by a second drying step for 16 h at 200 °C under vacuum. Data analysis was done 
using the Barret, Joyner and Halenda (BJH) model and taking into account multilayer 
adsorption in cylindrical pores.  
 
4.3.7 Dilatometry 
The dilatometer (802S, Bähr Thermoanalyse GmbH; Eidgenössische Technische 
Hochschule Zürich, Switzerland) used for the study of the sintering behavior of the TiO2-
nanoparticles was equipped with a quartz displacement bar and a sapphire reference. During 
the experiment, bulk samples were heated with a rate of 1 °C/min in argon atmosphere up to 
1000 °C. The relative length change as a function of time and temperature was recorded. 
 
4.4 Methods for the surface characterization of the thin films 
4.4.1 X-ray photoelectron spectroscopy 
The chemical composition of the TiO2-films on wafer supports (w730NRL, w730RL) 
and on stainless steel supports (ss730NRL, ss730RL) was determined by X-ray photoelectron 
spectroscopy (XPS). Measurements were performed on an AXIS ULTRA instrument 
(Kratos) in ultra high vacuum with a monochromatic Al Kαmono radiation at 15.0 kV and  
150 W. The survey scans were done in an energy range of 0-1100 eV with a pass energy of 
80 eV and an acquisition time of 120 s. The binding energy was referenced to the C 1s 
photoelectron peak at 285.0 eV. Curve fitting and quantification were carried out using the 
processing software CasaXPS, V2.3.14 (Neal Fairley). The elements in the spectra were 
referenced on spectra found in literature [25] and in the XPS database of the National 
Institute of Standards and Technology (NIST) [26].  
 
4.4.2 Contact angle measurements 
The contact angles of the TiO2-suspension with the wafer and the polished 316L 
stainless steel supports were determined by the sessile drop method on an OCA 35, Data 
Physics Instrument. Therefore 2 µl of suspension were pipetted manually on the surface of 
the sample. After 20 s a photo was taken and the contact angle automatically evaluated by 
the software SCA20. The same method was applied to measure the contact angles of the 
titania coatings w730NRL, w730RL, ss730NRL and ss730RL with water. 
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4.4.3 Roughness determinations 
The mean roughnesses, Ra, of the samples w730NRL, w730RL, ss730NRL and 
ss730RL were measured by mechanical profilometry (Alpha Step 200, TENCOR 
INSTRUMENTS). For comparison, the topography of the specimen w730NRL was 
additionally measured by atomic force microscopy (AFM) on a CPII instrument (Veeco). 
4.5 Results 
4.5.1 Structure of the films on stainless steel supports 
The SEM-micrographs of the top views of both, a titania non-reservoir layer (NRL) 
and a reservoir layer (RL), are shown in Figure 4-6. The sample ss730NRL, sintered at a 
maximum sintering temperature of 730 °C, exhibited slightly connected titania particles with 
some small agglomerates (sa) in the size of 300 nm (Figure 4-6 (b)). The TiO2-grains had a 
mean grain diameter of approximately 100 nm. A high porosity, represented by the dark 
grey, interconnected voids, was observed. Big, white spots in Figure 4-6 (a) represent 
agglomerates of the nanoparticles in a size of 1 μm (ba). They were present as agglomerates 
in the titania suspension and were deposited during dip coating. 
 
(a) (b)
(d)(c)
tcr
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10 μm 1 μm
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Figure 4-6 SEM-micrographs of the top views of (a), (b) the titania layer in the NRL-modification on a 
stainless steel support (ba: big agglomerate; sa: small agglomerate). (c) and (d) display the titania reservoir 
layer on a stainless steel support with partially closed reservoirs (pcr) and totally closed reservoirs (tcr). 
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The microstructures of ss730RL depicted in Figure 4-6 (c) and (d) show partially 
closed (pcr) and totally closed reservoirs (tcr), which exhibit a diameter of 1 µm. They were 
created by the burn of the spherical template particles and are surrounded by a porous 
structure, which is equal to the structure of a NRL. Whereas most of the reservoirs were well 
dispersed in the films, a few islands of arranged particles were present. They evolved from 
the agglomerate formation of the polymer beads during their deposition by dip coating. This 
could be could be visualized by optical microscopy, Figure 4-7. The density of microbeads 
was counted to be ∼150000 beads/mm2 geometric surface area.  
 
10 μm
 
Figure 4-7 Optical micrograph of deposited microbeads-templates on a non-sintered reservoir layer. The black 
arrows indicate agglomerated microbeads. 
 
Further analyses of the films on the steel supports turned out to be difficult. It was 
impossible to obtain cross sections of the specimens, revealing information about the 3D 
shape of the macropores, the TiO2-grain sizes and the overall film thickness. But some 
parameters could be deduced by ellipsometry. The measured ellipsometric parameters, 
tan(ψ) and cos(Δ), were fit by a regression model to calculate the thickness of the films: 
561.2 ± 5.5 nm, Figure A-2 in Appendix. However, the quality of the obtained mathematical 
fit was bad and was caused by the interference with signals from the rough, underlying SS 
support [18].  
 
The anatase phase content of the thin films on stainless steel did not depend on their 
morphology NRL or RL. Thin film XRD revealed an anatase phase content of  
73.93 ± 13.22 %wt and 77.87 ± 23.05 %wt of the coatings of the samples ss730NRL and 
ss730RL, respectively. The residual crystal phase was rutile, the high temperature stable 
form of TiO2, Figure 4-8. 
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Figure 4-8 XRD-spectrum of a non-reservoir titania coating on a stainless steel support. A: anatase, R: rutile, 
S: background from the steel support. 
 
One could deduce the theoretical densities of the films from the phase distributions:  
3.97 ± 0.05 g/cm3 for ss730NRL and 3.95 ± 0.09 g/cm3 for ss730RL. It was not possible to 
determine the skeletal and Archimedes densities, as well as the BET-surface areas. The films 
could not be scratched off the supporting steel, which would have been necessary to perform 
the analyses. They adhered too strongly on the support. On one hand, a good adhesion of the 
coatings is beneficial for the application in stents. This issue is discussed in the thesis of A. 
Tourvieille de Labrouhe [27]. On the other hand, this made it difficult to acquire basic and 
important information about the coating’s structure. The porosity could not be determined by 
mercury intrusion porosimetry (MIP) and nitrogen sorption porosimetry (NSP). Small angle 
neutron scattering (SANS), where the coating could have stayed on the support during 
analysis, was not performed of the titania films on steel. A high scattering from the steel 
itself would have overlapped the signal from the porous coating, making an evaluation of the 
PSD impossible [23].  
 
Ellipsometric porosimetry (EP) revealed no exact answer of the porosity of ss730NRL. 
That the porosity was greater than 5.8 % was obtained from an incomplete adsorption 
isotherm using toluene, Figure 4-9. At a high relative pressure, no plateau of the refractive 
index and thus of the adsorbed volume was attained in the isotherm. Hence it was not 
possible to evaluate the PSD from the data. The SS supports were in the following replaced 
by silicon wafers to being able to exploit the film structures. 
 
4.5.2 Structure of the films on silicon wafer supports 
The micrographs of the top views of the TiO2-films in a NRL- and RL-modification, 
which were produced on wafers and sintered with a maximum sintering temperature of  
730 °C, are displayed in Figure 4-10. They look alike the ones of the coatings on the steel 
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supports. The NRL of the sample w730NRL in Figure 4-10 (a) and (b) exhibited a high 
concentration of interconnected, randomly oriented pores between the TiO2-particles. The 
reservoir containing coating in Figure 4-10 (c) and (d), is characterized by randomly 
dispersed, partially closed (pcr) and totally closed reservoirs (tcr). They are embedded in a 
porous structure, which is equivalent to the one of the NRLs, having a high porosity. 
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Figure 4-9 Isotherms as obtained from ellipsometric porosimetry. (a) refractive index isotherm and (b) volume 
adsorbed isotherm of a NRL on stainless steel (“Ads”: adsorption; “Des”: desorption) [18]. 
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Figure 4-10 SEM-micrographs of the top views of (a), (b) the titania layer in the NRL-modification on a wafer 
support (ba: big agglomerate; sa: small agglomerate). (c) and (d) display the titania reservoir layer on a wafer 
support with partially closed reservoirs (pcr) and totally closed reservoirs (tcr).  
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The cross sections of the two thin TiO2-films in the NRL- and RL-modifications are 
depicted in Figure 4-11. Both films exhibited the same thickness of 1.1 µm. This was in 
accordance with the thickness of w730NRL determined by ellipsometry: 1.25 µm. The 
recorded ellipsometric parameters, tan(ψ) and cos(Δ), could be well fitted to a regression 
model to obtain the thickness of the coating (Figure A-3 in Appendix). No significant 
interferences of the signals from the support’s roughness were observed.  
 
(a) (b)
1 μm 1 μm
 
Figure 4-11 SEM-micrographs of the cross sections of the thin TiO2-films created on wafer supports. (a) non-
reservoir layer and (b) reservoir layer with totally closed drug reservoirs. 
 
The ellipsoidal voids of w730RL in Figure 4-11 (b) were entirely surrounded by the 
porous NRL-structure. They exhibited the greatest elongation of 1 μm in the directions 
parallel to the support. They were half that size, 0.5 µm, in the thickness direction of the 
film. The distribution of the TiO2-grain size was deduced from FIB-cross sections,  
Figure 4-12 (a). The median grain diameter of the number distribution, dN50, was 75 ± 8 nm, 
the most frequent diameter, dmode, 65 ± 10 nm and the mean diameter, dmean, 87 ± 11 nm, 
Figure 4-12 (b). This result was in good agreement with the mean diameter calculated from 
specific surface area with Equation (4-2), dBET, of 91.35 ± 5.52 nm, Table 4-6.  
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Figure 4-12 (a) SEM-micrograph of a non-reservoir layer on wafer support as obtained by FIB-milling for the 
grain size analysis. (b) number frequency distribution of the grain sizes in a non-reservoir TiO2-coating, 
obtained by the analysis of the SEM-images after FIB milling. 
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Table 4-6 Characteristics of the TiO2-films in the non-reservoir (NRL) and reservoir layer (RL) modifications. 
Films were sintered on silicon wafer supports, except f800NRL, which was sintered freely without support.  
sample SBET (m2/g) dBET (nm) anatase (%wt) ρtheo (g/cm3) ρS (g/cm3) 
w730NRL 16.68 ± 1.07 91.35 ± 5.52 79.21 ± 6.86 3.95 ± 0.03 n.p. 
w730RL n.p. n.p. 87.07 ± 2.04 3.92 ± 0.01 n.p. 
w800NRL 10.82 ± 0.47 135.93 ± 6.55 41.13 ± 7.81 4.09 ± 0.03  3.58 ± 0.20 
w800RL n.p. n.p. 56.6 4.03 n.p. 
f800NRL 3.91 ± 0.34 365 ± 32.39 3.40 ± 1.35 4.23 ± 0.01 3.83 ± 0.06 
n.p.: not possible to determine, because of a good adhesion or too small quantity of sample available. 
 
Besides the characterization of the titania films, which were sintered at a maximum 
sintering temperature of 730 °C, films prepared at Tmax of 800 °C were also characterized for 
comparison. The structure of the NRLs sintered at 800 °C (w800NRL) is presented in  
Figure 4-13 (a). It featured a similar structure like w730NRL, comprising a high porosity and 
slightly connected TiO2-particles. The mean grain diameter, dBET, was bigger than the one of 
w730NRL: 135.93 ± 6.55 nm. The structure differed furthermore to the one of a film, which 
was scratched off the support prior to sintering at Tmax of 800 °C, f800NRL, in  
Figure 4-13 (b) and Table 4-6. f800NRL exhibited a 2.7 times greater dBET: 365 ± 32.39 nm. 
A high porosity was still present in the freely sintered film. 
 
 
Figure 4-13 SEM-micrographs of (a) a top view of the titania coating sintered at 800 °C on wafer support and 
(b) of a NRL, which was sintered without the presence of the support at 800 °C. 
 
It was demonstrated that the presence of the support during the heat treatment of the 
films has constrained the sintering of the films. This was furthermore reflected by the 
distribution of the crystal phases, anatase and rutile, in the coatings. The NRLs on wafers 
comprised an anatase content of 41.13 %wt after the consolidation, whereas the same film 
sintered without the presence of the support material had a residual amount of anatase left, 
Table 4-6 and Figure 4-14.  
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Figure 4-14 XRD spectra of the TiO2-films (a) sintered on a wafer support at the maximum sintering 
temperature (Tmax) of 800 °C, (b) sintered freely at Tmax = 800 °C and (c) sintered on a wafer support at Tmax = 
730 °C. A: anatase, R: rutile. 
 
The densification in the films, which were sintered at the same Tmax of 800 °C, had 
progressed more in the freely sintered coating f800NRL compared to the one with the 
underlying support. This was verified by their densities. The theoretical and skeletal 
densities, ρtheo and ρS, were both higher for f800NRL than for w800NRL, Table 4-6. It was 
impossible to determine the bulk densities of these samples by the Archimedes method. The 
films were either attached on the support or present as crushed fragments after their 
detachment from the support. For determining the bulk density by the Archimedes method, 
the specimens have to exhibit a block-shape.  
 
The presence of the reservoirs in the coating w800RL, heat treated at Tmax = 800 °C, 
created a slightly higher anatase content of 57 %wt compared to the NRL, Table 4-6. The 
same tendency was apparent for the samples sintered at 730 °C: 79 %wt vs. 87 %wt for 
w730NRL and w730RL, respectively.  
 
To determine the porosity of the thin films, ellipsometric porosimetry (EP), small 
angle neutron scattering porosimetry (SANS) and mercury intrusion porosimetry (MIP) were 
chosen. The adsorption isotherms from the EP measurement of the sample w730NRL were 
deduced from the ellipsometric parameters, which are displayed in Figure A-3, Appendix. 
The isotherms reached no plateau at the high partial pressure domain, Figure 4-15 (a), (b). 
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The adsorption of toluene in the pores of the NRL-structure was incomplete. Hence the 
porosity of the sample could not be determined exactly. But it was estimated to be > 34.4 %. 
The pore size distribution (PSD) could not be accurately evaluated due to the incomplete 
adsorption, but the smallest pores in the coating had a width of 40 nm, Figure 4-15 (c).  
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Figure 4-15 Graphs recorded during ellipsometric porosimetry. (a) the refractive index isotherm, (b) the 
volume adsorbed isotherm and (c) the pore size distribution of the TiO2-non-reservoir layer on wafer, (“Ads”: 
adsorption) [18]. 
 
The scattering intensity curves obtained by the SANS-porosimetry of the w730NRL 
and w730RL coatings are depicted in Figure 4-16. They could be fitted to a mathematical 
model, which describes the scattering intensity as a function of spherical voids in-between 
dilute particles. Applying this model was favorable, because the titania particles had a 
spherical shape and they were slightly connected, as was observed in the SEM-micrographs 
(Figure 4-10, Figure 4-11). The voids in between the grains represented the inverse of the 
TiO2 and hence were assumed to be spherical. 
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Figure 4-16 Scattering intensity curves of the TiO2-coatings in the non-reservoir layer (NRL) and reservoir 
layer (RL) modifications on wafers and sintered at a maximum temperature of 730 °C, as obtained in the small 
angle neutron scattering (SANS) measurements. Represented are the measured data and their mathematical fits 
as a function of the scattering vector. 
 
The PSDs of the NRLs and RLs on wafers could be deduced from the scattering 
curves, Figure 4-17 and Table 4-7. The pore sizes of the NRL ranged from 20-100 nm, 
whereas the median pore diameter, dv50, was 45.21 nm. The RL was characterized by a 
broader pore size distribution of 17-200 nm and a dv50 of 60.39 nm.  
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Figure 4-17 Pore size distributions of (a) the non-reservoir titania layer and (b) the TiO2-reservoir layer on 
wafer supports, as obtained from the small angle neutron scattering porosimetry.  
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Table 4-7 Median pore diameters, dv50, and most frequent pore diameters, dmode, of several coatings, as 
measured by small angle neutron scattering (SANS), stereology and mercury intrusion porosimetry (MIP). 
Values were obtained in two different pore width regimes for MIP: (1) 0-100 or (2) 0-1000 nm. 
sample method range of pore diameters (nm) dv50 (nm) dmode (nm) porosity (%) 
w730NRL SANS 0-100 45.21 44.11 - 
w730RL SANS 0-100 60.39 53.45 - 
w730NRL stereology - - - 22.83 ± 6.78 
w730NRL MIP 0 – 1000 82.70 87.37 64.45 
 MIP 0 - 100 76.34 87.37 41.91 
w800NRL MIP 0 – 1000 138.31 ± 15.11 180.68 ± 7.04 55.04 ± 8.19 
 MIP 0 - 100 67.42 ± 4.15 95.69 ± 7.47 16.07 ± 2.33 
 
The porosity obtained by stereology of w730NRL, in which SEM-micrographs of 
cross sections were evaluated by image analysis, was 22.83 %, Table 4-7. The recorded pore 
size distributions of w730NRL and w800NRL by MIP were bimodal, such as displayed in 
Figure 4-18. One peak was detected for all film specimens at pore diameters below 1000 nm 
and a second one above that value.  
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Figure 4-18 Graph of the bimodal pore size distribution of a non-reservoir titania layer, sintered with a 
maximum temperature of 800 °C, as obtained by mercury intrusion porosimetry. 
 
The pore diameters in the region greater than 1000 nm were excluded from the PSD 
evaluation, because they were caused by an artifact. The films had to be scratched off the 
support prior to analysis and were given as a powder with unequal film fragments into the 
pressure capillary for MIP-analysis. The application of pressurized mercury caused the 
Chapter IV  Characterization of the structured titania films 
 
 
57 
compactation of the loosely packed fragments of the coatings at the beginning of the analysis 
and the filling of the inter-fragment voids. This generated the presence of the bigger pores in 
the PSD. The cut off pore diameter of 1000 nm for the analysis was chosen, because the 
coatings had a thickness of 1.2 µm and the pores could not exceed this length. This was 
furthermore validated by the SEM-images of the NRL in Figure 4-11 (a), where no 
continuous pores through the whole coating were visible.  
 
The pore diameters of w730NRL in the PSD depicted in Figure 4-19 (a) extended from 
a few nanometers up to 250 nm. The coating was hence composed of mesopores, having 
pore widths of 2-50 nm, and macropores, with pores greater than 50 nm. The median pore 
diameter from the volume distribution, dv50, of pores in the range of 0-1000 nm was  
82.70 nm. The one of the smaller interval (0-100 nm pore diameter) was 76.34 nm, Table 
4-7. The characteristic pore diameters in the range up to 100 nm were calculated to being 
able to compare them with the ones deduced by SANS. Because the maximum pore 
diameter, which could be detected by SANS, was ∼100 nm. 
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Figure 4-19 Pore size distributions of the non-reservoir layers sintered at a maximum temperature of (a) 730 °C 
and (b) 800 °C. Measurements were performed by mercury intrusion porosimetry.  
 
The pore size distribution of the NRL, which was heat treated at 800 °C (w800NRL), 
in Figure 4-19 (b) was in the same range like the one of w730NRL, but not as narrow. In the 
pore diameter regime up to 1000 nm the dv50 was 138.31 nm, in the interval up to 100 nm, 
dv50 was 67.42 nm. The porosities of the coatings were not computed by the MIP software. 
Values, which were automatically calculated from the MIP-run, like the specific surface area 
and the density, were invalid. They included data points from the big pore sizes (> 1000 nm), 
which were artifacts due to the sample preparation. Hence the porosities for both types of 
NRLs were calculated from the density of a cylindrical bulk, representative for the coating, 
and from the pore volume measured up to the critical pore diameters of either 100 or  
1000 nm. The density of the cylindrical bulk was 2.05 g/cm3 (c.f. following chapter). The 
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cylindrical bulk was prepared by slip casting and sintered at a maximum sintering 
temperature of 740 °C (b740). A porosity of 64 % for w730NRL and of 55 % for w800NRL 
in the interval of 0-1000 nm was obtained, Table 4-7. The porosity in the smaller regime was 
accordingly lower: 42 and 16 %, respectively. 
 
In all previously mentioned pore size evaluations NRL-modifications of the TiO2-films 
were used except in SANS porosimetry. But SANS did not deliver the PSD of the reservoirs, 
because their size exceeded the maximum scattering length of 100 nm. The reservoirs in the 
MIP measurements were destroyed during the detachment of the films from the supports and 
thus delivered false results. To get an estimation, how the presence of the reservoirs in a 
certain density and size could influence the overall porosity of the titania films, calculations 
with the parameters listed in Table 4-8 were carried out. The values of the parameters are 
based on the porosity measurements performed on the NRLs and on the SEM-micrographs 
of cross sections of RLs, Figure 4-11. The reservoir size factors represent the ratio of the 
reservoir size after heat treatment in a certain direction, to the size of the initial spherical 
templates of 1 μm. The thickness of the nanoporous layer represents the distance between the 
upper edge of the reservoir to the top of the coating’s surface, Figure 1-5. The base layer 
corresponds to the span between the lower edge of the reservoir to the surface of the support. 
 
Table 4-8 Parameters used for the calculation of the total film porosity as a function of reservoir size and 
density. 
entry values 
porous volume fraction 50 % 
reservoir size factor after shrinkage, x direction 88 % 
reservoir size factor after shrinkage, y direction 59 % 
nanoporous layer thickness 0.329 µm 
base layer thickness 0.250 µm 
 
The results of the calculation are depicted in Figure 4-20. A higher reservoir density 
results in a higher total porosity of the film, Figure 4-20 (a). However, a lower density of 
bigger reservoirs significantly increases the porosity of the layers. This is moreover 
demonstrated in Figure 4-20 (b), where the ratio of the pore volume occupied only by the 
reservoirs to the total pore volume is plotted as a function of reservoir density. A RL with a 
reservoir width of 1 µm and a density of 150000 reservoirs/mm2, which is the specification 
of the fabricated RLs in the present study, contains theoretically 3 % more porosity than the 
NRL. By increasing the size of the reservoirs to 2 µm and keeping the same reservoir 
density, the RLs occupy 16 % more pore volume than the NRLs. When increasing the 
reservoir width further, a lower macropore density can create high porosities. The overall 
porosity is then strongly influenced by the increase in layer thickness and consequently by 
the porosity of the porous structure surrounding the reservoirs. 
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Figure 4-20 (a) total porosity of the TiO2-films as a function of reservoir density and size. (b) Volume 
occupied by the reservoirs referenced to the total pore volume and as a function of reservoir density and size. 
 
4.5.3 Sintering behavior and structure of the bulks 
For understanding the sintering behavior of the TiO2-nanoparticles in a bulk green 
compact, in situ X-ray diffraction (XRD) and dilatometry measurements were conducted. 
The XRD spectra in Figure 4-21, recorded during the sintering of a slip cast bulk cylinder, 
show the progress of the phase transition from anatase (A) to rutile (R) during the heat 
treatment. Until the end of the first temperature plateau of 500 °C, no initiation of the phase 
transformation was present. The crystal phase was anatase. The phase transition started at the 
second heating interval from 500 up to 800 °C. The amount of anatase present before the 
plateau at a maximum sintering temperature, Tmax, of 800 °C of 56.2 %wt diminished until 
the end of the plateau to a value of 15.9 %wt. After the cooling to room temperature, rutile 
and a negligible amount of anatase (3.8 %wt) were remaining. 
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Figure 4-21 In situ XRD measurements of a bulk TiO2-sample. The progress of the phase transformation from 
A: anatase to R: rutile as a function of temperature profile is illustrated (r1, r2: heating/cooling rate). 
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These findings were compared with the result from the dilatometry run of a cylindrical 
bulk TiO2-specimen, Figure 4-22. The fist graph shows the relative change in length as a 
function of increasing temperature. Several rapid changes in length were observed and could 
be pointed out in more detail in the graph of the sintering rate, Figure 4-22 (b). By increasing 
the temperature from 23 °C to 500 °C, a slow, steady decrease in length of the bulk sample 
and changes in the sintering rate were recorded. This observation could be correlated to the 
evaporation of residual water from the specimen and to a re-orientation of the titania 
particles. Subsequently the shrinking rate slowed down until it increased at 780 °C,  
representing the phase transition from anatase to rutile, as was also detected by in situ XRD. 
From a temperature greater than 860 °C, the shrinkage rate augmented and reached its 
maximum of 7.1 µm/min at 1007 °C. The densification was taking place in that temperature 
regime. 
 
In the following, TiO2-bulks were to be prepared exhibiting identical properties like 
the thin NRLs on wafers. They were to be used for porosity and PSD determinations by MIP 
and NSP, representing the features of the films. Because the standardized measurements with 
the NRL-material were too elaborate: 10 coated wafers of a diameter of 12 cm had to be 
prepared for one measurement. The bulks, of which a high quantity could easily be prepared 
by slip casting, were hence favorable. In situ XRD and dilatometry limited the range of the 
maximum sintering temperature of the bulks to 700 < Tmax < 800 °C to yield anatase and 
rutile simultaneously in the bulks. Additionally this temperature range was in the focus of 
interest to study the mechanical properties of the coating, cf. Thesis A. Tourvieille de 
Labrouhe [14]. 
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Figure 4-22 Dilatometry of a bulk TiO2-sample in the NRL-modification. In (a) the relative change in length as 
function of time and temperature and in (b) the sintering rate are presented. 
 
In a first step, the bulk samples produced by slip casting and sintered with Tmax of  
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800 °C (b800) were characterized. The microstructure of b800 in Figure 4-23 looks alike the 
one of the freely sintered film (f800NRL), Figure 4-13 (b). The grains in the specimen were 
as big as 700 nm or much smaller. The mean grain size, dBET, obtained from the specific 
surface area was 356 nm and was equal to the one of f800NRL, Table 4-6. Only rutile was 
present in b800. The theoretical density was accordingly 4.24 g/cm3. Its skeletal density 
measured by pycnometry was 3.96 g/cm3.  
 
1 μm
 
Figure 4-23 SEM-micrograph of the bulk TiO2 sintered at a maximum temperature of 800 °C. 
 
The dependence of the maximum sintering temperature of the bulks on their structural 
parameters is demonstrated in Figure 4-24. The grain size dBET increased with augmenting 
Tmax from smaller than 100 nm at 740 °C up to 360 nm at 770 °C. The shape of the curve of 
the anatase phase content was inversely. 70 %wt anatase were measured for the specimens 
sintered at 700 °C. With increasing Tmax, the content decreased and only rutile was present in 
the bulks sintered at Tmax of 800 °C. High standard deviations were recorded for the phase 
content in the temperature range of 700 to 750 °C. The grain size dBET of the sample b750 
exhibited a high standard deviation. But lower ones were recorded for the specimens sintered 
at Tmax lower than 750 °C or higher than 770 °C. Hence the high standard deviations could 
be attributed to the region of the phase transformation of TiO2.  
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Figure 4-24 Grain size evaluation and anatase phase content of TiO2-bulks with a NRL-structure as a function 
of maximum sintering temperature.  
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The porosities of the bulk samples could be deduced from their densities according to the 
formulas  
 
(4-8), 
 
 
(4-9), 
 
with ρArch: Archimedes density, ρtheo: theoretical density and ρS: skeletal density of the 
porous bulks. The total porosity of the sintered bulk samples of 50 % does not change 
significantly in the temperature interval of 700-800 °C, Figure 4-25. A slight decrease was 
recorded for the specimens sintered at 820 °C. The open porosity of 42 % stayed constant for 
the bulks in the whole temperature range of interest.  
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Figure 4-25 Total and open porosities of the bulk TiO2-samples, as was calculated from their densities.  
 
The following aim was to produce a high quantity of bulk material with identical 
properties like the NRLs, sintered on wafer with a maximum temperature of 730 °C  
(w730NRL) to perform porosimetry measurements. The knowledge of the sintering behavior 
of the TiO2-bulks helped to select the production parameters of the bulks, which are to 
represent the NRLs. The specific surface area was the criteria chosen to select the equivalent 
bulks, because it is linked to the grain size and the phase composition. It was alike for the 
films w730NRL and the bulks b740, as depicted in Table 4-9. The bulk material calcined at 
740 °C was hence used to measure the pore size distribution by MIP. 
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Table 4-9 Specific surface areas, SBET, of the TiO2-films on wafer supports and of the TiO2-bulk samples, 
which hold equivalent properties. 
sample maximum sintering 
temperature (°C) 
SBET (g/m2) 
w730NRL 730 16.68 ± 1.07 
b740 740 18.11 ± 3.72 
 
A representative graph of the bimodal PSD of b740 obtained by MIP is pointed out in 
Figure 4-26. One peak of the volume distribution was detected below 100 nm, a second one 
above that value. The results of the three replicas are summarized in Table 4-10. Two pore 
diameter ranges were again accounted for in the evaluation: (1) 0-1000 nm and  
(2) 0-100 nm. They were selected to being able to compare the results with the ones of the 
films, which were measured by SANS and MIP. The pore widths exceeding 1000 nm are 
again excluded from the interpretation, because they represent artifacts in the PSD related to 
the compression of sample fragments. The median pore width, dv50, of two replicas of b740 
in the range of 0-1000 nm was 50 nm, whereas for the third one 270 nm was measured. The 
total pore volume of the first two replicas was predominated by the pores below 100 nm. The 
smaller pores below 100 nm occupied more pore volume in the third analogue. However, the 
total porosity of all replicas in the pore size interval up to 1000 nm was 47.10 ± 7.63 %.  
 
0
20
40
60
80
100
120
140
160
0 100 200 300 400 500 600 700 800 900 1000
Pore diameter (nm)
dV
/lo
g(
dR
)
0
20
40
60
80
100
120
C
u
m
ulativ
e
freq
u
en
cy(%
)
 
Figure 4-26 Pore size distribution of the TiO2-bulks sintered at a maximum sintering temperature of 740 °C, as 
obtained by mercury intrusion porosimetry. 
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Table 4-10 Pore sizes and porosities as obtained by mercury intrusion (MIP) and nitrogen sorption porosimetry 
(NSP) of the bulk TiO2-specimens sintered with a maximum temperature of 740 °C (dv50: median pore 
diameter, dmode1,2: most frequent pore diameter 1, 2). 
sample method range of pore 
diameters (nm) 
dv50 (nm) dmode1 (nm) dmode2 (nm) porosity (%) 
b740_1 MIP 0-1000 45.61 43.97 290.52 50.45 
  0-100 45.54 43.97 - 40.67 
b740_2 MIP 0-1000 55.67 58.18 289.51 51.70 
  0-100 53.79 58.18 - 28.32 
b740-3 MIP 0-1000 271.47 47.16 271.47 52.52 
  0-100 52.67 47.16 - 3.04 
b740-1 NSP 0-100 59.47 52.10 - 38.86 
b740-2 NSP 0-100 49.59 30.26 - 27.03 
b740-3 NSP 0-100 65.90 28.77 - 8.64 
 
The PSD of b740 was additionally measured by nitrogen sorption porosimetry (NSP) 
for comparison. The results are displayed in Table 4-10 and in Figure 4-27. The monomodal 
distribution exhibited a median pore diameter, dv50, of 58.32 ± 8.21 nm. The porosity, 
deduced from the pore volume with pore diameters up to 100 nm, was 30 % for two of the 
replicas and as small as 9 % for the third specimen. In addition to the characterization of the 
intrinsic structure of the films and bulks, the surface properties of the coatings were 
analyzed. 
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Figure 4-27 Pore size distribution of the TiO2-bulk, sintered at a maximum temperature of 740 °C, as measured 
by nitrogen sorption porosimetry. 
 
4.5.4 Surface characterization of the thin films 
The findings of the chemical analysis of the TiO2-coated stainless steel (SS) by X-ray 
photoelectron spectroscopy (XPS) are displayed in Figure 4-28. The intensity of emitted 
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photoelectrons from the sample as a function of their binding energy was recorded. The 
peaks labeled are consistent with the characteristic peaks of the electron configuration of the 
electrons within the specific atoms, e.g., O 1s or Ti 2p. The number of detected electrons in 
each of the characteristic peaks is directly related to the amount of element within the 
volume irradiated. The spectra of the NRL and RL featured peaks corresponding to titanium 
(Ti), oxygen (O), carbon (C) and nitrogen (N). Vanishing small peaks of chromium (Cr) and 
iron (Fe) were also detected. The following deconvolution of the peaks revealed that Ti is 
present in the coating as stoichiometric TiO2. Cr and Fe were bound as metal oxides and 
were present as trace amounts. C and N were contaminations on the coating.  
 
 
Figure 4-28 (a) X-ray photoelectron spectra of the TiO2 thin films on stainless steel supports in the non-
reservoir modification and sintered at a maximum temperature of 730 °C (ss730NRL), (b) the corresponding 
deconvolution of the Ti-peak. In (c), the spectra of the reservoir layer ss730RL and in (d) the deconvolution of 
the Ti-peak are represented. 
 
The XPS spectra of the titania coatings calcined on the wafer support are depicted in 
Figure 4-29. The coating consisted of stoichiometric TiO2, oxygen and carbon. The latter 
was contamination on the coating’s surface. 
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Figure 4-29 (a) X-ray photoelectron spectra of the TiO2 thin films on wafer supports in the non-reservoir 
modification and sintered at a maximum temperature of 730 °C (w730NRL), (b) the corresponding 
deconvolution of the Ti-peak. In (c), the spectra of the reservoir layer w730RL and in (d) the deconvolution of 
the Ti-peak are represented. 
 
The arithmetic mean roughnesses, Ra, of various titania coatings and of the supports 
are listed in Table 4-11. The coatings on SS exhibited a Ra of 76.38 nm and 54.13 nm for the 
NRL (ss730NRL) and the RL (ss730RL) modification, respectively. The roughness of the 
NRL on the wafer support was 16.70 nm and for the RL 25.30 nm. A mean roughness Ra of 
22.74 nm of w730NRL was additionally deduced from AFM-microtopography, Figure 4-30. 
The roughness of the support materials influenced the coating’s roughness. Whilst the wafer 
with Ra smaller than 5 nm had less impact on the film’s roughness, the stainless steel support 
with Ra of 75.25 nm gave distinction to the topography of the titania coating in the sample 
ss730NRL, Table 4-11. 
 
Table 4-11 Mean roughnesses, Ra, of the TiO2-coatings on wafers and stainless steel, as well as of the supports. 
Contact angles, θc, of the coatings with water and of the supports with the TiO2-suspension TP1. 
sample ss730NRL ss730RL w730NRL w730RL wafer stainless steel 
Ra (nm) 76.38 ± 5.19  54.13 ± 6.54 16.70 ± 1.96 25.30 ± 4.28 < 5 75.25 ± 19.19 
θc (°), water 45.33 ± 22.70 53.06 ± 17.08 16.43 ± 3.63 17.91 ± 3.10 - - 
θc (°), TiO2-
suspension 
- - - - 35.05 ± 2.44 34.15 ± 5.38 
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Figure 4-30 AFM-topography of the non-reservoir titania film on a wafer support, heat treated at a maximum 
temperature of 730 °C.  
 
The contact angles θc of the NRL and RL titania coatings on wafers with water showed 
similar values: 16.43 ° and 17.91 °, respectively, Table 4-11. The TiO2-coatings on stainless 
steel exhibited a more hydrophobic character with θc of 45.33 ° for ss730RL and of 53.06 °  
for ss730RL. The high standard deviations of 20 ° of the coatings on steel resulted from the 
measurements of specimens produced in different batches. One sample itself did not exhibit 
these high deviations in θc. To check if the thickness of the TiO2-film deposited by dip 
coating was influenced by the wettability of the colloidal TiO2-suspension with the supports, 
their contact angles were measured. They were identical with θc of 35.05 for the wafer and 
of 34.15 ° for the stainless steel.  
 
4.6 Discussion 
4.6.1 Influence of the support type on the characteristics of the films 
The thin nanostructured TiO2-coatings were successfully created on 316L stainless 
steel (SS) or silicon wafer supports by multi-step dip coating followed by a heat treatment. 
They consisted of either a homogeneous meso- and macroporous non-reservoir layer (NRL)-
structure or of drug reservoirs embedded in that structure to create a reservoir layer (RL). 
The ellipsoidal drug reservoirs featured a maximum elongation of 1 μm, equivalent to the 
diameter of the polymer templates used to produce them. The RL is to be applied on metal 
stents as a drug carrying matrix to create a drug-eluting stent (DES). It exhibited a good 
adhesion to the SS support, which is recommended for its usage in stents, because stents 
experience a deformation of max. 10 % during stenting [28, 29]. The adhesion of the film 
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might have been caused on one hand by the high contact area between the TiO2-
nanoparticles and the support. On the other hand, the built-up of an intermediate layer 
between the steel and the TiO2 can have further endorsed the adhesion. This interlayer may 
be composed of chromium oxide and complexes made of iron and other elements, caused by 
diffusing metal atoms from the steel during the sintering [14]. This topic was in detail 
investigated by A. Tourvieille de Labrouhe [14]. Because of the strong adhesion, it was 
impossible to scratch the film off the steel support, which would have been necessary to 
conduct common analyses like BET, pycnometry or mercury intrusion porosimetry (MIP). 
Cutting the steel samples to produce cross sections, which would have given information 
about the thickness of the coating and the structure of the pores in thickness direction, failed. 
 
The coatings produced on silicon wafer supports were a good model to represent the 
coating’s structure on the steel support. They were used to acquire the structural information 
of the coating. The support material type itself did not have a significant influence on the 
structure of the coating, as was seen in the SEM-micrographs of the top views of the 
coatings on either steel or wafer supports in Figure 4-6 and Figure 4-10. The coatings 
produced on either type of support exhibited TiO2-grain diameters smaller than 100 nm. 
They were slightly connected via neck formation created during sintering. Another 
parameter which proved the similarity of the coatings on wafers to the ones on steel was the 
anatase phase content measured by X-ray diffraction. It was 73.93 ± 13.22 %wt for the NRL 
on SS and 79.21 ± 6.86 %wt for the NRL on wafer support. The coatings, which contained 
reservoirs, exhibited 77.87 ± 23.05 %wt anatase when prepared on SS and 87.07 ± 2.04 %wt 
when fabricated on wafer. The high standard deviations of the films on SS were caused by 
the background signal from the steel support, which was recorded in the XRD spectra in 
Figure 4-8.  
 
Small agglomerates of the TiO2-nanoparticles with a size of 300 nm were detected in 
the micrographs of the coatings on either support, labeled as “sa” in Figure 4-6 and Figure 
4-10. Agglomerates are unfavorable for the processing, since they can lead to differential 
sintering and therefore non-uniform microstructures [1]. The initial powder from the supplier 
had a mean particle size, dBET, of 21.5 nm. It was electrostatically stabilized with ammonia in 
a water based phase at a pH of 10.5. The particles of this suspension possessed a monomodal 
particle size distribution with a median pore diameter, dv50, of 60 nm, cf. Table 4-1 and 
Figure A-1 in Appendix. Small agglomerates of initial particles were hence formed in the 
suspension. However, some agglomerates detected in the coating after sintering had a 
diameter of 1 μm, delineated with “ba” in Figure 4-6 and Figure 4-10. These big 
agglomerates must have been present in the suspension and were deposited during dip 
coating. An increase in the time of ultrasonication of the titania suspension prior to usage did 
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not eliminate these residual agglomerates. The agglomerates might have been generated by 
the addition of the polyvinyl alcohol (PVA) binder into the suspension. It is a molecular 
binder, which adsorbs on the TiO2-particles via hydrogen bonding between its OH-groups 
and the particle surface. An intermolecular bonding, due to the dipolar attraction of the OH-
groups, builds additionally a polymer-polymer bonded network, in which the particles are 
dispersed [2]. PVA is a degradable polymer, which has good film forming properties. This 
makes it a favorable ingredient of the suspension for applying the TiO2-films onto complex 
geometries like a stent [2]. The specific PVA used had a degree of hydrolysis of  
96.8 to 97.6 %mol [30]. A higher hydrolysis rate promotes its tendency for crystallization 
[31]. Therefore the binder might have re-crystallized after a certain time in suspension. This 
might have resulted in a local segregation of the suspension and the TiO2-particle clusters 
might have been formed, which were then deposited in the film. However, suspensions were 
prepared freshly before usage and it was assumed that PVA was perfectly dissolved. It is 
important in further studies to control the suspension’s properties over time by 
thermogravimetric analysis (TGA) and particle size measurements. Maybe it would be 
optional to test other binders, like poly aspartic acid or PVA with a lower hydrolysis grade, 
to reduce its re-crystallization tendency.  
 
Moreover, attention has to be given to the physical properties of the binder. The 
viscosity of the suspension depends besides its solid content on the type of binder used: a 
lower molecular weight of the binder reduces the viscosity [32]. This has an influence on the 
thickness of the films fabricated by dip coating, as can be deduced from the Landau-Levich 
equation, Equation (4-1). The thickness of the film decreases with lowering viscosity of the 
suspension, whilst the other parameters are kept constant. Equation (4-1) also illustrates that 
the liquid vapor surface tension, γLV, influences the thickness of the deposited film. It is 
related to the wettability of the suspension with the support and depends on the contact angle 
between them. The Young equation relates these parameters: 
 
(4-10), 
 
with γSV solid/vapor, γSL solid/liquid surface tension and θc contact angle [33]. The contact 
angles of the TiO2-suspension with the wafer and steel were equal: 35 °. Therefore one 
would expect identical wetting properties and the same film thickness on the two types of 
supports. The films on steel nevertheless were 500 nm, the ones on wafers 1.2 μm in 
thickness. The process parameters were identical. It could be excluded that a small change in 
withdrawal speed, which was adjusted manually on the dip coater, could have caused this 
effect. Even if a small variation of ± 2 mm/min in the withdrawal speed of 90 mm/min can 
)cos( cLVSLSV θ⋅γ+γ=γ
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cause a thickness change of the wet TiO2-layer of ∼ 20 nm, the evaporation of 90 %wt water 
from it would leave only a negligible change in thickness in the dried film. However, an 
effect observed by A. Tourvieille was the saturation of the film thickness on wire shaped 
steel supports after multiple dips. The phenomenon is not well understood, but might also 
have been the reason for the thinner coatings on the steel supports in this study. 
 
The TiO2-coatings produced on wafers instead of on SS initiated ways to characterize 
the NRL- and RL-structures, which were not viable when steel supports were used. It was 
feasible to easily cut cross sections with a diamond knife and consequently to acquire SEM-
images of them. Hence one could measure the coating’s thickness: 1.2 μm. The drug 
reservoirs were not spherical, but ellipsoidal with the shortest axis of 500 nm in the thickness 
(z) direction and the longest one of 1 μm in the plane parallel to the support. This 
phenomenon can be explained by constrained film sintering [34]. In presence of a substrate, 
the direction of the film shrinkage is the thickness direction due to the directed mass 
flow/diffusion during sintering [35]. Shrinkage does less occur in the planes parallel to the 
support (x and y direction, Figure 1-5).  
 
The influence of constrained sintering on the film’s structure was further pointed out 
by comparison of the properties of the films sintered without support (f800NRL) and with 
support (w800NRL). The freely sintered specimens showed a smaller specific surface area, a 
higher grain size and only a trace amount of anatase compared to w800NRL. The features of 
f800NRL equaled the properties of the NRL-structure in the bulk specimen b800: both were 
mainly composed of rutile and had a dBET of 360 nm. These samples were more progressed 
in sintering than the constrained films on the supports. In constrained film sintering, a 
geometrical constraint, such as the presence of the support, gives rise to bi-axial stresses in a 
coating [35, 36, 37, 38]. They can be caused on the one hand by the film forming process. 
Drying for instance results in shrinkage strains in particulate films on rigid supports. They 
will be increased by following densification. On the second hand, different expansion 
coefficients of the film and the support at elevated temperatures can contribute to directed 
strains in a film [34]. The rigid support, such as the silicon wafer or SS, can exert a tensile 
stress on the film at the interface between the substrate and the coating. It is opposed by the 
sintering stress acting to produce in-plane, that means parallel to substrate, shrinkage in the 
film [35, 37, 39, 40]. The sintering stress, as the driving force for densification, is the stress 
generated by interfacial energies acting over curved surfaces in a sintering system and can be 
described by the Laplace equation [2]: 
 
(4-11), 
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+⋅γ=σ
21 r
1
r
1
Chapter IV  Characterization of the structured titania films 
 
 
71 
with σ: stress over a curved surface, γ surface energy, r1 and r2 the radii of curvature of the 
surface. If one now imagines the initial sintering of two identical spheres, a neck forms 
between them. The stresses arising from the curvature of the interparticle neck is different to 
the ones along the surface away from the neck. This stress gradient is the driving force of 
mass flow into the neck during sintering. As a result, the grains grow and the surface area is 
reduced. The system reduced its surface energy. However in the final stage of sintering, the 
sintering stress is composed of two terms: one is attributed to the grains and the second one 
to the pores: 
 
(4-12), 
 
 
with γss solid/solid grain boundary energy, γsv solid/vapor surface energy, dg: grain size, dP: 
pore size. For small gain sizes, the first term is dominant. For small pore sizes, which arise 
when the sintering is progressed, the second term is dominant [41]. From this explanation it 
gets clear that the particle size and the particle arrangement in a powder compact play an 
important role in neck formation and thus in densification. It can be used to explain the 
phenomenon of delayed densification in the constrained films. The arrangement of the 
primary ceramic particles can be described by their coordination number. That is the number 
of nearest neighbors of a particle having actual physical contact [36]. The higher the 
coordination number is, the higher is the number of necks formed during sintering and thus 
the higher is the densification and the crystallite growth. A difference of the coordination 
numbers of the freely and the constrained sintered TiO2-films in the present study have 
contributed to the different consolidation. This difference did not arise from the drying 
process, because both films were prepared by the same dip coating technique. The only 
difference between the both was that f800NRL was removed from the support prior to 
sintering. The difference of the coordination number aroused in the initial stage of sintering, 
where the necessary re-arrangement of the TiO2-particles was partially inhibited in 
w800NRL by the particle-support interaction. This resulted in a relatively low number of 
physical contact points in the constrained film and consequently in a lower sintering activity, 
crystallite growth and phase transition [36]. Indeed a higher anatase content-the low 
temperature stable form of TiO2-in w800NRL was detected compared to f800NRL. The 
anatase to rutile phase transition depends on the primary particle size, as well as on the 
coordination number [11]. This issue will be discussed later in this chapter. Besides the 
particle size and their arrangement, the stiffness of the support and the particle’s attachment 
to it might have prohibited the phase formation to rutile, because it requires a contraction 
[42]. 
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Another effect which is related to constrained film sintering is the development of a 
directional anisotropic structure in the film [43]. Garino and Bowen suggested that particle 
motion is prohibited laterally in the planes parallel to the support. This leads to directional 
pore growth, as the centers of two adjacent regions of relative high density remain separated 
[35]. Guillon et al. investigated the microstructure change in dip coated alumina thin films 
and reported an anisotropy. With increasing densification, the pores got anisomeric and 
oriented along the thickness direction [43], Figure 4-31. SEM-micrographs of the TiO2-film 
on wafer support (w730NRL) in Figure 4-12 (a) revealed a homogeneous meso and 
macroporous structure with no directional pores. The formation of an anisotropy was not as 
progressed in the initial state of sintering, in which the present films were sintered, as in the 
intermediate or end phases of sintering. The TiO2-films might furthermore have been too 
thin to observe an anisotropy. Because the films under investigation by Guillon et al. were 
sintered in the final stage of sintering and were 10 times thicker than the present ones. They 
recorded a well distinct anisomery with a lower pore density in the region distant to the 
support and an increased mean grain size compared to the structure close to the support. 
Moreover the pores oriented along the thickness-direction of the coating, Figure 4-31.  
 
 
Figure 4-31 Gradients of the pore density and pore orientation along the thickness direction of an alumina thin 
film prepared by dip coating and having a relative density of 97 % [43]. 
 
The following aspects hence have to be kept in mind when optimizing the structured 
TiO2-coating for its application in a stent. An increase in the film-thickness for achieving a 
higher drug-load, or an augmentation of the sintering temperature to improve the mechanical 
properties, can result in the generation of an anisotropy in the coating. Most likely different 
grain sizes and oriented pores will evolve. Directed pores in the films might increase the 
drug-release, because their smaller tortuosity will decrease the diffusion path of the drug 
molecules out of the coating.  
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In our days it is still a challenge to determine the pore size distribution (PSD) and 
porosity of thin, structured, highly porous films. Several methods were employed in the 
present study to ascertain these values, because they are essential to assess the drug-load and 
release capability of the coating. Ellipsometry porosimetry (EP) is a fast, cheap and non 
destructive method to determine open pore sizes in the range of pore diameters of  
0.32 to 65 nm and the overall open porosity of thin films [16]. In this study EP did not reveal 
the exact PSD and porosity of the NRLs on SS and on wafer supports. Only the onset pore 
diameter of 40 nm was detected in the coating on the wafer, and a porosity of greater than 34 
% was deduced. The porosity and the pore widths in the titania coatings exceeded the limit 
of detection. The adsorbate toluene did not saturate the total pore volume and the adsorption 
isotherms were incomplete. One way to measure the PSD by EP in the future might be to use 
another adsorbate, which has a longer carbon chain than toluene. This can be illustrated by 
the Kelvin equation in Equation (4-3). The Kelvin radius rK of toluene at the pressure ratio 
p/p0 of 0.8 is 10.9 nm. The rK of decane at the same partial pressure is bigger: 16.8 nm [18]. 
Hence a smaller amount of adsorbate molecules is necessary to fill the pores, when the 
relative pressure is varied in the same range like for toluene. This should lead to complete 
adsorption isotherms and should give access to measure bigger pores and higher porosities. 
Analyses using decane will be performed in the future on the present specimens. EP can 
furthermore deliver information about the film thicknesses, refractive indices, extinction 
coefficients and the Young Moduli of the thin films. This makes it an interesting technique 
to be used later for the quality control of the thin TiO2-films on flat supports. 
 
Small angle neutron scattering (SANS) porosimetry gave structural information of the 
thin TiO2-films when staying attached to the supporting wafer. The aim of the measurements 
was to detect a difference in the scattering patterns of the NRLs and RLs and to determine 
the PSDs of the thin films. The median pore diameter dv50 of the NRLs on wafer supports 
was lower than for the RLs: 45.21 nm and 60.39 nm, respectively. The scattering length of 
the voids, representing the PSD, and of the TiO2-particles was evaluated during SANS. The 
reservoirs in the RL created a higher quantity of higher scattering lengths, shifting the 
median pore width to higher values than in the NRL. Another reason for the difference in the 
dv50 between the NRL- and RL-structures is, that in SANS the amount of open and closed 
pores were recorded. The distribution of small, closed pores was homogeneous in the 
isotropic NRL. In the big voids of the RL instead, this amount of small, closed pores was 
missing and thus shifting its PSD to higher pore diameters. For both measurements, the 
range of detectable pore diameters was limited to 0-100 nm, which was the maximum 
scattering length of the neutrons. The pore sizes evolving from pores greater than that critical 
size could therefore not be included as whole pores in the measurements. They were 
measured as multiple pores with a maximum length of 100 nm. Hence the reservoirs, with a  
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mean diameter of 800 nm, could not be evaluated. SANS is not the most common method to 
determine PSDs, because it is expensive, desires a high working effort and one has restricted 
access to the machines. However, this technique might be used in the future to study the 
dissolution of a drug, which is incorporated into the NRL TiO2-coating, with time in situ. 
Neutrons are beneficial compared to the application of X-rays, because they have a neutral 
charge. They do not show electrostatic interaction with the electrons of the atoms in the 
coating and are scattered by the nucleus itself. X-rays in comparison interact with the atoms 
they pass through [44], resulting in a weakening of the beam intensity and possibly 
damaging the material. Neutrons on the contrary can pass through materials without harming 
them. This has directed the application of SANS for hard and soft matter characterizations 
[19]. Thus the observation of the dissolution of the “soft” organic drug in the “hard” TiO2-
coating seams feasible. A next SANS experiment could hence be the following. A NRL on 
wafer support, sintered at a maximum temperature of 730 °C, should be loaded with the 
drug. A recorded scattering pattern of that sample should be different to the one of the non-
loaded samples obtained in this study. Then one could immerse the drug-loaded specimens 
into a mixture of water and deuterate-water (D2O). The contrast variation of H2O and D2O 
during penetration should be recorded. Subsequent comparison of the scattering patterns 
with the ones of the dry, drug-loaded samples should give information about the diffusion of 
water in the coating and furthermore of the dissolution of the drug. This might give 
fundamental information of molecule transports in nanoporous, thin films and might be 
further applied to the transport of substances in membranes and filters. 
 
Mercury intrusion porosimetry (MIP) is a standardized method for the determination of 
PSDs and porosities. This method covers the measurements of pores in the range of 5 nm up 
to several millimeter [9]. However, the preparation of the TiO2-coatings for the 
measurements showed some disadvantages. The PSD by MIP could only be ascertained on 
coatings without reservoirs. Because the detachment of the coating from the support prior to 
analysis has created small fragments, which were preferably broken at sites of a high 
reservoir density. The reservoirs were destroyed and not incorporated in the measurement. 
MIP results were defined in two different pore diameter ranges: (1) between 0-100 nm to 
compare with the results of the SANS-measurements, (2) between 0-1000 nm, to incorporate 
all pores in the coating, Table 4-10. The median pore diameter,dv50, of the NRL on wafer and 
sintered with a maximum temperature of 730 °C (w730NRL) was 76.34 nm in the range of 
0-100 nm and 30 nm bigger than the one obtained in the SANS measurements. The reason 
for the difference lies in the various pore volumes accessible by the different methods. 
Whereas in MIP only the open pores were included in the measurement, in SANS open and 
closed pores were evaluated. The small, closed pores shifted the distribution to smaller 
values. Another factor for the deviation was addressed to the different models used for the 
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evaluation: in MIP a cylindrical pore model was applied, whereas in SANS spherical pores 
were assumed. In the wider pore diameter regime of 0-1000 nm the dv50 of w730NRL was 
only slightly bigger than for the smaller range. One could hence conclude that the void 
volume was predominantly occupied by pores with a diameter smaller than 100 nm. The 
porous structure of the NRL could be classified into meso and macroporous. The porosity 
occupied by pores up to 1000 nm was 64.45 %. 
 
The PSD of the NRLs sintered at a maximum sintering temperature of 800 °C  
(w800NRL) was also evaluated by MIP. The dv50 in the range up to 100 nm was 67.42 nm  
and smaller than for the film sintered at 730 °C. However, when taking into account the 
bigger diameter range up to 1000 nm, a dv50 of 138.31 nm was obtained. The presence of 
more pores, which are smaller than in w730NRL sintered at a maximum temperature of  
730 °C, and of a higher quantity of pores with a diameter greater than 100 nm, clearly 
showed the sintering progress of w800NRL compared to w730NRL. This phenomenon is 
described in literature. Allemann, Hofmann and Gauckler showed for zirconia that small 
pores shrink first when sintering a powder compact, followed by the bigger ones at a higher 
sintering temperature. This is related to the presence of small pores in agglomerates, the so-
called intra-agglomerate pores, depicted in Figure 4-32. They disappear earlier during 
consolidation. The bigger inter-agglomerate pores get eliminated later in the sintering [45]. 
The presence of small agglomerates in the coating with a diameter of about 300 nm was 
shown by electron microscopy in the Figure 4-6 and Figure 4-10. Hence the findings of the 
pore size development in the present study correlates with the theory. 
 
 
Figure 4-32 Illustration of primary particles, agglomerates and their packing in a powder compact [46]. 
 
The porosity in the pore diameter interval up to 1000 nm decreased from 64.45 % to 
55.04 %, when increasing the maximum sintering temperatures of the films of 70 °C from 
730 °C to 800 °C. This is coherent with the sintering theory, where an increase of 
densification is attended by porosity reduction [41]. This is related to re-orientation of the 
primary particles and to grain growth. Coarsening of the titania grains was observed: the 
mean grain diameter dBET of w800NRL was 1.5 times the size of the one of w730NRL. 
Nevertheless the films w800NRL were still sintered in the initial stage. Because the SEM-
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micrographs in Figure 4-13 (a) revealed that the TiO2-particles were connected slightly via 
neck formation and a low densification has taken place [2]. This was furthermore coherent 
with the results of the dilatometry of the bulk titania cylinders in Figure 4-22. 
 
During this study, the amount of pore volume occupied by the reservoirs was not 
measured, but calculated, like depicted in Figure 4-20. The RL applied in the present study 
contained 3 % more porosity than a NRL of the same thickness. The calculation has shown 
that an increase in reservoir size and density can significantly increase the porosity of the 
coating. For instance densely packed reservoirs of a diameter of 4 μm can create an overall 
porosity of 65 %. But an increase in reservoir size is related to an incorporation of bigger 
polymer templates, which need to be covered by the TiO2-suspension. This is attended by an 
augmentation of the film’s thickness and an accession of the porous ceramic structure 
surrounding the reservoirs. The amount of porosity occupied by the porous ceramic structure 
surrounding the reservoirs contributes significantly to the overall porosity. The density of 
reservoirs in the coating and their size might in the future need to be optimized for individual 
applications of the drug-eluting coating. Bigger reservoirs might be favored for incorporating 
sufficient amounts of therapeutical agents. But when aiming for a high porosity and greater 
film thicknesses, one has to consider that the coating’s mechanical stability depends on these 
parameters and might deteriorate.  
 
The sintering behavior of the thin titania films and their structural characterization 
have now been discussed. It was clear that the constrained sintering of the film creates less 
densification than in a bulk sample sintered at the same maximum temperature of 800 °C. A 
disadvantage observed during the characterization of the films was the high amount of 
coating necessary to perform analyses, such as the determination of the specific surface area 
or the porosity. Many supports had to be coated and fired to being able to perform one 
measurement. The characterization of the structure of the TiO2-films on SS supports was 
only restricted possible. The aim in a next step was to produce a high amount of bulk 
material exhibiting equivalent properties like the NRLs.  
 
4.6.2 Sintering of titania nanoparticles in the bulks 
Dilatometry of the bulk samples showed that the sintering rate increased drastically 
exceeding 850 °C, which was the temperature where the intermediate stage of sintering 
started, Figure 4-22. That there was almost no densification happening before 850 °C was 
confirmed by the calculation of the total porosity of the bulk samples sintered between  
700 and 820 °C, Figure 4-25. The total porosity remained constant until 800 °C. From these 
two experiments it could be concluded that until at least 800 °C, sintering was in its initial 
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stage. In this period, the necks between the grains in the powder compact formed by means 
of surface diffusion, as was also deduced from SEM-images, Figure 4-23. The pore shapes 
were randomly and not spherical, as they would be in the final stage of sintering [41]. The 
specific surface area of the bulk bodies changed drastically between 740 and 770 °C,  
although there has no densification occurred. The amount of anatase phase decreased with 
diminishing specific surface area, Figure 4-24. This was attributed to the growth of the 
titania particles, which from a critical size on trigger the transformation from anatase to 
rutile [11]. A strong drop in the anatase phase content took place when the titania particles 
reached a size of 190 nm at 750 °C, Figure 4-24. The anatase to rutile transformation is of 
reconstructive nature [47], meaning that bonds between atoms are cleaved, and rebuilt during 
the transition. This may lead to much more mobility of the atoms and one could imagine that 
this facilitates material transport and thus grain growth. A plot from Ranade et al. was 
modified to display not only the surface area as in the original paper, but also the mean grain 
diameter dBET calculated with Equation (4-2), Figure 4-33 [11]. For small particles, anatase 
is the most stable phase. As soon as the particle size exceeds 120 nm, rutile is the most stable 
polymorph of TiO2. The formation of brookite, which is displayed in Figure 4-33, was 
kinetically blocked.  
 
142.1 51.3 30.8 22.0 17.1 14.0 11.8 10.3
0
grain size (nm)
 
Figure 4-33 Polymorphs of TiO2, anatase, rutile and brookite, at room temperature as a function of specific 
surface area and grain size, as modified from Ranade et al. [11]. 
 
The phase transition of TiO2 at 750 °C sintering temperature of the bulks correlated 
further with work deduced by Kim and coworkers [48], who reported a start of the phase 
transformation of anatase particles with an initial size of 21 nm-such as in the present study-
at 750 °C. It was completed at 800 °C.  
 
From the in situ XRD measurements of the bulk titania compact it was clear that the 
phase transformation from anatase to rutile was initiated during the temperature ramp of  
500 to 800 °C, proceeded during the plateau of the maximum sintering temperature of  
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800 °C and came to the end after cooling to room temperature, Figure 4-21. These findings 
fit the thermodynamic phase diagram of TiO2, which shows that at atmospheric pressure the 
phase transformation of TiO2 starts at 600 °C [49], Figure 4-34.  
 
 
Figure 4-34 Phase diagram of the polymorphs of TiO2: anatase and rutile [49]. 
 
The phase transition from anatase to rutile is a first order transition, represented as a 
line in the phase diagram. The transition should have been taking place simultaneously for 
all anatase particles. Nevertheless, a temperature region for the transformation was observed, 
represented by a temporary increase in the sintering rate between 760 and 800 °C, Figure 
4-22. This fits the findings from XRD measurements (Figure 4-21), where the phase 
transformation was almost finished after the plateau of 800 °C. To correlate the increase in 
shrinkage rate in this temperature interval with the phase transformation is reasonable. It also 
was observed by Kim et al., who measured shrinkage curves with a hillock in the region of 
the phase transition from anatase to rutile [47]. Legros et al. suggested that in alumina the 
phase transformation is coupled with a grain rearrangement, which leads to a densification of 
the ceramic [50]. If the same happened in the titania powder compacts, this could explain the 
increase in shrinkage occurring at the phase transformation.  
 
Furthermore a deviation between the temperature region of the phase transition of the 
bulk samples, heat treated during dilatometry and by the conventional method was observed. 
In dilatometry the phase transition was initiated at 760 °C. The bulk sample, which passed 
through the whole sintering cycle with the maximum sintering temperature of 770 °C,  
contained already mainly rutile. The higher amount of anatase in the dilatometry specimen 
compared to the conventionally sintered one was associated to the different heating cycles 
and to the time points when the XR-diffractograms were recorded [46, 50]. The ones of the 
conventionally fabricated bulks were recorded after the whole sintering cycle was complete. 
Chapter IV  Characterization of the structured titania films 
 
 
79 
The nucleation sites of rutile were initiated during the heating and grew bigger during the 
isothermal hold at the maximum sintering temperature Tmax and the cooling. On the contrary, 
in dilatometry the temperature was increased continuously up to 1000 °C with the same rate 
and without any isothermal holds-the phase transition was hence more rapid. Significant 
high standard deviations were observed in the mean grain size dBET and the phase 
composition of the conventionally sintered bulks in the temperature range of 700-770 °C. 
They might be related to the presence of agglomerates of different sizes in the titania green 
body. Gribb and Banfield showed that the phase transition, once initiated in a crystallite, 
proceeds rapidly through the entire crystallite. These seeds lower the energy needed for 
transformation, as they serve as nucleation sites. A higher concentration of seeds leads to a 
lowering of the phase transition temperature [51]. A variation of the number of seeds in the 
samples might thus have created the deviations. The number of seeds depends on the particle 
size distribution in the green compact and the presence of agglomerates in the specimens. 
Varying amounts of agglomerates in individual samples might have triggered the standard 
deviations.  
 
The understanding of the sintering behavior helped to set the production parameters of 
cylindrical bulks, which are “equivalent” to the ones of the NRL-structured film sintered at a 
maximum temperature of 730 °C. The bulk samples sintered at 740 °C were selected to 
represent the structure of w730NRL. Their surface areas were almost identical with 17 and 
18 m2/g, respectively. The BET surface area was the used criterion to select the production 
parameters of the bulk, because it is linked to the grain size and the phase composition as 
was shown by Ranade et al., Figure 4-33, and in the present study, Figure 4-24.  
 
The PSD of the bulks sintered at 740 °C (b740) was measured by MIP and nitrogen 
sorption porosimetry (NSP). The obtained values of the median pore diameter dv50 in the 
range of 0-100 nm as a function of the two methods correlated: MIP revealed 51 nm and 
NSP 58 nm. The PSD by MIP was bi-modal for b740 when performing the same analyses 
taking into account the bigger pore size interval (0-1000 nm). Two most frequent pore 
diameters were detected, one at 58 nm and the second one at 283 nm. Hence pores exceeding 
a width of 100 nm existed, but most of them were smaller than 100 nm. For w730NRL a 
mono-modal distribution was obtained with a dv50 of 76 nm in the range of 0-100 nm, 83 nm  
in the range of 0-1000 nm, and a most frequent diameter of 87 nm. Mainly pores with a 
diameter smaller than 100 nm existed. The features of the bulks b740, which were to be 
equivalent to the films w730NRL, were not equal in regards to their PSD. The difference 
was associated to the production methods. The films were prepared by a multi-step dip 
coating procedure, in which the TiO2-particles could get ordered during the withdrawal of 
the substrate from the suspension [52]. After the deposition of each thin layer the samples 
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were dried under controlled atmosphere in a climatic chamber. The aqueous phase 
evaporated quickly from the few microliter of suspension deposited as the thin film. The 
TiO2-nanoparticles did not have time to re-arrange and to build up big agglomerates. 
Particles were densely and homogeneously packed in the films, as was seen in the SEM-
micrographs. A few big agglomerates with a diameter of 1 μm were located, but they were 
already formed in the suspension prior to deposition. The situation was different for the 
bulks fabricated by slip casting. During slip casting, several milliliter of the TiO2-suspension 
were poured into one opening of the mould to create cylindrical specimens. The evaporation 
of the aqueous phase took accordingly longer than for the films. The TiO2-particles hence 
had time to re-arrange in the liquid phase and to build big agglomerates. The presence of 
these agglomerates caused the recorded bi-modal pore size distribution in the bulks.  
 
The influence of agglomerates in a powder compact on the PSD was in more detail 
analyzed by J. Allaman et al. [45]. Smaller pores were attributed to be inter-particle pores, or 
“intra-agglomerate pores”. The bigger ones were caused by the voids between the 
agglomerates and are termed inter-agglomerate pores, Figure 4-32. During consolidation, the 
intra-agglomerate pores get eliminated and bigger pores grow. This could be verified by the 
characteristics of the bulks sintered at different maximum temperatures. Up to 800 °C, the 
calculated open and closed porosities stayed constant at 50 and 42 % respectively, Figure 
4-24. A slight decrease of the total porosity was obtained between b800 and b820, but the 
open porosity stayed constant. These findings can be explained by the elimination of closed 
intra-agglomerate pores upon proceeding neck formation between the particles in b820. The 
neck formation can be correlated with a lower specific surface area in b820 compared to 
b800.  
 
When in the future bulks with equivalent properties like the films have to be produced, 
one might choose tape coating instead of slip casing. In tape coating a high area of support 
can be coated in a short period of time. The evaporation of the water phase is accordingly 
faster compared to slip casting. This might prevent the formation of big agglomerates and 
thus the formation of big pores. The tape coated films might be removed from the support 
prior to heat treatment. The maximum sintering temperature of the tape coated films can be 
the same as for the constrained films, as long as the sintering stays in the early initial stage. 
Because the present study has shown, that the influence of constrained film sintering on 
densification was less severe during the early initial stage of sintering. NRLs and bulk 
specimens sintered at the same temperatures below 750 °C exhibited the same specific 
surface areas and similar anatase phase contents.  
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In the future the properties of the films might need to be adapted to the desired 
application. For instance the sintering temperature might need to be increased to improve the 
mechanical stability. The problem to determine the PSD in the films will still exist. One 
might then use the equation established by Scherer and Garino, Equation (4-13), to predict 
the shrinkage of the constrained film compared to a freely sintered film, which can be 
prepared and characterized easily. 
 
(4-13), 
 
 
with (ρ’/ρ)c the densification rate of the constrained film, (ρ’/ρ)u the densification rate of the 
unconstrained film and νp viscous Poisson’s ratio, which is a function of porosity and the 
microstructural properties [35, 37]. The densification rate of the unconstrained film might be 
measured by dilatometry.  
 
4.6.3 Surface properties of the films 
Surface properties of implants are a key issue in the interaction of a biomaterial with 
the biological environment [3, 53]. The structural makeup of the implant’s surface directs 
and influences the response of proteins, cells and the organism [3]. But besides the 
performance in the biological media, the surface properties of the titania coating can also 
influence the drug-load behavior, when it is to be applied in a drug-eluting stent. To evaluate 
the influence of the preparation methods of the TiO2-coating on its surface structure, 
analyses concerning its chemical composition, topography and wettability were deduced. 
 
The NRL and RL TiO2-films on wafer supports were similar. They exhibited the same 
chemical composition on the outer 10 nm of the coating: stoichiometric TiO2, as was 
determined by X-ray photoelectron spectroscopy (XPS). No diffusion of Si-ions from the 
support to the outer part of the coating was detected, if a maximum calcination temperature 
of 730 °C was applied. The determined mean roughness, Ra, of the two types of coatings was 
similar with a slightly higher value of the RL of 25.30 nm compared to 16.70 nm of the 
NRL. The reasons for the slightly higher Ra in the RLs were small elevations in the films, 
which were produced by the drug reservoirs, as was observed by SEM. The contact angles θc 
of these two types of coatings with water showed similar values with w730NRL: 16 ° and 
w730RL: 18 °. No significant influence of the presence of the reservoirs on the contact 
angles was deduced. The contact angles measured were comparable with the ones obtained 
in studies by Wu et al. [54], who reported a θc of an anatase crystalline surface of 24 ° and 
for rutile 58 °. In this study the coating was mainly composed of anatase and small amounts 
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of rutile were present. Therefore one has expected a θc dominated by the features of anatase. 
The slightly lower values obtained in this study compared to Wu and coworkers might be 
caused by the roughness of the surface. A roughness factor f can be included into Young’s 
equation for the calculation of the contact angle, Equation (4-10). The factor f can be defined 
as 
 
(4-14), 
 
 
with Aeffective: the effective surface area of the rough sample and Aapparent: the apparent 
geometrical area. If the surface is rough, f  1. For a smooth surface, f =1. Modifying 
Equation (4-10) reveals 
 
 
(4-15), 
 
with θc0 the ideal contact angle. It is connected to the effective contact angle by 
 
(4-16). 
 
From these equations it gets obvious, that if 0 ° < θc0 < 90 °, 0 < cos(θc0) < 1 and the surface 
gets more hydrophilic [3]. A higher roughness can increase the hydrophilicity of an 
otherwise hydrophilic smooth surface of the same material. The higher roughness on the 
TiO2-coatings in this study, when compared to the findings of Wu et al., might have 
increased the hydrophilicity. 
 
The higher hydrophilicity of anatase compared to rutile is explained as follows. When 
water is brought into contact with the TiO2-surface, its molecules form intermolecular 
interactions with the surface atoms. The degree of wetting is determined by a balance 
between adhesive and cohesive forces between the involved molecules. The TiO2-molecule 
on the surface is a dipole with positive Ti+ and negative O- sites. In an aqueous environment 
OH- bonds to the Ti cation form Ti-OH groups [55]. The OH-groups then can form hydrogen 
bonding with the water molecules from the liquid. The more –OH groups are formed on the 
surface, the more water can bind and thus the more hydrophilic is the system. The different 
behavior of anatase and rutile is caused by their different interfacial tensions with water. The 
interfacial energies of water with anatase and rutile, γsl, were determined by Wu et al. to be  
-12.1 and 11.1 mJ/m2 respectively. The free energy of adhesion of water to a solid surface, 
ΔG, could be calculated by 
 
apparent
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A
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(4-17). 
 
The free energy of anatase was evaluated to be -139.4 mJ/m2 and for rutile -112.6 mJ/m2  
[54]. Because the free energy is lower for anatase, water molecules adhere more favorably 
on anatase and thus make it more hydrophilic. The free energy itself depends on the different 
crystal structures of the two TiO2-morphologies.  
 
The NRLs- and RLs on stainless steel supports exhibited differences to the coatings on 
the wafer supports. XPS revealed that Ti was bound as stoichiometric TiO2. Trace amounts 
of iron in iron oxide and chromium in chromium oxide have been present in the upper layer 
of the coating on SS.  
 
The roughnesses Ra of the coatings were directed by the roughness of the underlying 
supports. Ra of the wafer was below 5 nm and of the coatings on top 16.70 nm and 25.30 nm  
for the NRL and RL, respectively. The SS exhibited a Ra of 75.25 nm and the coatings NRL 
and RL 76.38 nm and 54.13 nm, respectively. A thicker coating on the SS supports might 
decrease Ra.  
 
The mean contact angles θc of the titania coatings on SS were higher than on the wafer 
supports: 45.33 ° and 53.06 ° for the NRL and RL, respectively. The presence of the 
vanishing amounts of iron and chromium oxides on top of the surface might have altered the 
wetting properties [56]. Significant variations of θc for the coatings on SS were observed. θc 
measured on different spots on one individual sample did not cause these deviations. But the 
wettabilities of samples produced in different batches with the same parameters were 
different. Therefore it is important to establish quality controls in several steps during the 
complex production cycle of the TiO2-coatings. The surface roughness of the steel after 
electropolishing should always be measured for at least 3 samples from one batch. The 
additionally fast and inexpensive measurement of θc can give reliable information of the 
chemical state of the polished steel before the coating is applied. The determination of the 
microbeads’ density by microscopy should in the future be followed for each batch of 
samples, like was done here. An automation using image processing to evaluate this 
characteristic might be advantageous. It might even be of advantage to control the 
atmosphere during the deposition of the beads to increase the reproducibility. Because it was 
impossible on some days to create the wanted microbeads-density of 150000 beads/mm2. 
The environmental factors affecting the deposition of the templates were not systematically 
analyzed in the present study. In a last quality control step, the contact angle of the coating 
with water should be measured to get information about the quality of the nanoporous titania 
films.  
lvsvslG γ−γ−γ=Δ
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4.7 Conclusion 
The following conclusions could be drawn in respect to the production and 
characterization of the nanostructured titania (TiO2) coatings for stent-implants. The thin 
TiO2-coatings were successfully created on stainless steel (SS) and silicon wafer supports by 
a dip coating technique and a following sintering step. The micrometer-sized holes, which 
will serve as drug reservoirs, were surrounded by a porous ceramic structure with smaller 
pores. The characterization of the structure of the films on SS supports was not possible in 
terms of their specific surface area, porosity or density. The coatings fabricated on silicon 
wafer supports represented a good model to measure these parameters, which are important 
to be defined to apply the coating as a drug-eluting matrix in stents.  
 
The specifications of the thin TiO2-coatings, which were heat treated at a maximum 
sintering temperature of 730 °C and do not containing reservoirs (NRLs), were determined. 
Their properties are equivalent to the porous structure surrounding the reservoirs in a 
reservoir layer (RL). The pore size distribution (PSD) of the NRL-structure exhibited a 
median pore width below 100 nm and an open porosity of more than 50 %. The influence of 
the reservoir size and density in the coatings on the overall porosity could not be measured, 
but calculated. The used RLs in this study, which had a reservoir density of 150000 
reservoirs/mm2 and a reservoir size of 1 µm, increased theoretically the overall porosity of 3 
% compared to an equivalent NRL. The calculations have shown that the pore volume can 
further be increased by creating thicker coatings with bigger reservoirs, as well as by 
increasing the reservoir density. In addition it could be deduced that the porous structure 
surrounding the reservoirs has a significant influence on the overall porosity. 
 
In our days it is still a challenge to measure the PSD and porosity of thin ceramic 
films, which contain bimodal PSDs of different orders of magnitudes. Ellipsometric 
porosimetry is not yet advanced enough and the constraint of small angle neutron scattering 
and nitrogen sorption porosimetry is a pore diameter of 100 nm. A high quantity of NRLs 
was required to perform one measurement by mercury intrusion porosimetry (MIP). Hence 
bulk, cylindrical samples with a NRL-structure, representing the NRL-structure of the films, 
were easily and effectively prepared by slip casting. Their PSD and porosity were measured 
by MIP.  
 
By comparing the results of the bulk specimens sintered at a maximum sintering 
temperature of 800 °C with the ones of a NRL, which was heat treated identically, it could 
be concluded that the bulks were more progressed in sintering than the films. The geometric 
constraint of the support has directed the film to constrained sintering and hence to a lower 
densification. The effect of constrained film sintering in the beginning of the initial stage of 
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sintering, represented by lower sintering temperatures, was not as progressed as in the end of 
the initial stage, the intermediate or the final stage. Hence similar properties of the TiO2-
bulks and the NRLs, which were sintered with the same method and with a maximum 
sintering temperature of 730 °C, in regard to their specific surface area and porosity were 
detected. Only the PSD of the bulks was shifted to higher values compared to the one of the 
films. This could be correlated to the presence of agglomerates of the TiO2-primary particles 
in the bulks, which were formed during the drying after slip casting.  
 
The TiO2-films, which were fabricated on either silicon wafer or SS and heat treated at 
a maximum sintering temperature of 730 °C, were composed of mainly anatase. The residual 
amount was rutile, which is the high temperature stable morphology of TiO2. Whilst the 
surface of the titania coatings on wafer supports contained only stoichiometic TiO2, the same 
coatings on SS supports exhibited in addition trace amounts of iron oxide and chromium 
oxide. The roughness of the porous NRLs and RLs depended on the roughness of the 
underlying support material. Hence the roughness of the films on the smooth silicon wafers 
exhibited a lower mean roughness than the films on SS.  
 
The TiO2-coatings on wafers were hydrophilic, as was deduced from contact angle 
measurements with water. The titania films on SS featured a more hydrophobic character, 
which was most probably affected by the presence of the metal ions in the coating. The 
presence of the drug reservoirs in the coating did not significantly change the wettability 
behavior of the films.  
 
For the application of the nanostructured titania coating in a medical implant it might 
be necessary to adopt some characteristics of the coating, such as the porosity to create a 
higher drug-load capacity or a higher densification for a better mechanical stability. These 
features can easily be modified by changing the process parameters, such as increasing the 
sintering temperature. But one has to be aware, that with increasing sintering temperature 
and increasing film thickness an anisotropy in the film might arise due to the effect of 
constrained film sintering. This can be beneficial, if aligned pores are wanted to increase the 
drug diffusion out of the coating. But this is also accompanied by a reduction in porosity and 
hence a lower drug-load capability. Inhomogeneous, bigger grain sizes are then formed and 
they might be unfavored in regard to the mechanical stability. One also needs to pay 
attention to the behavior of the underlying support material during heating, because metals 
can form precipitates in their grain boundaries leading to lower corrosion protection. 
 
A change in calcination temperature can also affect the surface properties of the 
coating. A higher sintering temperature might change the morphology of TiO2 to consisting 
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of a higher amount of rutile and thus creating a higher hydrophobic character of the surface. 
Furthermore the diffusion of metal ions from the stainless steel support along the titania 
grains, which depends on the temperature, increases. The presence of these ions on the upper 
layer of the coating might alter its performance in the biological environment. This will be 
evaluated in future tests. 
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CHAPTER V 
5 DRUG-LOADING OF THE THIN TITANIA FILMS AND 
DRUG-RELEASE 
5.1 Background and introduction 
This chapter focuses on the loading of the previously presented thin, nanostructured 
titania (TiO2)-films with the therapeutical agent paclitaxel (PTX). PTX served as a model 
drug, because it is used in commercially available drug-eluting stents (DESs) and drug-
release studies are available for comparison [1, 2, 3]. Solvent evaporation methods were 
chosen to incorporate the agent into the coatings. The targeted load was 1 µg/mm2 geometric 
surface area of the coating, which is a value consistent with the load of PTX in the 
commercially available TaxusTM stent [1]. The release of the drug should last several 
months, corresponding to a release rate smaller than 1 % of initially incorporated drug per 
day. These specifications were predetermined by the industrial partner of this project and 
were educed from the TaxusTM stent.  
 
The implantation of the TaxusTM stent into patients suffering from atherosclerosis 
reduced the restenosis rate to 7.9 % after 6 month of implantation. For comparison, it was as 
high as 26.5 % for the application of bare metal stents [1, 2]. The in vitro release kinetics of 
PTX from the titania coatings into water and into bovine plasma will be presented and 
evaluated in the present chapter. 
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When working with PTX as a pharmacological agent to being incorporated into a drug-
delivering coating for stents, one has to consider its chemical and physical features for the 
processing. PTX has a molecular weight of 853.9 g/mol and a melting point of 213-216 °C.  
It hydrolyzes in aqueous solutions and undergoes transesterification in methanol [4]. The 
application of methanol during processing was thus not recommended. The drug exhibits a 
lipophilic character, which makes it well soluble in different types of glycols or oils, like 
depicted in Table 5-1. For instance it is soluble in a concentration of 1400 μg/ml in 75 %  
propylene glycol, 300 μg/ml in soybean oil and 74000 μg/ml in Triacetin. The PTX-
molecule, which is shown in Figure 5-1 (a), does not possess suitable chemical functionality, 
such as having an amine or carboxylic acid for salt formation. Hence it is badly soluble in 
water and reported solubility concentrations range from 0.3 to 30 µg/ml. The recorded values 
vary greatly in literature and depend on the experimental conditions [5, 6].  
 
Table 5-1 PTX-solubilities in different solvents and oils. 
solvent solubility concentration (μg/ml) 
dimethyl sulfoxide (DMSO) 50000 [4] 
dichloromethane (DCM) > 19000 [5] 
ethanol ca. 39000 [5] 
acetone (ACET) not known 
ethyl acetate (EA) 103610* 
75 % propylene glycol < 1400 [5] 
75% polyethylene glycol 400 31000 [5] 
35 % polyethylene glycol 400 30 [5] 
soybean oil 300 [5] 
triacetin 74000 [5] 
water < 30 [5] 
 0. 7; 6; 30; 0. 34 [6] 
* determined in the present study as will be explained in Chapter 5.4.2.2 
 
The variations in the PTX-solubilities can be explained by the existence of paclitaxel 
polymorphs. PTX-dihydrate has an aqueous solubility lower than the anhydrous form, as was 
reported by Burt et al. [6]. The dissolution measured depended on the time PTX was 
exposed to water and the time when the data points were recorded. A short time after 
anhydrous crystalline PTX is immersed into water, it has the apparent solubility of the 
anhydrous form, which is as high as 3 µg/ml. After 12 h it decreases to 1 µg/ml, which 
corresponds to the solubility of the dihydrated crystalline form [6]. 
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Figure 5-1 (a) molecular structure of paclitaxel [4], (b) 3D-structure and dimensions of a PTX-molecule.  
 
Many pharmaceuticals exist as polymorphs, having different crystalline or an 
amorphous morphology. The drug molecules in the particular crystalline morphologies 
exhibit different arrangements or conformations in the crystal lattices. The solid amorphous 
drugs feature a disordered arrangement of the molecules. The polymorphs can hence have 
different chemical and physical properties, such as a different melting point, chemical 
reactivity, solubility and dissolution rates. Generally, an amorphous form is 
thermodynamically less stable than any crystalline form. It exhibits a higher apparent 
aqueous solubility and a higher dissolution rate. In the pharmaceutical industry the most 
stable polymorph is used to ensure the stability of the drug with time and under 
environmental conditions [7, 8, 9].  
 
To optimize the PTX-release from the TiO2-coatings, it was therefore interesting to 
evaluate the effect of the specific PTX-morphology on the release kinetics. The production 
of the PTX-polymorphs by mainly solvent evaporation procedures has been described in 
different studies [6, 10, 11]. Lee et al. and Burt et al. used simple methods, such as infrared-
spectroscopy (IR) and differential scanning calorimetry (DSC), to determine the polymorphs 
of the drug. Typical Fourier-transform IR (FT-IR) spectra of the polymorphs are depicted in 
Figure 5-2 (a). They clearly show differences in the absorption at several wave number 
regions. Amorphous PTX exhibits only one carbonyl absorption near 1720 cm-1, whereas all 
the others show 2 carbonyl absorptions. Other absorption peaks at 1650 and 1522 cm-1 also 
show differences. The thermograms of the PTX-polymorphs displayed in Figure 5-2 (b)  
illustrate the transitions of PTX during heating. The anhydrous crystalline form of PTX 
exhibits one endothermic peak in the DSC-thermogram at 224 °C, representing the melting. 
The decomposition of PTX is shown by the second peak at 240 °C. The plot of the 
amorphous PTX is characterized by a glass transition at 140 °C before the peak of the 
exothermic decomposition at 220 °C. The DSC-curve of dihydrated crystalline PTX holds 
two endothermic peaks close to 100 °C, referring to the PTX-dehydration and the 
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vaporization of residual solvents. A solid-solid transition is recorded at 160 °C and a melting 
endothermal peak at 220 °C, before its decomposition. The IR- and DSC-graphs, which are 
depicted in Figure 5-2, will be used as reference-curves for comparison. 
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Figure 5-2 Left: IR spectra of PTX-polymorphs (a) amorphous, (b) dihydrated crystalline, (c) anhydrous 
crystalline and (d) anhydrous crystalline, modified from [11]; right: DSC thermograms of (e) anhydrous 
crystalline, (f) amorphous, (g) dihydrate crystalline PTX and (h) anhydrous crystalline PTX, modified from 
Burt et al. [6]. 
 
When wanting to incorporate PTX into the porous TiO2-network of the coating, the 
pore width-to-PTX-size ratio has to be considered. A study of Kuroda et al. has shown that 
PTX was adsorbed in 2-D hexagonal, mesoporous silicas exhibiting pore diameters larger 
than 1.8 nm. It did not adsorb into channels having pore width less than 1.6 nm [12]. The 
reason was the size exclusion of PTX by the pores. The longest dimension of the molecule 
was measured in Figure 5-1 (b) to be 2.067 nm. Hence the molecule was too big to enter the 
silica pores. In the present study, the pores in the ceramic structure surrounding the 
reservoirs were bigger, like was shown in Chapter 4.5.2. The median pore width of the 
porous structure was 76 nm, leading to a ratio of molecule-to-pore diameter, χ, of 0.027. No 
steric hindrance of the PTX-molecule to penetrate the porous TiO2-network of the films 
during drug-loading was therefore expected [13].  
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The aim of the drug-load and release study was to establish methods and to prove the 
feasibility to load the nanostructured TiO2-coatings with PTX. The factors influencing the 
drug-release had to be identified, to eventually adapt the coating to create a sustained drug-
release. The target was not to optimize the coating. This will be the scope of future work and 
depends on the individual application. 
 
5.2 Theory of drug-release kinetics 
The measured amount of drug released from a pharmaceutical dosage form as a 
function of time is a so-called drug-release profile. By applying different mathematical 
models to the drug-release profiles, the transport mechanisms involved in the drug-liberation 
can be identified. Some models will now be introduced. 
 
5.2.1 Korsmeyer-Peppas model 
The Korsmeyer-Peppas model is a semi-empirical model, which can be used to analyze 
the data of the controlled release of water-soluble drugs from polymers [14, 15]. The model 
is generally employed when the release mechanism is not well known or when more than 
one type of release phenomenon could be involved. In the Korsmeyer-Peppas model the 
fractional release of the drug, Mt/M0, is exponentially related to the release time t by 
 
(5-1), 
 
 
with Mt: amount of drug released at time t, M0: the initial amount of drug incorporated into 
the system
 
and kKP is the Korsmeyer-Peppas release constant, incorporating structural and 
geometric characteristics of the device. The release exponent n can give information about 
the transport mechanisms involved. If the drug-delivery occurs from a slab, a release 
exponent n of 0.5 indicates Fickian diffusion, n between 0.5 and 1 indicates anomalous or 
non-Fickian transport, which is often termed first-order release. If n equals 1, the transport 
equates a zero-order release, also known as case-II-transport. A value of n greater than 1 
describes a super case II transport, in which the drug-release is faster than in the release 
following Fickian diffusion or case II transport [14].  
 
By applying this model, the drug amount released as a function of time is fitted by an 
exponential approximation, which delivers n. Caution has to be given to the following 
restrictions to apply this model: 
n
KP
0
t tk
M
M
⋅=
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? For the determination of n, only the initial portion of the release curve should be 
used, in which Mt/M0 < 0.6. 
? Perfect sink conditions during the analysis are required. Thus the concentration in the 
release media at time t, Ct, should be much smaller than the drug’s maximum 
solubility concentration in that media, Cs. In the present study, sink conditions were 
set to be fulfilled for Ct  1/3 ·  Cs. 
? The diffusion coefficient is concentration-independent. 
? The diffusion occurs one-dimensional, that means that the aspect ratio of the slabs, 
width over thickness, is at least 10/1. 
 
5.2.2 Zero order release kinetics 
The release mechanism, in which the drug dissolution and release from the dosage 
form is constant, is called zero order kinetics. It is the ideal method of drug-release in order 
to achieve a pharmacological prolonged action. These kinds of formulations are used in 
some transdermal systems, in matrix tablets with low soluble drugs or in osmotic and 
reservoir systems. For instance in a reservoir system, the drug is surrounded by a film. The 
diffusion of the agent through that film is the rate-limiting factor. To maintain a constant flux 
out of the reservoir systems, the concentration gradient across the membrane needs to be 
constant. It can be achieved by keeping a constant high drug concentration at the internal 
wall of the membrane. This is possible by loading a powdered drug into the reservoir, whose 
concentration at the internal wall of the membrane will be the saturation concentration Cs 
[15, 16, 17, 18]. 
 
The same premises apply for the pure dissolution of a low soluble drug. If the 
concentration of the drug in solid form is high during a certain period of time, Ci, a constant 
concentration gradient exists between the saturation concentration at the surface of the solid 
drug, Cs, and the bulk concentration in the surrounding media, Figure 5-3 (a).  
 
The flux J of the drug can then be described by Fick’s law as 
 
(5-2), 
 
with Mt: amount of drug dissolved in time t, Deff : effective diffusion coefficient of the drug, 
dC: concentration difference of the drug between the surface of the solid drug and the 
surrounding release media, and h: thickness of the stagnant diffusion layer. 
h
dCD
dt
dMJ efft ⋅−==
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Figure 5-3 Theoretical drug concentration profiles. (a) zero order release, where the concentration gradient and 
hence the flux into the sink release media is constant. In (b) the Higuchi model, where the release from a matrix 
in direct contact with the release media, is illustrated ((b) modified from [15]). h represents the thickness of the 
diffusion layer with h1 at release time t1 and h2 at release time t2, whereas t1 < t2. Ci: initial drug 
concentration; Cs: saturation concentration. 
 
For the dissolution of a low soluble drug, Deff ≈ DSE. DSE is the Stokes Einstein diffusion 
coefficient expressed as 
 
(5-3), 
 
and it describes the self diffusion of a molecule in a media. kB is thereby the Boltzman 
constant of 1.381 · 10-23 J/K, T: temperature, η: dynamic viscosity of the media and  
rh: hydrodynamic radius of the molecule [19]. For the drug-release from reservoir systems, 
another Deff needs to be applied. For microporous membranes in reservoir systems, the flux 
is then dependent on  
 
(5-4). 
 
 
The effective diffusion coefficient incorporates structural parameters of the membrane, such 
as the porosity of the membrane ε and the tortuosity τ of the pores [17]. Integrating Equation 
(5-2) by keeping the concentration gradient constant and the concentration in the bulk media 
time-independent, the zero order release model can be deduced as 
 
(5-5), 
 
 
with Mis: initial amount of drug in solution and k0: zero order release constant [15], 
containing Deff. Therefore the plot of Mt as a function of t reveals a straight line with the 
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slope of k0. For employing this model the following restrictions exist: 
? The pharmaceutical dosage form should not disaggregate, 
? The drug is released slowly, 
? The area, from which the drug gets released, does not change, 
? Perfect sink conditions prevail, 
? The diffusion coefficient is independent of the concentration and time, 
? And it is valid as long as the saturation concentration is present at the formulation’s 
surface. 
 
5.2.3 First order release kinetics 
This type of release kinetics is the most common one to describe the dissolution of 
drugs from pharmaceutical formulations. The Noyes-Whitney equation describes the 
dissolution of a solid in a liquid media: 
 
(5-6), 
 
with Ct: time dependent concentration of the drug in the bulk media, K: first order 
proportionality constant and Cs: maximum solubility concentration of the drug in the release 
media. This equation was modified by several scientists assuming that under steady state 
conditions a thin stagnant fluid layer at the solid surface is build. With the incorporation of 
Fick’s law of diffusion and subsequent integration, Equation (5-7) is derived: 
 
(5-7), 
 
with Mt: amount of drug released at the time t, Mis: initial concentration of drug in solution 
and with the first order release constant  
 
(5-8). 
 
D is the diffusion coefficient in the dissolution media (≈DSE), S: the solid area accessible to 
dissolution, h: width of the diffusion layer and V: volume of the liquid release media [15]. A 
graph of the decimal logarithm of the released amount of drug versus time will be linear and 
the slope will represent k1/2.303. The premises to apply this model are: 
? The released amount of drug decreases with time, 
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? A constant area is accessible to dissolution, 
? And perfect sink conditions exist during the experiment. 
 
5.2.4 Higuchi model 
The last model of interest in this study is the Higuchi model. It describes the release of 
solid drugs incorporated into solid matrices. The release from a planar system, which has a 
granular matrix from which the drug diffusion occurs through intergranular openings, can be 
described by 
 
(5-9), 
 
 
with Mt: amount of drug released in the time t, M0: initial amount of drug incorporated into 
the matrix, D: diffusion coefficient of the drug in the permeating liquid, U: specific volume 
of the drug in the porous structure (1/density of the drug, when M0 is expressed in mass per 
volume), Cs: solubility of the pharmaceutical in the media, τ: tortuosity of the pores and  
kh: Higuchi dissolution constant [20]. Therefore a plot of the fractional amount of drug 
released as a function of square root of time should yield a straight line, in which the slope 
represents kh. Some restrictions to apply the model have to be made: 
? The elution test should be performed in perfect sink conditions, 
? The cross sectional area of the diffusion path is reduced by a porosity factor and the 
diffusion front in the matrix changes as is illustrated in Figure 5-3 (b), 
? The model is valid as long as Ci > Cs. 
 
5.3 Materials and methods to quantify paclitaxel and to characterize 
its solid state 
The quantification of paclitaxel (PTX) in the liquid phase by high performance liquid 
chromatography (HPLC) and extraction will be described in the first part of this section. The 
production of PTX-polymorphs will further be documented, the methods for the drug-load 
and release studies explained.  
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5.3.1 Paclitaxel 
Paclitaxel (PTX) as a white powder was purchased from Sigma-Aldrich (T1912,  
min. 97 % purity by HPLC) and used in pre-tests of the drug-load and release studies. It was 
named PTX_S. A second batch of PTX, PTX_K, was bought from Knowshine (Shanghai) 
Pharmachemicals Inc. (99.8 % purity by HPLC) and applied in the main drug-load and 
release experiments. 
 
5.3.2 Quantification by high performance liquid chromatography 
When PTX was dissolved in ultrapure water (UP-water, MilliQ-Systems), acetonitrile 
(AcN, Biosolve, HPLC grade), or a mixture of both, it was quantified by high performance 
liquid chromatography (HPLC). The HPLC-system consisted of an Alliance 2690 pump 
module (Waters) connected to the analytical column ODS-3 (Inertsil®, particle size 5 µm; 
4.6 x 150 mm), which was protected with an ODS-3 conventional guard column (Inertsil®, 
particle size 5 µm; 4.6 x 50 mm). The analysis procedure applied in this study was adapted 
from S.-H. Lee et al. [21] and M.S. Alexander et al. [22]. The mobile phase consisted of UP-
water and AcN in a gradient elution, Table 5-2. The flow rate was set to 1 ml/min. Detection 
was performed at 227 nm with a Photodiode Array Detector 996 (Waters) with connection to 
the Millenium 3.05.01 software data station (Waters). 100 µl of each sample were injected 
via autosampler for analysis. The absorption of PTX as a function of retention time was 
recorded in the chromatograms. 
 
Calibration curves of PTX_S and PTX_K were obtained either in pure AcN, a mixture 
of AcN/water of 50/50 %vol or in UP-water. Therefore a stock solution of ∼ 500 µg/ml PTX 
was prepared by weighing the appropriate amount of PTX with a thermo-balance (TG50, 
Mettler) and diluting it in AcN in a 10 ml glass screw vial. This solution was mixed by a 
vortex mixer (REAX 2000, Heidolph) for 2 min prior to its application. Standard solutions in 
known concentrations were prepared from the stock solution by dilution with the appropriate 
solvent or solvent/UP-water mixture. They were injected into the HPLC-system by an 
autosampler. The PTX-peak in the recorded chromatogram was integrated to obtain its area, 
which was proportional to the concentration of PTX in the standard. Standards were each 
prepared and measured in triplicates. Calibration curves were finally deduced from the linear 
regression of the mean measured peak areas of the standards as a function of the defined 
concentrations of PTX. Sample analysis was performed in the same way. During the 
continuous analyses, an external standard was analyzed each 5 injections to evaluate 
eventual drifts of the PTX-peak positions and areas. 
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Table 5-2 Elution gradient used for the quantification of PTX by high performance liquid chromatography. 
time (min) AcN (%vol) UP-water (%vol) 
0 20 80 
2 20 80 
20 80 20 
22 100 0 
24 40 60 
26 20 80 
 
5.3.3 Liquid-liquid extraction from bovine plasma 
If PTX was incorporated into bovine plasma, a liquid-liquid extraction had to be 
performed prior to the quantification by HPLC. If this step would not have been 
accomplished, the ions, proteins and other components of the plasma would have blocked 
the analytical column during the HPLC-analysis. The extraction method to transfer PTX 
from bovine plasma (2-18F00-I, Amimed) into AcN for HPLC analysis was adopted from 
S.H. Lee et al., who reported a PTX-recovery rate of greater than 97 % [21].  
 
In order to determine the recovery efficiency of PTX from the plasma, preliminary 
tests were performed, in which plasma samples were spiked with known concentrations of 
the drug. A stock solution S1 of PTX in AcN at a concentration of 520 µg/ml was prepared 
like described in the previous section. In a next step, standard solutions in the concentrations 
of 10.4; 1.04; 0.83; 0.62; 0.42; 0.21; 0 μg/ml PTX in plasma were prepared in 10 ml glass 
screw flasks. Each standard solution was vortex mixed for 1 min to disperse PTX well in the 
plasma. 750 µl were each pipetted into 2 ml cryogenic vials (Nalgene) and the same volume 
of tert.-butyl methyl ether (TBME, Riedel-de-Haën, min. 99.7 % purity) was added to each 
of the aliquots, Figure 5-4. The following procedure was composed of two identical cycles. 
After mixing the two phases TBME and plasma with PTX and centrifugation, the organic 
phase, which was enriched with PTX, was pipetted into a 2 ml HPLC glass vial (Infochroma 
AG). The residual PTX in plasma was subjected again to the extraction cycle. The organic 
phase with PTX of the second run was added to the one of the first run. After TBME was 
evaporated at room atmosphere for 120 h, the dry PTX in the vial was reconstituted with  
1.5 ml AcN and then injected into the HPLC for quantification.  
 
The percentage extraction recovery of PTX was determined by comparing the PTX-
peak-area ratios from standard solutions of the appropriate concentrations (PTX in AcN) 
with those obtained in the samples subjected to the complete extraction procedure. 
Extraction recovery was determined as the mean (± SEM) of 3 samples after ANOVA 
statistical analysis using the software of Statistical Design of Experiment by J. Lemaître, 
EPFL [23]. The error risk was set to 5 %. The PTX-plasma-eluates from the release test 
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R_LPEA1_plasma were exposed to the same procedure prior to quantification by HPLC. 
 
PTX in plasma
TBME centrifugation: 
10 min, 4000 rpm
750 µl
750 µl
mix: 60 s
I
II
I
IIIIHPLC
(a) (b) (c)
(d)
(e)(f)(g)(h)
750 µl
drying: 
120 h, rt
reconstitution:
1.5 ml AcN
 
Figure 5-4 Schemata of the extraction of PTX from plasma. 750 µl of each, PTX in plasma (red) and TBME 
(blue) were transferred into a cryo vial (a). They showed separated phases with TBME being at the top. After 
mixing for 60 s, both phases were well dispersed (b). The phases were again separated after centrifugation (c) 
with PTX in the TBME-organic phase on top, plasma plus residual PTX at the bottom. The organic phase was 
transferred with a pipette into the 2 ml HPLC vial (e, I) and the residual PTX in plasma (d) reconstituted with 
750 µl TBME (a). The steps up to (d) were repeated. The second PTX-TBME organic phase (II) was added to 
the fist one (e). TBME was then evaporated (f) for 120 h at room temperature (rt) and dry PTX was left in the 
vial (g). It was re-constituted with 1.5 ml AcN (h) and analyzed by HPLC. 
 
5.3.4 Solid state of paclitaxel by infrared spectroscopy and differential scanning 
calorimetry 
PTX can exist in different polymorphs, like anhydrous crystalline, dihydrous 
crystalline or amorphous [6, 10, 11]. It is crucial to know the solid state of PTX to 
understand and modify its release behavior from the thin porous TiO2-films. IR-spectra of 
the drug were accomplished with a powder FT-IR spectrometer (Spectrum One, Perkin 
Elmer Instruments). The spectra were obtained by placing the powder or the drug-loaded 
coatings onto the sample holder. A spectral width of 4000-500 cm-1 and a spectral resolution 
of 4 cm-1 were applied to record the spectra. 
 
Differential scanning calorimetry (DSC)-measurements were employed to determine 
the crystallinity of PTX. Samples were placed in an aluminum crucible, in which two 
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pinholes were made on top. The cell of the calorimeter (DSC 25, Mettler Toledo) was 
purged with nitrogen flow of 20 ml/min and the samples were heated with a rate of 5 °C/min.  
The flux of heat was recorded as a function of time. The DSC-measurements were 
performed using only one replica, because the available amount of PTX was limited. 
 
5.3.5 Production of paclitaxel polymorphs by solvent evaporation 
Assays were performed to modify the PTX-morphology by solvent evaporation [10, 
11]. The drug was dissolved in a concentration of 50 mg/ml in different solvents and pipetted 
onto a TiO2-surface, Table 5-3. The solvents of interest were dichloromethane (DCM, 
VWR/Prolabo, min. 99.5 %), acetone (ACET, Fluka, min. 99.5 % purity), ethyl acetate (EA, 
Fluka, min. 99.5 % purity) and dimethyl sulfoxide (DMSO, CHROMASOLV, Sigma-
Aldrich, min. 99.7 % purity). In addition to the usage of the pure solvents, 1 ml UP-water 
(MilliQ-system) was dispersed on the TiO2-coating and the same volume of PTX/solvent 
mixture added to it. PTX as a solid was obtained by evaporating the solvent or solvent/water 
mixtures at 60 °C for 48 h in a heat and drying cabinet (Rumed®). PTX was then scratched 
off the TiO2-coating with a spatula prior to its chemical analysis by FT-IR spectroscopy and 
the analysis of its physical properties by DSC. 
 
Table 5-3 Solvents and solvent/water mixtures, which were used to prepare PTX-polymorphs by a solvent 
evaporation technique. 
sample solvent concentration of solvents 
(%vol/%vol) 
DMSO_w730NRL DMSO 100/0 
WDMSO_w730NRL DMSO/water 50/50 
DCM_w730NRL DCM 100/0 
WDCM_w730NRL DCM/water 50/50 
ACET_w730NRL ACET 100/0 
WACET_w730NRL ACET/water 50/50 
EA_w730NRL EA 100/0 
WEA_w730NRL EA/water 50/50 
 
5.4 Materials and methods for the drug-loading of the films and the 
drug-release  
5.4.1 Titania films  
Two different nanostructured titania coatings were prepared on wafer supports and 
used to study the drug-loading. One type was the non-reservoir layer (NRL) w730NRL, the 
second one was the reservoir layer (RL) w730RLs. Both films were sintered at a maximum 
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sintering temperature of 730 °C. The structures of both were well characterized, Chapter 4. 
The NRLs were used to establish the drug-loading procedure and to test the reproducibility 
of the PTX-load in the coating in pre-tests. RLs, which are to be applied on the stent-implant, 
were finally loaded with PTX in main tests. 
 
5.4.2 Drug-loading procedures 
To load PTX into the titania layers, parameters of two loading procedures were varied 
arbitrarily in the initial steps of development. In the first procedure, PTX was dissolved in 
different solvents and loaded into the coating at atmospheric pressure. In the second method, 
PTX was dissolved in two selected solvents and incorporated into the coating at lower 
pressure.  
 
5.4.2.1 Drug-loading at atmospheric pressure  
The objective of applying atmospheric pressure during the drug-loading was to form 
different morphologies of PTX in the coatings [11]. In the present test, only NRL titania 
films were employed. No RLs were applied, to avoid deviations in the PTX-load caused by 
variations in the reservoir densities. The preparation of the drug/solvent solutions involved 
the dissolution of 50 mg PTX_S in 1 ml of each of the solvents: dichloromethane (DCM), 
acetone (ACET) or ethyl acetate (EA) at room temperature. The rectangular shaped TiO2-
coated plates, which had a size of 1.5 x 4 x 7 ⋅ 10-5 cm, Figure 5-5, were first dried at 100 °C  
in a dry and heat cabinet (TC100, Thermocenter) to evaporate adsorbed water from the 
porous structure (step 1, Table 5-4). They were then manually immersed into the 
PTX/solvent solutions, step 2. 
 
top
middle
bottom
5
2.52.5 30
15
40
 
Figure 5-5 Schemata of a TiO2-coated silicon wafer plate, which was cut after drug-loading to obtain small 
samples (top, middle, bottom) for the drug-load quantifications and the drug-release experiments (all 
dimensions in mm). 
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After 48 h the PTX/solvent solution penetrated throughout the capillaries of the 
coating and the specimens were pulled out of the solution manually. They were dried for  
10 min at room atmosphere, step evaporation 1 in Table 5-4. To then trigger a certain 
morphology of the drug in the coating, some of the samples were immediately immersed into 
UP-water for 30 s, while manually agitating. Samples, which were loaded with PTX 
dissolved in ACET and rinsed in UP-water, were called WACET_w730NRL, the ones 
loaded with PTX in DCM and rinsed with water WDCM_w730NRL, and the ones loaded 
with PTX dissolved in EA and rinsed with water WEA_w730NRL. Drug-loaded specimens, 
which were not rinsed with water, were termed ACET_w730NRL if a solution of PTX in 
ACET was applied, DCM_w730NRL when PTX in DCM was used and EA_w730NRL 
when PTX in EA was employed during the drug-loading. A second drying step in the 
climatic test cabinet (RUMED®) at 37 °C and 10 % relative humidity in the dark followed 
for all samples. Blank reference specimens, which did not contain PTX, underwent the same 
drug-loading procedure, except that pure solvents were applied.  
 
Prior to the determination of the quantity of loaded drug, the plate shaped samples in 
Figure 5-5 were cut by a diamond knife into small pieces called top, middle and bottom. 
Only these parts of the plates were used for the drug quantification and release experiments. 
The residual parts close to the edges of the plates were not applied, because they contained 
an inhomogeneous PTX-content, as will be demonstrated later.  
 
5.4.2.2 Drug-loading with a low pressure technique 
The objective of the drug-loading using a low pressure technique was to better control 
and to increase the PTX-load compared to the one achieved by the atmospheric pressure 
technique. Attention had to be given to the solvent’s boiling point when exposing the 
PTX/solvent solution to low pressure. Because if one would apply a pressure lower than the 
saturation pressure of the PTX/solvent solution, it will boil and thus might lower the activity 
of the pharmaceutical. The saturation pressures of the different solvents were estimated by 
the Clausius Clapeyron equation  
 
 
(5-10), 
 
with p: atmospheric pressure of 1.0133 bar, p2: saturation pressure of the solution at the 
temperature T2, ΔHv: evaporation enthalpy of the solution, R: gas constant of  
8.3145 J/(mol · K), T1: boiling point of the solution at room temperature, T2: room 
temperature. The results listed in Table 5-5 clearly showed that the saturation pressures of 
( )
21
21v
2 TT
TT
R
H
p
pln
⋅
−
⋅
Δ
=⎟⎟⎠
⎞
⎜⎜⎝
⎛
Drug-loading of the thin titania films and drug-release Chapter V 
 
106 
DCM, ACET and DMSO were already reached at 593, 327 and 522 mbar. For EA a lower 
saturation pressure of 150 mbar was calculated. The parameters in the drug-loading 
procedure were thus adapted to not reach the solvents’ boiling points. 
 
Table 5-4 Parameters of the drug-loading at atmospheric pressure. 
name of procedure APDS 
coating specification NRL  
step parameter value 
1 drying time (h) 48 
 temperature (°C) 100 
2 immersion solvent DCM, ACET, EA 
 type of PTX PTX_S 
 concentration PTX (mg/ml) 50  
 time (h) 48 
 temperature (°C) 22 ± 2 
 pressure (bar) 1 
3 pull method manual, sequentially 
4 evaporation 1 time (min) 10  
 temperature (°C) 22±2 
 pressure (bar) 1 
5 rinsing solvent H2O 
 time (s) 30 
 temperature (°C) 22 ± 2 
 pressure (bar) 1 
6 evaporation 2 time (min) 30 
 temperature (°C) 60 
 pressure (bar) 1 
7 repetition number of total dips 1 
8 drying 2 temperature (°C) 37 
 time (h) 24 
 relative humidity (%) 10 
 dark (y/n) y 
 
Table 5-5 Calculated saturation pressures of the solvents, which were applied in the drug-loading procedures. 
ΔHv: evaporation enthalpy of the solution; T1: boiling point of the solution at 20 °C and 1 bar; p2: saturation 
pressure of the solution. 
solvent ΔHv  (J/mol K) [24] 
T1(20°C,1bar) 
(°C) [24] 
p2(25°C)  
(bar) 
DCM 28.1 40 0.593 
ACET 29.7 56 0.327 
EA 32.1 77 0.148 
DMSO 52.9 189 0.522 
 
Drug-loading of the titania coatings was performed at lower pressure in a modified 
embedding chamber (Epovac, Struers), like illustrated in Figure 5-6. Plate shaped samples 
were prepared by a drying step at 100 °C in a dry and heat cabinet, to evaporate water in the 
porous structure (step 1 in Table 5-6). They were then mounted-without cutting-onto the 
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holder in the embedding chamber and a low pressure was applied to “evacuate” the porous 
structure (step 2 in Table 5-6). By dipping the samples into the PTX/solvent solution at low 
pressure (step 3) and applying atmospheric pressure (step 4), the liquid was forced to 
penetrate the porous network. The samples were pulled out either all at ones (LPDMSO) or 
consecutively (LPEA) manually after a certain time (step 5 in Table 5-6). The solvent was 
evaporated at varying conditions (steps 6 to 8). Upon completion of the drug-loading and in 
order to preclude undesirable PTX clusters on top of the TiO2-surface, specimens in LPEA2 
were immersed into solutions of different concentrations of AcN in UP-water. They were 
manually agitated for 30 s before they were pulled out (step 11). Accordingly specimens 
were dried in a final step (step 12). Blank reference samples without PTX were prepared by 
performing exactly the same drug-loading, except that a pure solvent was applied instead of 
the PTX/solvent solution. 
 
 
Figure 5-6 Chamber to perform drug-loading at lower pressure. (a) preparation of samples under low pressure 
in a plexi-glass chamber (1) with an elevating mechanism (2) in the lid of the chamber, on which the samples 
(yellow) were attached. The solutions in the cuvettes or beakers, (3) PTX-solution and (4) solvent solution as a 
reference, were mounted in a base plate in the chamber. With the pressure regulator (5) the pressure in the 
chamber was adopted (6). In (b) a dip of the samples (7) into the solutions is illustrated. 
 
Three different drug-loading methods were applied to study the influence of different 
process parameters on the drug-load, Table 5-6. The method LPDMSO was used to study the 
reproducibility of the PTX-load into the NRLs and to evaluate the effect of 1 compared to 4 
consecutive dips into the PTX/DMSO solution, which had a concentration of 10 mg/ml.  
Dimethyl sulfoxide (DMSO) was used, because it is commonly employed as a carrier for 
pharmaceuticals in medicine, it is water soluble and the maximum solubility of PTX in it 
was known to be 50 mg/ml [4]. 
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The drug-loading method LPEA1 was applied to study the effect of the immersion time, 
step 4 in Table 5-6, onto the total drug-load. The maximum solubility concentration of PTX 
in EA was not found in literature. It was determined by consecutively adding PTX_K into 
EA, stirring the solution for 5 min with a magnetic stirrer at 300 rpm at room temperature 
and observing the opacity of the solution. If the solution was transparent after each stirring 
period, more PTX was added. As soon as the solution stayed cloudy, it was assumed to be 
saturated. Thus the saturation concentration was deduced to be 103.61 mg/ml.  
 
In LPEA2 the effect of rinsing after the drug-loading to remove undesired PTX on top 
of the surface was evaluated. The PTX-loaded coatings were therefore immersed into a 
solution of acetonitrile (AcN) and UP-water in different concentrations or into EA for 3 s.  
SEM-micrographs were taken and the residual quantity of PTX in the coatings determined 
by HPLC, cf. Chapter 5.4.4. 
 
Because the PTX/solvent solution already had to be situated in the embedding chamber 
at lower pressure during step 2, a suitable time had to be chosen for that step to avoid the 
total evaporation of the solvent and hence an up-concentration of PTX in the solution. The 
time for step 2 in the methods LPEA1 and LPEA2 was set by performing an evaporation 
experiment of EA. Therefore two quartz cuvettes (Hellma) with each an open area of 1 cm2  
were filled with 1.6 g of EA. They were then exposed to 350 mbar in the embedding 
chamber. After each 20 min, up to a total time of 120 min, the cuvettes were taken out and 
weighted. A curve of the mean mass of EA as a function of time it was exposed to lower 
pressure was plotted. Its slope correlated to the evaporation rate of EA. 
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Table 5-6 Parameters used for the drug-loading with the low pressure technique.  
Name of 
procedure 
 LPDMSO LPEA1 LPEA2 
coating 
specification 
 NRL NRL, RL NRL, RL 
step parameter value 
1 drying 1 time (h) 24  24  24  
 temperature (°C) 100 100 100 
2 low pressure time (min) 30 10 10 
 temperature (°C) 22±2 22±2 22±2 
 pressure (bar) 0.200 0.350 0.350 
3 immersion  solvent DMSO  EA EA 
 concentration PTX (mg/ml) 10  103.61 ± 21.82 103.61 ± 21.82 
 time (s) 30 60  60  
 temperature (°C) 22 ± 2 22 ± 2 22 ± 2 
 pressure (bar) 0.200 0.35 0.35 
 position sample in solution 
4 high pressure time (h) 0.02 0.02; 0.5; 1; 5; 24 24 
 temperature (°C) 22 ± 2 22 ± 2 22 ± 2 
 pressure (bar) 1 1 1 
 position sample in solution 
5 pull method manual, all at 
once 
manual,  
sequentially 
manual,  
sequentially 
6 evaporation 1 time (min) 2 2  2  
 temperature (°C) 22±2 22±2 22±2 
 pressure (bar) 1  1  1  
7 evaporation 2 time (min) 25 60  60 
 temperature (°C) 22±2 22±2 22±2 
 pressure (bar) 0.200 0.350 0.350 
8 evaporation 3 time (min) 30 30 30 
 temperature (°C) 60 60 60 
 pressure (bar) 1 1 1 
9 repetition number of total tips 1; 4  1 1 
10 drying 2 time (h) 24 24 24 
 temperature (°C) 37 37 37 
 relative humidity (%) 10 10 10 
 dark (y/n) y y y 
11 rinsing solvent - - AcN in UP-water 
(%vol): 
0; 20; 40, 60; 80; 100 
EA: 100 %vol 
 time (s) - - 3 
 temperature (°C) - - 22 
 pressure (bar) - - 1 
12 drying 3  - - cf. step 10 
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5.4.3 Microscopy 
Photos of the drug-loaded coatings, which were cut from the top, middle and bottom 
position of the plate shaped samples illustrated in Figure 5-5, were taken by a light 
microscope (MZ8, Leica). The correct, geometric area of these samples was subsequently 
determined analyzing the images by the imaging software ImageJ (V 1.38x). The drug-
loaded films were furthermore examined at higher resolution by an optical microscope 
(Olympus B071). Micrographs of the cross sections of the drug-loaded, nanostructured 
titania film samples were taken by a high resolution scanning electron microscope (HRSEM, 
XL-30SFEG, Philips). 
 
5.4.4 Quantification of the total drug-load 
After the plate shaped specimens depicted in Figure 5-5 were loaded with PTX, the 
amount of pharmaceutical in the porous coating was determined. Simple weighing was not 
possible, because the amount of PTX was below the detection limit of the balances. The only 
way to quantify was by first cutting the big plates in Figure 5-5 into the small pieces called 
top, middle and bottom with a diamond knife. Their geometric area was determined by 
microscopy, cf. Chapter 5.4.3. No slices, which were cut close to the edges of the plates, 
were employed for the quantification. The droplet formation of the PTX/solvent solution on 
the edges of the sample after withdrawal from the solution has caused an inhomogeneous 
PTX-load in the region close to the edges. The small samples were then each transferred into 
a 2 ml, glass HPLC vial and 1.5 ml AcN added to any of them. After 1 hour of agitation with 
250 1/min (VIBRAX VXR basic, IKA) at 37 °C, PTX was dissolved in the coating and was 
diffused into the surrounding AcN. The titania coated supports were removed from the 
HPLC vial and the PTX/AcN solution stored at -81 °C (-86 Ultralow freezer, NUAIRETM) 
prior to their analysis by HPLC. From the determined concentration of PTX in AcN by 
chromatography, the PTX-load as mass per geometric area was calculated. 
 
That the total amount of PTX was diffused out of the coating into AcN after 1 h of 
agitation was verified at the early stages of this study. Thereby the drug-loaded specimens 
were exposed to AcN for 3 h, whereas AcN was re-freshed every hour. The PTX in all of 
these solutions was quantified. PTX was only measured in the eluate after 1 h. The 
concentrations in the eluates after 2 and 3 h were below the detection limit of the HPLC and 
were estimated to be maximal 0.0015 % of the initially incorporated amount of PTX, and 
hence negligible.  
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5.4.5 Drug-release tests into water and bovine plasma 
The PTX-release from the titania coatings was studied in elution tests, using either UP-
water or bovine plasma as elution media. Water was applied for simplification, because the 
eluates did not need to be subjected to the extraction step prior to the injection into the 
HPLC. Hence the results were obtained in a reasonable time and could be compared to 
simulations. PTX, which was eluted into plasma, had to be extracted from the plasma prior 
to the analysis by HPLC. This was accompanied by a bigger working effort and only 
selected titania coatings were used for this test. 
 
After the drug-loaded plates were cut into small pieces from the regions top and 
middle of the plates in Figure 5-5, their geometric area was determined by microscopy as 
was previously described in Chapter 5.4.3. Each small drug-loaded sample was transferred 
into a 2 ml HPLC glass vial and 1.5 ml media, UP-water or plasma, added. After slight 
agitation at 250 1/min at 37 °C in the dry and heat cabinet for a designated time, the 
specimens were each transferred into a fresh HPLC vial and reconstituted with 1.5 ml fresh 
media. They were again placed into the dry and heat cabinet for the next time interval. This 
procedure was repeated multiple times, according to Table 5-7. The time points for the total 
exchange of the media were varied from test to test, because appropriate time spans for each 
interval had to be found. They depended on the maximum dissolution concentration of PTX 
in that particular media and on the detection limit of PTX by the HPLC method. Furthermore 
the diffusion of PTX from the films depends on a concentration gradient of the drug between 
the coating’s surface and the surrounding media. To not limit the diffusion, the gradient had 
to be kept at perfect sink conditions. Those were defined in Chapter 5.2: the concentration of 
PTX in the media should always be lower or at most 1/3 of its maximum solubility 
concentration in that media. 
 
The PTX/media solutions, obtained in each elution interval between the total exchange 
of the media, were stored at -81 °C prior to extraction and/or analysis by HPLC. Because 
PTX strongly adsorbs on various surfaces, each eluate was vortex mixed for 30 s to detach it 
from the glass vial before the analysis [25]. 750 µl of each eluate of PTX in water were 
transferred into a 2 ml HPLC glass vial. The same volume of AcN was added to stabilize the 
drug in solution and to keep it detached from the vial’s wall to allow the application of the 
auto-sampler of the HPLC.  
 
The quantification of PTX in the plasma-eluates of the test R_LPEA1_plasma was 
achieved by performing a liquid-liquid extraction (cf. Chapter 5.3.2) followed by HPLC-
analysis. A Taxus Express2TM stent (Boston Scientific) was also subjected to the release test 
into bovine plasma for comparison. In each drug-release test, drug-loaded and non-drug-
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loaded coatings were used, each in triplicates, Table 5-7. 
 
Table 5-7 Parameters of the in vitro drug-release tests of PTX from the TiO2-coatings.  
release test loading 
procedure 
sample release media time points  
R_APDS APDS DCM_w730NRL 
ACET_w730NRL 
EA_w730NRL 
WDCM_w730NRL 
WACET_w730NRL 
WEA_w730NRL 
w730NRL (blank) 
UP-water 1; 5; 10 h;  
1; 2; 3; 4 d 
R_LPEA1_water LPEA1, 24h EA_w730RL 
w730RL (blank) 
UP-water 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11 h 
1; 1.5; 2; 3; 4; 6; 7; 8; 9; 10; 11;    
13;  14; 15; 16; 17; 18; 20; 21; 22; 
23; 24; 25; 27; 28; 29; 30; 31; 32 d 
R_LPEA1_plasma LPEA1, 24h EA_w730RL 
w730RL (blank) 
TaxusTM stent* 
plasma 0.5; 1; 2; 3; 4; 5; 6; 7 d 
* specification: Taxus Express2TM, Monorail, 3.5 x 24 mm, Boston Scientific  
 
5.4.6 Surface wettability by contact angle measurements  
The contact angles of the PTX-loaded coatings with water were measured with an 
OCA 35 (Data Physics Instrument GmbH). 2 μl of water were placed manually on the 
surface of the sample. After 20 s, a photo was taken and the contact angle automatically 
evaluated by the software SCA20. 
5.4.7 Simulation of the diffusion coefficient 
Simulation of the free diffusion coefficient of PTX in water was performed by U. 
Aschauer, LTP, using the molecular dynamics software MS Modeling v4. (Accelrys 
Software Inc). One molecule of PTX was placed into a cubic amorphous cell of water 
molecules. The cell had a side length of 2.9 nm. The mean square displacement of PTX in 
the amorphous water during 0.5 ns was simulated. The self diffusion coefficient of PTX 
could then be calculated from that value. 
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5.5 Results 
5.5.1 Validation of the high performance liquid chromatography and the extraction 
methods 
A representative chromatogram of paclitaxel (PTX) in acetonitrile (AcN), as obtained 
by high performance liquid chromatography (HPLC), is presented in Figure 5-7. PTX eluted 
with a single sharp peak from the analytical HPLC-column at a retention time of 18.6 min. 
 
 
Figure 5-7 Chromatogram of a paclitaxel standard in acetonitrile.  
 
Calibration curves were measured for each of the two types of PTX applied, PTX_S 
and PTX_K, in ultra pure (UP)-water, AcN and in AcN/UP-water in a mixing ratio of  
50/50 vol%. To establish the calibration curves in various solvents was necessary, because 
they were employed to quantify the PTX-loads in the nanostructured titania coatings, as well 
as to study its drug-release in in vitro release tests. Examples of the calibration curves of 
PTX_K in AcN and AcN/UP-water are depicted in Figure 5-8. Linearity between the PTX-
peak areas and its concentrations were accepted, when the correlation coefficient R2 between 
the measured data and the linear regression was bigger than 0.9900. Typical equations of the 
linear regression and the regression coefficients are pointed out for the particular calibration 
curve in the graphs. Depending on the concentrations of PTX detected in the media of the 
drug-release tests, additional calibration curves to the ones in Figure 5-8 were measured, to 
quantify in this particular PTX-concentration range. The limit of detection of PTX in 
AcN/UP-water was measured to be at a concentration of 0.02 µg/ml. This was the 
concentration, at which the signal to noise ratio was 3:1 [26]. 
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Figure 5-8 Calibration curves of paclitaxel in (a) acetonitrile and in (b) a mixture of acetonitrile and water. 
 
To evaluate the efficiency of the extraction of PTX from plasma, the plasma, which 
was spiked with known concentrations of PTX, was subjected to the liquid-liquid extraction. 
The PTX-concentrations of these extracts were then analyzed by HPLC and linear related to 
the known peak areas. A typical equation obtained by regression of the data points was  
y = 193887 · x with a correlation coefficient of 0.9958. The extraction recovery of PTX with 
the applied method was 96.54 % for a concentration range of spiked plasma of 0.2 to  
1 µg/ml, Figure 5-9. The detected recovery rate was similar to the one recorded by Lee et al. 
[21]. No significant differences of the PTX-recovery between the measured mean values at 
the particular concentrations were detected after analysis of variance (ANOVA) with an 
error risk of 5 %. Hence the extraction efficiency was alike at the depicted concentration 
interval. The method of liquid-liquid extraction hence could be applied for the quantification 
of PTX in plasma in the in vitro drug-release tests. 
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Figure 5-9 Recovery rate of PTX after extraction from plasma. Displayed are the adjusted mean values 
(columns), the non-adjusted mean values (Δ) and the standard deviations (-) after ANOVA analysis with  
p < 0.05.  
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5.5.2 Solid states of the polymorphs of paclitaxel 
Solid PTX can have different morphologies. The as-received forms of PTX, PTX_S 
and PTX_K, were characterized to be anhydrous crystalline, when comparing their FT-IR-
spectra and DSC-thermograms with the findings of Lee et al. and Pyo et al., Figure 5-10 and 
Figure 5-2 [10, 11]. Both IR-spectra in Figure 5-10 (a) show the same characteristic bands at 
wave numbers between 2500 and 500 cm-1. Those are particularly the two characteristic 
carbonyl absorptions in the region of 1720 cm-1 and a sharp long band at 1650 cm-1. 
 
30 70 110 150 190 230 270
Temperature (°C)
H
ea
t f
lo
w PTX_S
PTX_K
Exo
5001000150020002500
Wavenumber (cm-1)
Tr
an
sm
is
sio
n
PTX_S
PTX_K
(a) (b)
1720
1650
1522
 
Figure 5-10 FT-IR spectra of (a) the as-received forms of paclitaxel PTX_S, PTX_K and (b) DSC-
thermograms of PTX_S and PTX_K. 
 
The recorded DSC-thermograms of the as-received types of PTX in Figure 5-10 (b)  
exhibited the same characteristic peaks representing phase transitions. No transitions were 
observed up to 220 °C. At 222.04 °C an endothermic peak was recorded, which denoted the 
melting of the drug. The melting point correlated with the one in literature [4, 6]. The heat of 
fusion, ΔH, was calculated from the peak area to be 77.86 ± 0.17 J/g. The adjacent 
exothermic peak at 230 °C was representative of the decomposition of PTX.  
 
The morphology of PTX, which was formed by solvent evaporation, was also 
determined by FT-IR- and DSC-measurements. The FT-IR spectra of the PTX-polymorphs 
are pointed out in Figure 5-11. The labeling of the samples was the following. Samples, 
which were loaded with PTX dissolved in ACET and rinsed in UP-water, were called 
WACET_w730NRL. The ones loaded with PTX in DCM and rinsed with water were termed 
WDCM_w730NRL, and the ones loaded with PTX dissolved in EA and rinsed with water 
WEA_w730NRL. Drug-loaded specimens, which were not rinsed with water, were termed 
ACET_w730NRL if a solution of PTX in ACET was applied, DCM_w730NRL when PTX 
in DCM was used and EA_w730NRL when PTX in EA was employed during the drug-
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loading. The spectra of the individual morphologies clearly showed differences in several 
wave number regions. DCM_w730NRL, WDCM_w730NRL and EA_w730NRL showed 
one carbonyl absorption near 1720 cm-1, whereas all the others exhibited two carbonyl 
absorptions. Other absorption bands near 1650 and 1522 cm-1 also featured differences in 
their shape. While at 1650 cm-1, DCM_w730NRL, WDCM_w730NRL, 
WACET_w730NRL, EA_w730NRL and WEA_w730NRL held a small, round shaped band, 
the other samples exhibited a long, sharp band. 
 
Figure 5-12 presents the DSC-thermograms of PTX formed by the evaporation of 
different solvents. A glass transition was observed at 144 °C in the graph of 
DCM_w730NRL and an exothermic peak at 230 °C, representing the decomposition of PTX. 
The morphology of PTX was identified with the reference spectra and thermograms in 
Figure 5-2 to be amorphous, Table 5-8. 
 
 
Figure 5-11 IR spectra of paclitaxel-polymorphs, which were formed by solvent evaporation.  
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Figure 5-12 DSC-thermograms of paclitaxel-polymorphs, which were formed by solvent evaporation. 
 
An endothermic dehydration and vaporization peak with its maximum at 81 °C was 
detected for the PTX in WDCM_w730NRL. The intermediate PTX, which was formed after 
the dehydration, was identified to be dehydrated paclitaxel dihydrate, when comparing with 
literature [6]. At higher temperatures, two small endothermic peaks occurred. They were 
solid-solid transitions at 164 °C and 171 °C, in which the intermediate PTX was converted to 
a semi-crystalline material. This semi-crystalline PTX melted at 218 °C with a heat of 
fusion, ΔH, of 20.28 J/g, like pointed out in Table 5-8. A glass transition could not be 
identified by DSC measurements, but the IR spectrum of WDCM_w730NRL in Figure 5-11  
exhibited at 1720 cm-1 and 1650 cm-1 characteristic bands for the amorphous form of PTX. 
Therefore PTX created from H2O and DCM was composed of amorphous and dihydrated 
crystalline PTX-morphologies. The DSC-thermogram of ACET_w730NRL was 
characterized by a single melting endotherm at 215 °C with ΔH of 55.78 J/g. PTX was hence 
classified as anhydrous crystalline, which is in accordance to the findings from the IR-
measurements. WACET_w730NRL exhibited a similar DSC-curve like WDCM_w730NRL. 
The endothermic peak with its maximum at 88 °C represented the dehydration/evaporation 
of residual water and solvent and the formation of the intermediate form of PTX. At 164 °C,  
a solid-solid transition was detected. A melting transformation at 218 °C followed, which 
consumed the heat of fusion of 28.25 J/g. WACET_w730NRL was hence dihydrated 
crystalline, as was also proven by the IR-measurements. EA_w730NRL exhibited a glass 
transition at 147.83 °C and a decomposition peak at 230 °C. It was amorphous. By adding 
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water to the PTX/EA solution on the titania coating, the dihydrated morphology of PTX was 
created. The corresponding DSC-thermogram showed a dehydration/evaporation endotherm, 
a solid-solid transition and a melting endotherm, Figure 5-12. The IR-spectrum was also 
characteristic for that morphology. DMSO_w730NRL and WDMSO_w730NRL exhibited 
only a melting transition in the thermograms at 222 °C. Both forms were identified as 
anhydrous crystalline. A summary of the formed morphologies of PTX can be found in 
Table 5-8. Various PTX-polymorphs were formed by simply applying various solvents or 
solvent/UP-water mixtures. Their influence on the drug-load and release will be explored in 
the following. 
 
Table 5-8 Polymorphs of paclitaxel, which were formed by solvent evaporation.  
sample morphology Transition T (°C)/ΔH (J/g) 
  peak I glass transition solid-solid  melting  
DCM_w730NRL amorphous - 143.94/- - - 
WDCM_w730NRL amorphous +       
dihydrated crystalline 
80.93/-48.33 - 163.81/-7.12  
171.14/-1.32 
218.45/-20.28 
ACET_w730NRL anhydrous crystalline - - - 215.21/-55.78 
WACET_w730NRL dihydrated crystalline 87.61/-84.99 - 164.17/-12.17 218.39/-28.25 
EA_w730NRL amorphous - 147.83/- - - 
WEA_w730NRL dihydrated crystalline 84.30/-79.82 - 163.85/-9.67 215.28/-21.94 
DMSO_w730NRL anhydrous crystalline - - - 222.61/-71.62 
WDMSO_w730NRL anhydrous crystalline - - - 222.25/-82.82 
 
5.5.3 Preliminary tests to identify parameters influencing the drug-load and release 
Preliminary tests were performed to identify factors, which influence the drug-loading 
into the porous TiO2-coating. Some errors occurring during these tests were not 
systematically analyzed. Although the results are presented at this point, because some 
findings might be relevant for the optimization of the coating for drug-eluting stents (DESs) 
in future studies. 
 
5.5.3.1 Polymorphs of paclitaxel 
Drug-loading at atmospheric conditions with the method APDS was chosen to create 
different polymorphs of PTX in the coating. The amounts of drug in the non-reservoir layers 
(NRLs) as a function of applied solvent are pointed out in Figure 5-13. For DCM_w730NRL 
and WDCM_w730NRL an amount of 1.241 ± 0.257 µg/mm2 geometrical surface area of the 
coating was obtained. For ACET_w730NRL and WACET_w730NRL  
1.094 ± 0.443 µg/mm2 and for EA_w730NRL and WEA_w730NRL 0.411 ± 0.128 µg/mm2 
were detected. The polymorphs, which were formed by the evaporation of the solvents and 
solvent/water mixtures, were identical to the ones characterized in the previous chapter: 
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DCM_w730NRL and EA_w730NRL: amorphous, WDCM_w730NRL: amorphous and 
dihydrated crystalline, ACET_w730NRL: anhydrous crystalline, WACET_w730NRL and 
WEA_w730NRL: dihydrated crystalline. High standard deviations in all of the measured 
loads were discovered, but not systematically investigated at this stage of development.  
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Figure 5-13 Paclitaxel-loads of the non-reservoir titania layers as a function of applied solvent, solvent/water 
mixture.  
 
The release profiles of PTX from these drug-loaded NRLs into water clearly showed 
differences one to each other, like depicted in Figure 5-14. The samples not rinsed in water 
after the loading were characterized by a fast release at the beginning up to 10 h, followed by 
a continuous, slower release up to 4 d, Figure 5-14 (a). At the beginning of elution, 
EA_w730NRL released the highest amount of drug in the so-called burst-release, compared 
to the other specimens. After 4 d, 33 % of initially incorporated drug, were released. The 
profile of DCM_w730NRL was similar, but with a lower burst-release. ACET_w730NRL 
was characterized by the slowest liberation of the pharmaceutical: 16 % of totally 
incorporated drug eluted after 4 d. The shapes of the release curves of the specimens rinsed 
with water after loading in Figure 5-14 (b) were similar and with a lower burst-release 
compared to the samples not rinsed in water. The quantities of released PTX up to 4 d were 
different: WEA_w730NRL: 12 %, WDCM_w730NRL: 10 % and WACET_w730NRL: 5 %.  
The test was stopped after 4 d of elution, because it was a preliminary test. Even if the 
dissolution yielded an incomplete drug-release from the coating after these 4 d, the release 
kinetics were analyzed. The mathematical models, which were introduced in Chapter 5.2, 
were employed.  
 
The release data of all samples were fitted to the Korsmeyer-Peppas, Higuchi, zero-
order and first order models. Only data from selected time intervals of the release curves 
were chosen because of the following. The concentrations of PTX detected in the aqueous 
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media for DCM_w730NRL, ACET_w730NRL and EA_w730NRL were as high as 10 µg/ml  
after 1 h, and 5 µg/ml after 5 h of elution. 
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Figure 5-14 In vitro release of paclitaxel from non-reservoir titania coatings into water as a function of time 
and PTX-morphology. 
 
These values exceeded the maximum solubility concentration of PTX in water of  
3 µg/ml, which was deduced from literature, cf. Table 5-1. Hence perfect sink conditions, 
which are required for the application of the mathematical models, were not fulfilled. The 
detected high PTX-concentrations were caused by the breaking of loose PTX-fragments on 
top of the titania coating. The same phenomenon of high PTX-concentrations in water was 
observed for WDCM_w730NRL, WACET_w730NRL and WEA_w730NRL. The drug 
concentrations in the media up to 10 h of elution were then as high as 6 µg/ml for 
WDCM_w730NRL and 1 and 3 µg/ml for WACET_w730NRL and WEA_w730NRL, 
respectively. The data points of the release up to 10 h of elution were excluded from the 
evaluation. Only the part of the release curve between 24 to 96 h was employed in the 
analysis. The PTX-concentrations in water were smaller than 1 µg/ml in this interval and 
hence fulfilled perfect sink conditions.  
 
The exponent n of the Korsmeyer-Peppas model, the release rate constants k and the 
correlation coefficients R2 for all samples are depicted in Table 5-9. The Korsmeyer-Peppas 
model revealed for the drug-release from any coating n < 0.5 and thus predicted a diffusion 
transport. The kinetic model that best fitted the experimental data was deduced by R2. The 
samples DCM_w730NRL, ACET_w730NRL, WDCM_w730NRL, WACET_w730NRL 
exhibited the best linearity for the zero-order approach with regression coefficients of  
0.973, 1.000, 0.997, 0.991. The highest regression coefficients for EA_w730NRL and 
WEA_w730NRL were evaluated for the Higuchi model with R2 of 0.998 and  
0.989, respectively.  
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Table 5-9 In vitro release kinetics of PTX from the TiO2-coatings. Shown are the release exponent n, the 
regression coefficients R2 of the mathematical fits and the release constants k of the individual models.  
sample morphology Korsmeyer-  
Peppas 
Higuchi  zero order  first order  
  n R2 kh ⋅ 10-5 
(µg/(mm2 s)) 
R2 k0 ⋅ 10-5 
(%/s) 
R2 k1 ⋅ 10-6 
(%/s) 
R2 
DCM_w730NRL amorphous 0.206 0.950 30.732 0.967 2.819 0.973 1.122 0.971 
ACET_w730NRL anhydrous 
crystalline 
0.181 0.974 13.530 0.990 1.415 1.000 0.990 0.999 
EA_w730NRL amorphous 0.218 0.991 14.986 0.998 3.330 0.996 1.172 0.988 
WDCM_w730NRL amorphous, 
dihydrated 
crystalline 
0.236 0.974 12.344 0.985 1.136 0.997 1.285 0.996 
WACET_w730NRL dihydrated 
crystalline 
0.416 0.962 7.979 0.973 0.838 0.991 2.273 0.990 
WEA_w730NRL dihydrated 
crystalline 
0.312 0.984 5.827 0.989 1.293 0.984 1.672 0.975 
 
By comparing these findings it seems that the drug-release from the coatings depended 
on the dissolution rate of the drug rather than on the diffusion of PTX from the porous 
structure, except for the EA_w730NRL and WEA_w730NRL. An effective diffusion 
coefficient, Deff, was not calculated from the release constants, because the precise transport 
mechanisms involved in the drug-release were unknown. PTX was present in the pores of 
the NRLs as well as in a so-called burst-layer on top of the coating, which will be illustrated 
later in this chapter. Hence it was unclear, from which position of the coating PTX was 
released. A Deff of PTX dissolved from the burst-layer must be different to a Deff when PTX 
is diffused through the porous structure of the coating. The geometric factors to calculate Deff 
were hence inexplicit. But the release constants k could be evaluated. The higher k0 in the 
zero order release is, the faster is the release. For amorphous PTX in DCM_w730NRL and 
EA_w730NRL, k0 of 2.819 · 10-5 and 3.330 · 10-5 %/s (% of initially loaded drug released 
from the matrix per second) was obtained, respectively. The zero order constants of the 
anhydrous crystalline PTX in ACET_w730NRL was 1.415 · 10-5 %/s and smaller than for 
the amorphous forms. WACET_w730NRL and WEA_w730NRL with dihydrate crystalline 
morphologies exhibited k0 of 0.838 · 10-5 and 1.293 · 10-5 %/s, respectively. The release rates 
were smaller than the ones of the anhydrous crystalline and amorphous forms of PTX. 
WDCM_w730NRL, as an amorphous and dihydrate crystalline form, exhibited k0 of  
1.136 · 10-5 %/s. Thus the dissolution rate is coherent with the physical properties of the 
different morphologies of PTX. The amorphous forms dissolved faster than any crystalline 
ones. The dihydrate crystalline polymorph, which has a lower aqueous solubility than the 
anhydrous crystalline one (cf. Chapter 5.1), showed the smallest dissolution rate. 
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5.5.3.2 Dip coating and number of dips 
The relatively distinct standard deviations in the PTX-loads, which were observed in 
the previous test, were connected to a non-uniform PTX-load in the big TiO2-plates. A 
systematic analysis of the PTX-quantity loaded into the small pieces cut from the positions 
top, middle and bottom of the big plates, illustrated in Figure 5-5, was carried out. The big 
titania coated plates with a NRL-structure were hence drug-loaded with the low pressure 
technique LPDMSO. One single dip of the plates into the PTX/DMSO solution was performed.  
 
The amount of medicament loaded into the small pieces, which are located in the top 
and middle of the big plates, was equal: 0.016 µg/mm2, like depicted in Figure 5-15. The 
samples from the bottom, 5 mm distant from the lowest edge of the plates, held a PTX 
amount of 0.159 µg/mm2. This value was of an order of magnitude of 1 bigger than for the 
other specimens. The same tendency of inhomogeneous drug-load was detected for samples 
loaded with 4 consecutive dips into the PTX/DMSO solution. Specimens from the top 
position of the plates contained 0.016 µg/mm2, from the middle location 0.022 µg/mm2 and 
from the bottom region 0.110 µg/mm2. Whereas the quantity in the top piece did not increase 
after 4 consecutive dips, the amount in the middle piece contained 37.5 % more drug than 
after 1 single dip. The PTX-load in the bottom piece decreased after 4 dips compared to 1 
dip, but was still much higher than for the other specimens. This accumulation of PTX at the 
bottom was caused by the droplet formation of the PTX/DMSO solution after withdrawal of 
the plate-samples. This effect was still significant on the drug-load in regions of the NRLs, 
which were 5 mm distant from the bottom edge of the plate. In future drug-loading tests, 
only 1 dip into the PTX/solvent solution was performed. Quantification of the drug-load was 
only performed on small specimens cut from the top and middle regions of the big plates, 
because the drug-load was there reproducible. 
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Figure 5-15 PTX-loads of non-reservoir layers as a function of the position on the big, drug-loaded plates and 
of the number of dips into the PTX/DMSO solution. Shown are the mean values and the two individual data 
points.  
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5.5.4 Optimization of the drug-load using a low pressure technique  
The objectives to apply low pressure during drug-loading were (1) to evacuate the 
pores of the titania coating prior to immersion into the PTX/solvent solution and (2) to apply 
a pressure gradient, which forces the solution into the coating. Small tests were performed 
first, to set parameters of the drug-loading. 
 
A test to determine the evaporation rate of the solvent EA at 350 mbar was deduced to 
set the preparation time of the NRLs at lower pressure, step 2 in Table 5-6. The pressure of 
350 mbar was chosen instead of the solvent’s saturation pressure of 150 mbar, to provide 
reliability by reducing the evaporation rate and hence by keeping the level of solvent in the 
glass beakers constant for a longer period of time than at 150 mbar. A glass cuvette was 
filled with EA and exposed to 350 mbar. At certain times the mass of EA in the cuvette was 
measured. A linear decrease of the solvent’s mass in the cuvette as a function of time was 
recorded, Figure 5-16. After 120 min, 45 %wt of the initial EA in the quartz cuvette was left. 
For the methods LPEA1 and LPEA2 a time span of 10 min was applied to prepare the NRLs at 
low pressure. Because after that time, 95 %wt of the EA initially poured into the cuvette was 
still present. The up-concentration of the drug in the PTX/solvent solution due to the 
evaporation of the solvent was hence negligible.  
 
Another parameter changed for these drug-loading procedures, compared to the ones 
previously used, was the concentration of PTX in the solvent. The saturation concentration 
of PTX in EA of 103.61 ± 21.82 µg/ml was applied in the following. 
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Figure 5-16 Mass of EA as a function of time, in which it was exposed to a pressure of 350 mbar. 
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5.5.4.1 Influence of the coating’s structure and the immersion time  
The immersion time of the NRLs into the PTX/EA solution was varied in the test 
LPEA1: 1 min, 0.5 h and 5 h. Two big titania coated plates were loaded with the same method 
to check the reproducibility of the drug-loading. From each one, three small samples from 
the top and middle position were cut and the PTX-quantity determined, Figure 5-17. Each of 
the columns of the PTX-loads in Figure 5-17 corresponds to the mean value of drug-loads of 
one big plate. The two columns at one immersion time represent plate 1 and 2, which were 
drug-loaded identically. No significant differences in the mean values of the PTX-loads of 
plate 1 and 2 at each immersion time were deduced after ANOVA analysis with an error risk 
of 5 %. The drug-loading was hence reproducible. Significant differences of the PTX-loads 
as a function of immersion time were recorded. The adjusted mean value for an immersion 
time of 0.02 h (1 min) was 0.706 µg/mm2, for 0.5 h 0.504 µg/mm2 and for 5 h  
0.818 µg/mm2, Table 5-10. 
 
The PTX-load in the NRLs depended on the immersion time of the specimens into the 
PTX/EA solution during the drug-loading. After 1 h of immersion, a load of 0.472 µg/mm2  
and after 24 h 1.056 µg/mm2 was measured, Table 5-10. Starting the drug-load with an 
immersion time of 1 min and increasing it to 1 h decreases the PTX-load in the coating, 
whereas the opposite behavior was expected. The decrease in drug-load might have been 
caused by the different thicknesses of the PTX-layer, which was build on top of the porous 
coating, Figure 5-18. The NRL, which was loaded with an immersion time of 1 min 
exhibited the thickest layer of PTX, whereas the layers were thinner after 0.5 and 1 h of 
immersion.  
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Figure 5-17 PTX-loads as a function of immersion time. Shown are the adjusted mean values (columns), the 
mean values as obtained (Δ), the standard deviations (-) after ANOVA analysis with p < 0.05. 
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Table 5-10 Adjusted mean values of the PTX-loads as a function of immersion time and coating type. Values 
were obtained after ANOVA analysis with an error risk of p < 0.05. 
sample type coating specification immersion time (h) PTX-load (µg/mm2) 
EA_w730NRL NRL 0.02 0.706 ± 0.055 
 NRL 0.5 0.504 ± 0.055 
 NRL 1 0.472 ± 0.055 
 NRL 5 0.818 ± 0.055 
 NRL 24 1.056 ± 0.055 
EA_w730RL RL 5 0.941 ± 0.066 
 RL 24 1.211 ± 0.066 
 
By increasing the immersion time above 1 h, the PTX-quantity in the coating 
increased. The maximum PTX-load of 1.056 µg/mm2 in the NRL was obtained after 24 h. 
Up to now, only NRLs were used for the drug-loading and release tests. The objective of the 
study was to incorporate PTX into the RLs and to accumulate the pharmaceutical agent in its 
reservoirs. A calculation was first deduced to estimate the PTX-load in the RLs. If a 
prismatic envelope around the PTX-molecule in Figure 5-1 (b) is drawn, one can calculate 
the volume in that envelope to be 2.132 nm3. This represents the volume of one PTX-
molecule. This approximation, as well as the determined structural parameters of the coating, 
served to estimate the amount of drug, which could theoretically be loaded into the coating. 
The input parameters, which were used for the calculation, are listed in Table 5-11. It was 
assumed that 50 % of the volume of the pores in the coating were filled with the drug. The 
application of this value gets reasonable, if one takes a look at the cross sections of drug-
loaded RLs in Figure 5-20. 
 
The results of the calculation are displayed in Figure 5-19. The theoretical load of a 
NRL was estimated to be 0.195 µg/mm2. The theoretical load of a RL, which has a reservoir 
density of 150000 reservoirs/mm2 and a reservoir size of 1 µm, was 0.201 µg/mm2. The RL 
theoretically would contain 3.08 % more drug than the NRL. By increasing the reservoir 
size, a smaller density of them is necessary to augment the PTX-load. But by enlarging the 
reservoirs, the TiO2-layer gets thicker and also the pore volume in the porous structure 
surrounding the reservoirs. The amount of PTX in that structure significantly influences the 
total PTX-load in the coating.  
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Figure 5-18 SEM-micrographs of cross sections of paclitaxel-loaded, non-reservoir layers. Immersion time 
into the PTX/solvent solution was (a) 1 min, (b) 0.5 h and (c) 1 h.  
 
Table 5-11 Parameters used to calculate the theoretical PTX-load in the TiO2-coatings. 
entry values 
PTX molecular weight PTX 854 g/mol 
 PTX unit volume = volume 1 molecule 2.13 ⋅ 10-9 µm3 
 PTX reservoir and void fill 50 % 
 Avogadro’s constant 6.02 ⋅ 1023 1/mol 
porous TiO2-coating TiO2 porous volume fraction 50 % 
 reservoir size factor after shrinkage, x direction 88 % 
 reservoir size factor after shrinkage, y direction 59 % 
 nanoporous layer thickness 0.329 µm 
 base layer thickness 0.250 µm 
 
The calculation revealed that it would be impossible to load the targeted amount of  
1 µg/mm2 PTX into the RLs. The experiments proved differently: this load was obtained for 
the NRLs loaded with immersion times of 5 or 24 h. These two immersion times were hence 
chosen to perform the drug-loading on RLs. The presence of the reservoirs promoted a 
higher drug-load in both cases compared to the NRLs. The RL contained 14.63 % more drug 
after 5 h and 14.15 % more PTX after 24 h of immersion compared to the NRLs, Table 5-10. 
The total loads after 5 h and 24 h were significantly different one to another in the coatings: 
0.941 µg/mm2 and 1.211 µg/mm2, respectively. Electron microscopy verified that PTX was 
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accumulated in the drug reservoirs, Figure 5-20. Moreover it was present in the porous 
structure surrounding the reservoirs and on top of the coating as a so-called burst-layer. 
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Figure 5-19 PTX-load as a function of reservoir density and reservoir size, as was obtained from calculations. 
The red arrow indicates the properties of the titania reservoir layer used in this study. 
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Figure 5-20 SEM-micrographs of cross sections of paclitaxel-loaded reservoir layers. The immersion time into 
the paclitaxel/solvent solution was 24 h. In (a) reservoirs totally filled with the drug are shown. In (b) only 
partially filled reservoirs are depicted. 
 
5.5.4.2 Influence of the paclitaxel burst-layer on the wettability  
Because PTX has an extremely hydrophobic character, the presence of the PTX-burst-
layer on top of the titania coatings influenced their wettability with water, Table 5-12. The 
mean contact angles for the drug-loaded NRLs and RLs with water were 50.36 ° and 66.74 °, 
respectively. They were much higher than the contact angles of the native coatings with 
water, Table 4-11 in Chapter 4.5.4. A standard deviation of 22 ° was recorded for the drug-
loaded NRLs. This deviation was caused by different wettabilities of the coating with water 
Drug-loading of the thin titania films and drug-release Chapter V 
 
128 
on various spots of one sample.  
 
Table 5-12 Contact angles θc of the PTX-loaded non-reservoir layers (NRL) and reservoir layers (RL) with 
water. 
sample EA_w730NRL EA_w730RL 
θc (°), water 50.36 ± 22.20 66.74 ± 6.41 
 
5.5.4.3 Rinsing  
The total drug-load of the titania coatings was affected by the amount of PTX 
accumulated in the burst-layer. Up to now it was not measured, how much PTX was present 
only in the porous network and how much was localized in the burst-layer. The rinsing test 
LPEA2 to remove the PTX-burst-layer from the coating was therefore accomplished. PTX is 
well soluble in acetonitrile (AcN) and less soluble in water. Rinsing solutions of different 
volumetric concentrations of AcN and UP-water were prepared. They were applied in a 
rinsing step, step 11 in Table 5-6, after the titania coatings were drug-loaded at lower 
pressure with the method LPEA2 and with an immersion time of 24 h.  
 
The influence of the rinsing with the AcN/UP-water mixtures on the total load of PTX 
in the NRLs and RLs can be found in Figure 5-21. If only water was employed for rinsing, 
the total PTX-load in the coatings did not change and was equal to the amount of initially 
loaded PTX. If a mixture of 20 %vol AcN in UP-water was applied, the PTX-load did not 
change. No PTX was dissolved from the coating. However, the top views of the coatings, 
which were observed by an optical microscope, changed, Figure 5-22 (a)-(i). Whereas the 
surface of the water-washed sample looked like the one of the initially drug-loaded sample, 
the PTX in the coating after rinsing in a mixture of 20 %vol AcN showed the formation of 
big, star-like PTX-crystals, (g), (h). They were not only seen on top of the coating, but also 
in the reservoirs, (i). PTX was not as compact as it was in the initial drug-loaded coating (f). 
The morphology of crystal-like PTX was determined by IR spectroscopy as dihydrated 
crystalline. Thus it was possible to change amorphous PTX into a crystalline form in the 
film, by applying an AcN/water mixture for a short period of time to the coatings. 
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Figure 5-21 PTX-load in (a) a NRL and in (b) a RL after washing for 3 s in solutions of different 
concentrations of AcN and UP-water. Shown are the mean values and the individual two data points.  
 
When a mixture of 40 %vol AcN in water was used, the PTX-load in the coating 
decreased more than 50 % in the NRL and of 30 % in the RL, Figure 5-21. The photos (j) to 
(l) in Figure 5-22 show that the amount of crystals on top of the coating was depleted 
compared to the samples washed with 20 %vol AcN. PTX did not occupy as much space in 
the reservoirs as before and showed long, needle shaped crystals. By using a rinsing solution 
of 60 %vol AcN, only 10 % of the initial PTX-load was left in the NRLs, 30 % in the RLs. A 
less amount of crystals was localized on top of the coating’s surface and no PTX was 
detected in the reservoirs, images (m) to (o) in Figure 5-22. If the amount of AcN in water 
was 80 %vol, a trace amount of PTX was left in both types of coatings. No medicament was 
detected in the reservoirs by microscopy. A solution of 100 % AcN caused the total amount 
of PTX being eluted from the coating during only 3 s of rinsing. 
 
Because it was impossible to just remove the upper PTX-burst-layer from the TiO2-
coating using solutions of water and AcN, one assay was performed applying 100 % EA as a 
rinsing solvent, cf. drug-loading method LPEA2, Table 5-6. Only trace amounts of PTX were 
left in the layers: 0.020 µg/mm2 for the NRLs and 0.019 µg/mm2 for the RLs. No PTX was 
seen by electron microscopy in the coatings. 
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Figure 5-22 Optical micrographs and SEM-micrographs of cross sections of drug-loaded RLs after washing in 
solutions of different concentrations of AcN and UP-water.  
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5.5.5 Drug-release of Paclitaxel from the films into water and bovine plasma 
The RLs with a drug-load of 1.21 μg/mm2 and an amorphous PTX-morphology, Table 
5-8 and Table 5-10, were exposed to drug-release tests. The medium was either water in the 
test R_LPEA1_water or bovine plasma in the experiment R_LPEA1_plasma.  
 
The PTX-liberation from the RLs into water was continuous up to 32 d, by which only 
11 % of the initially incorporated quantity of drug were released, Figure 5-23. The test was 
still continuing at the time of writing this chapter. It is expected that the drug-release follows 
this linear behavior until 100 % are released. Different mathematical models were applied to 
the release data. The release constants k were evaluated in the time interval of 24-768 h of 
elution. The kinetic model with the best fit to the release profile was evaluated by the 
correlation coefficient R2, Table 5-13. The zero order release kinetic, with a release constant 
k0 of 0.335 %/s, best described the data. This model predicts a slow, continuous release of 
low water-soluble drugs, cf. Chapter 5.2.2. 
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Figure 5-23 In vitro paclitaxel-release from a reservoir layer. The test was still continuing at the time of report.  
 
Table 5-13 Drug-release kinetics of amorphous paclitaxel from a reservoir layer and from the commercially 
available Taxus Express2TM stent into water or bovine plasma. 
Korsmeyer Higuchi  zero order  first order  release test 
(time interval) 
coating  
specification n R2 kh ⋅ 10-5  
(µg/(mm2·s)) 
R2 k0 ⋅ 10-5 
(%/s) 
R2 k1 ⋅ 10-6 
(%/s) 
R2 
R_LPEA1_water 
(24 – 768 h) 
RL 0.581 0.969 6.426 0.974 0.335 0.994 0.638 0.919 
R_LPEA1_plasma 
(0-7d) 
RL 0.171 0.698 50.494 0.715 4.839 0.454 0.606 0.419 
R_LPEA1_plasma 
(0-7d) 
TaxusTM stent 
 
0.504 0.976 2.769 0.964 0.319 0.857 2.061 0.784 
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The PTX-release from the RLs into bovine plasma exhibited a different release curve 
than the one into water, Figure 5-24. After one day of elution, 43 % of the initial PTX-load 
were liberated. After 4 d, no more pharmaceutical was released and 54 % stayed trapped in 
the coating. No kinetic model introduced in Chapter 5.2 fitted well the data, Table 5-13. All 
correlation coefficients were far below 0.900. Nevertheless, the highest correlation 
coefficient was obtained for the Higuchi-kinetic, with a R2 of 0.715. This model describes 
the release of a solid drug from a solid, porous matrix.  
 
That more than 50 % of the drug stayed trapped in the coating was also observed by 
electron microscopy of the cross sections of a drug-loaded RL, which was exposed for 38 d  
to the elution into plasma, Figure 5-25 (a). The reservoirs of the titania layers were still filled 
with PTX. The morphology of PTX in the reservoirs looked alike the one of the “freshly” 
drug-loaded coatings shown in Figure 5-20. 
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Figure 5-24 (a) In vitro release of PTX from reservoir layers and from the commercially available TaxusTM 
stent. (b) shows a higher resolution of the release curves. 
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Figure 5-25 SEM-micrographs of a reservoir layer, which contains paclitaxel after 38 d of elution into bovine 
plasma. (a) cross section and (b) top view. 
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The SEM-micrographs revealed further that a layer on top of the TiO2-film was built, 
Figure 5-25 (b). This layer was not observed in the SEM-micrographs of drug-loaded RLs 
exposed to the drug-release into water. It could be deduced from this experiment that  
~ 0.6 µg/mm2 PTX were present in the porous structure of the RLs. The residual  
~ 0.6 µg/mm2, which were released up to 4 d, equaled the quantity of PTX in the burst-layer.  
 
The in vitro drug-release curve of the TaxusTM stent into bovine plasma is pointed out 
in Figure 5-24. The PTX-release from this drug-eluting stent (DES) is slower than the 
release from the RLs. Only 2 % of initially incorporated drug-referenced to a load-
concentration of 1 µg/mm2 and a total load of 85 µg [1, 2]-were eluted into plasma up to 7 d. 
The release up to that time was continuous and did not contain a burst-effect at the 
beginning. The release data were best described by the Higuchi model, Table 5-13, with the 
regression coefficient R2 of 0.964. Also in literature it was described that the Higuchi kinetic 
model best describes the PTX-release from the TaxusTM stent [1, 2]. The release was thus 
determined by the diffusion of PTX through the polymer matrix system. This was verified 
further by the release exponent n of 0.504 of the Korsmeyer-Peppas model, which predicts a 
diffusion controlled release mechanism.  
 
The detailed transport mechanisms of PTX from the RLs into water or bovine plasma 
could not be deduced. The system was too complex to correlate appropriate release kinetics 
to the release data. PTX was present in the reservoirs, in the pores of the surrounding 
ceramic structure and it was present as a burst-layer on top of the coating. It was unknown at 
which time PTX got eluted from the burst-layer or from the reservoirs. Hence parameters 
which would have an impact on the effective diffusivity Deff, such as the diffusion layer 
thickness h or the porosity, were not specified. It was not possible to calculate the correct 
Deff from the data and to compare it with the free diffusivities of PTX represented in Table 
5-14. The Stoke’s Einstein diffusion coefficient of PTX in water, DSE, of 3.86 · 10-10 m2/s 
was calculated with Equation (5-3). The simulated diffusion coefficient Dsim of  
5.50 · 10-10 m2/s was equal to DSE.  
 
Table 5-14 Stoke’s Einstein diffusion coefficient (DSE) and simulated diffusion coefficient (Dsim) of paclitaxel 
(PTX) in water. 
Diffusion coefficients of PTX · 10-10 (m2/s) 
DSE 3.86 
Dsim 5.50 [27] 
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5.6 Discussion 
The feasibility to use the nanostructured titania coatings as drug-eluting films for stent-
implants will be discussed. The influence of the structure of the TiO2-layer and the process 
parameters of the drug-loading on the drug-load are depicted. Factors, which influence the 
PTX-release kinetics into UP-water or bovine plasma, will be pointed out. 
 
5.6.1 Characterization of the polymorphs of paclitaxel 
In the present study, various PTX-polymorphs were formed on the nanostructured 
titania coatings. The polymorphs of PTX were varied by dissolving the as-received 
anhydrous crystalline form in different solvents or solvent/water mixtures and evaporating 
the liquid phase [6, 10]. PTX constituted from dichloromethane (DCM) was amorphous, 
which is in accordance with the results from Pyo et al. and Lee et al. [6, 10, 11]. The 
addition of water to PTX, which was dissolved in DCM, changed its morphology to co-
existing forms of amorphous and dihydrated crystalline. This result was comparable with the 
findings of Pyo et al., who observed this kind of morphology after spray drying of PTX 
dispersed in DCM. If acetone (ACET) was employed, the constituted PTX was anhydrous 
crystalline. A combination of water and PTX dissolved in ACET generated a dihydrated 
crystalline morphology of PTX on the titania coating. If the solvent ethyl acetate (EA) was 
utilized, the resulting PTX was amorphous. This was in discrepancy with the findings of  
Pyo et al. and Lee et al., who observed the anhydrous crystalline form [10, 11]. The 
differences of the findings in literature and to the ones in the present study might have been 
caused by the purity grades of the solvents, because impurities can influence the nucleation 
of drug crystals. For instance residual water in the solvent can attach to the drug molecules 
to form hydrogen bonding. This can alter the conformation of the drug molecules in the 
solvent and can contribute to generate a certain drug morphology, e.g. the dihydrated 
crystalline form of PTX instead of the anhydrous crystalline one. This effect, the partial 
charge distribution between the particular solvent and the drug molecules, as well as the 
different supersaturating conditions of PTX in the solvent system have caused the formation 
of the different PTX-morphologies by single solvent evaporation [9, 28].  
 
If PTX in EA was added to water and the liquid phase was evaporated, dihydrated 
crystalline PTX evolved. PTX dissolved in pure dimethyl sulfoxide (DMSO) or DMSO and 
water, yielded the anhydrous crystalline morphology in both cases. Hence the production of 
certain PTX-polymorphs on the titania coating could be controlled simply by varying 
solvents or solvent/water mixtures. The influence of the PTX-polymorph on the drug-load 
and release from the coating will now be discussed. 
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5.6.2 Factors affecting the drug-load capacity 
The drug-load capacity of the TiO2 nanostructured coatings can be influenced by two 
types of factors: one type is related to the structure of the ceramic coating and the second 
type to the process parameters used during the drug-loading.  
 
5.6.2.1 Structural parameters of the titania coating 
Structural factors, which influence the overall drug-load, are the thickness of the 
coating and its porosity, like was illustrated in Figure 5-19. By increasing the thickness of 
the coating, the amount of porous structure surrounding the reservoirs increases. This 
structure was characterized by 50 % porosity. Thus a duplication of the film’s thickness will 
add 50 % more pore volume accessible to store a drug and will hence double the drug-load. 
The influence of the reservoir density in the coating and their size on the drug-load 
capability is also evident: increasing each of them increases the drug-load. Nevertheless, the 
amount of porous structure surrounding the reservoirs significantly influences the total drug-
load, as was deduced from the theoretical calculations. The reservoirs with a diameter of  
1 μm and a density of 150000 reservoirs/mm2 in the coating, which equals the specification 
of the used reservoir layer (RL), added theoretically 3 % more drug into the coating 
compared to a coating with a non-reservoir structure (NRL). 14 % more PTX were loaded in 
the experiments into the RLs compared to the NRLs. This value was much higher than 
predicted by the calculations and this can be explained by the following. One has to consider 
that PTX was present in the reservoirs of the coating, in the pores of the surrounding ceramic 
and as a burst on top of the coating. When subtracting the amount of PTX in the burst-layer, 
a total load of ~ 0.6 μg/mm2 is obtained in the RLs. This value is still 3 times the value 
obtained by the calculations. One has to take into consideration that the calculation of the 
theoretical load contained assumptions. For instance the volume of one PTX-unit was 
approximated to be identical to the volume of one PTX-molecule. In reality, the drug 
molecules might have arranged themselves densely to create small PTX-units containing 
more than one molecule. One can hence use 2 or 3 molecules of PTX in a unit volume in the 
calculations to correlate the theoretical PTX-load in the RLs with the one obtained by the 
experiments.  
 
5.6.2.2 Process parameters of the drug-loading 
In preliminary tests, drug-loading was performed using an atmospheric pressure 
technique and different solvents, in which PTX was dissolved. The loads of the coatings 
were different. The coatings with a NRL-structure, loaded with PTX dissolved in either 
DCM, ACET or in addition rinsed in water, contained 1 µg/mm2 PTX. This drug-load is 
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comparable to the one applied in the commercially available TaxusTM drug-eluting stent 
(DES) [1, 29]. The PTX-load of the NRLs, loaded by dissolving PTX in EA, or additionally 
rinsing it in water, was lower: 0.4 µg/mm2. The standard deviations obtained for the PTX-
loads in the titania coatings were as high as 0.443 µg/mm2 for the NRL loaded with ACET, 
Figure 5-13. The process parameters, which influence the drug loading hence had to be 
investigated. 
 
Influence of the wettability and the process pressure on the penetration speed 
 
The wettability of the PTX/solvent solution with TiO2 can influence the penetration 
depth of the solution into the pores of the titania coating. It was not possible to measure the 
wettability of the solvents with the TiO2-coating using the contact angle method. The 
deposited solvent-droplets spread on the surface leading to a total wettability. The 
penetration depth or the position of PTX in the pores of the coating could not be deduced by 
electron microscopy. But one could make estimations of the filling velocity of the NRL-
porous structure by applying the Washburn equation 
 
(5-11), 
 
 
with pc: capillary pressure, γLV: surface tension of the liquid, θc: contact angle and rp: radius 
of the cylindrical pore. It describes the dynamic filling of a capillary with a circular cross 
section under non-slip conditions [30]. The meniscus velocity v, referred to as the filling 
rate, is given by 
 
(5-12), 
 
with η: dynamic viscosity of the liquid and l: distance between the capillary meniscus and 
the capillary inlet [31, 32]. If one assumes a good wettability, θc → 0 and cos θc → 1. Thus 
the Equation (5-12) simplifies to  
 
(5-13). 
 
 
The ratio rp/l was calculated from the mean pore radius of the NRL of 46.68 nm and the total 
thickness of the titania coating of 1200 nm, cf. Chapter 4.5.2, to 0.04. If this ratio is kept 
constant, the velocity is a function of the surface tension and the viscosity of the solvents. If 
one now inserts the solvent parameters listed in Table 5-15 into Equation (5-13), one can 
calculate the filling velocities of the capillaries. This NRL-structure equals the porous 
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structure surrounding the reservoirs in a RL.  
 
Table 5-15 Dynamic viscosities and surface tensions of various solvents. Values for 20 °C unless stated 
otherwise [33, 34, 35]. 
solvent η (Pa⋅s) γLV (mN/m) v (m/s) 
DCM 0.44 ⋅ 10-3 [33] 23.70 [34] 0.51 
ACET 0.33 ⋅ 10-3 [33] 26.50 [34] 0.78 
EA 0.45 ⋅ 10-3 [33] 23.70 [35] 0.51 
DMSO 1.99 ⋅ 10-3 (25 °C) [33] 43.50 [34] 0.21 
 
The obtained filling velocities of the NRLs are equal for DCM and EA with 0.51 m/s.  
The filling velocity of ACET is higher: 0.78 m/s and for DMSO lower with 0.21 m/s. About 
half a meter of a capillary in the NRL-structure of the coating could be filled in only one 
second. Thus all types of PTX/solvent solutions should have well penetrated throughout the 
porous structure of the coating during the drug-loading. PTX should have been present in all 
pores of the ceramic structure. However, PTX was not detected by SEM in cross sections of 
the NRL, drug-loaded with PTX dissolved in EA in the preliminary test using the 
atmospheric pressure technique. Either PTX was adsorbed as a thin layer on the pore’s walls 
and could not be detected by SEM. Or residual air in the pores built a counterforce to the 
capillary pressure of the penetrating PTX/solvent solution and no PTX was present in the 
pores of the coating.  
 
The reasons to apply low pressure in the low pressure drug-loading technique were 
hence the following: a better control of the drug-loading and the “evacuation” of the porous 
structure prior to its immersion into the PTX/solvent solution. An additional effect was to 
force the penetration of the PTX/solvent solution into the porous coating by applying a 
pressure gradient. This pressure gradient was generated by applying atmospheric pressure, 
after the samples were immersed into the PTX/solvent solution at lower pressure. The 
laminar flow of the PTX/solvent solution through the coating as a function of applied 
pressure gradient can be expressed by the Carman equation [36]: 
 
(5-14), 
 
 
with Δp: pressure drop, L: thickness of the porous coating, K": dimensionless constant,  
ε: fractional porosity, SBET: specific surface area, η: dynamic viscosity of the fluid and  
vp: average velocity through the pore channels. To apply this equation, the flow is 
approximated to be one-dimensional in the z direction of the coating, Figure 1-5 in Chapter 
1.2. In many materials, 3.5 < K" < 5.5 is valid and a value of 5 was applied in the 
calculation. For spherical particles in the porous solid, like the slightly connected titania 
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grains which were observed in the NRLs and RLs in the present study, SBET equals 6/dg. dg is 
the grain diameter. With these two assumptions Equation (5-14) simplifies to [36] 
 
 (5-15). 
 
 
Usually a pressure drop Δp occurs naturally if a liquid flows through a porous 
structure. In the present study, Δp was represented by the applied pressure gradient. At the 
point, at which the atmospheric pressure is applied in the drug-loading (step 4 in Table 5-6), 
the pressure difference is at its maximum. Thus one can calculate the average velocity of the 
PTX/solvent solution in the pore channels with Equation (5-15). For simplification, the 
parameters of the pure solvents and not of the PTX/solvent solution were applied. The 
parameters of the coating, depicted in Table 5-16, were employed and the parameters η and 
γLV of the solvents EA and DMSO, Table 5-15. The pressure gradient Δp for the loading with 
the PTX/EA solution was 0.663⋅105 Pa and for PTX in DMSO 0.813⋅105 Pa. The velocity of 
EA to penetrate the entire coating was 0.0059 m/s and of DMSO 0.0017 m/s. This velocity 
corresponds to the penetration velocity only caused by the pressure gradient and it does not 
contain the velocity component generated by the capillary forces.  
 
Table 5-16 Structural parameters of the NRL-titania coatings, which were applied to calculate the velocity of 
the fluid flow through the coating. 
parameter value 
h 1.2 µm 
ε 0.5 
dg = dBET 93 nm 
 
The penetration velocity generated from only the capillary forces was of a factor of 
100 higher for EA. It can therefore be concluded that in the present case the dominant 
driving forces for the solvent penetration into the titania coatings were the capillary forces. 
The pressure difference, which was additionally applied in the low pressure technique, did 
not significantly alter the penetration velocity. But because the coating was subjected to 
lower pressure before immersion into the liquid, a smaller amount of residual air was present 
in the coating as compared in the atmospheric pressure technique. Thus the penetration of 
the PTX/solvent solution was not hindered by residual gas in the pores. PTX was detected in 
the coating by SEM, Figure 5-20. 
 
Parameters related to dip coating 
 
Dip coating in combination with low pressure was the favored method to load PTX 
into the titania coatings. Indeed it was possible to achieve reproducible drug-loads as high as 
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1.21 µg/mm2 for RLs. However, process parameters, which influence the drug-load, had to 
be identified in this context. They were in particular the droplet formation, the number of 
dips, the immersion time and the withdrawal velocity from the PTX/solvent solution.  
 
Droplet formation 
First tests using the low pressure technique were accounted for the establishment of 
reproducible drug-loads. NRLs were hence loaded with a solution of PTX in DMSO. It was 
found that the PTX-load in one plate-shaped sample with the NRL-structure was 
inhomogeneous. The small specimens, which were cut from the top and middle region of the 
drug-loaded plates as shown in Figure 5-5, contained 0.016 µg/mm2 PTX after one dip, the 
ones cut from the bottom were characterized by a 10 times higher amount, Figure 5-14. The 
droplet formation of the PTX/DMSO solution on the bottom of the big plates after 
withdrawal still had an influence 5 mm distant from the bottom edge. The high standard 
deviations in the drug-loads discovered at the beginning of the studies could therefore be 
addressed to the droplet generation and hence the accumulation of PTX at the bottom. For 
further testing, only samples cut from the middle and top piece of the plates were applied. 
The problem could thus be easily solved for the rectangular, TiO2-coated plates. But it has to 
be accounted for when using this dip coating, drug-loading technique to create the DES. The 
stent has a complex geometry with interconnecting metal struts, cf. Figure 2-1. Using the dip 
coating technique for drug-loading can create droplets at the connection-points of the stent’s 
struts and at the stent’s bottom edge. This can create an inhomogeneous PTX-load in the 
stent and can result in a non-homogeneous drug-release later. One has to think about 
methods to remove the droplets after drug-loading, like rotating the stent around its axis with 
a high speed. The thus created centrifugal force might detach the droplets. Another method 
would be to remove the PTX-droplets in a washing procedure following the drug-loading. 
But washing is not as trivial as it seems, as was observed in the experiments to remove the 
PTX-burst-layer, Chapter 5.5.4.3. 
 
Number of dips 
Multiple dips into the drug/solvent solution can increase the drug-load in a porous 
coating [37]. Four dips sequentially into the PTX/DMSO solution increased the load of the 
middle part of the drug-loaded plates in Figure 5-5 from 0.016 µg/mm2 after 1 dip to 0.022 
µg/mm2 after 4 dips. One can compare the findings with the theoretical PTX-load in the 
NRLs after 4 consecutive dips into the PTX/solvent solution. The calculation for the 
theoretical load was the following. The solvent should have completely penetrated the 
coating, as was obtained from the calculations of the penetration velocities. Assuming that 
the pores of the coating were totally filled with the PTX/DMSO solution of a concentration 
of 10 mg/ml, 0.006 µg/mm2 PTX should have been left in the coating after 1 dip. After 4 
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dips, 4 times that value, which equals 0.024 µg/mm2, should have been present in the 
coating. This value is only valid, if one assumes that the amount of adsorbed PTX in the 
pores did not change the pore volume and that no PTX got desorbed from the pore-walls in 
the subsequent dips. The measured value of 0.022 µg/mm2 thus fitted well to the calculation.  
 
The PTX-load of the small pieces at the top position of the plates did not change, 
Figure 5-15. It might have been caused by the 30 min of time, in which the samples were 
exposed to low pressure before getting immersed into the liquid. After 4 times that time span 
(120 min), the level of the PTX/DMSO solution in the glass beaker might have decreased. 
No more PTX/solvent solution was added to again increase the liquid level. Thus the liquid 
did not totally cover the plates any more for drug-loading. Hence no more PTX could be 
loaded into the top area of the plates. This has illustrated that it was important to set the 
correct immersion time for drug-loading to avoid the evaporation of the solvent.  
 
Immersion time 
The drug-loading tests of the nanostructured titania coatings revealed a dependence of 
the PTX-load on the time, during which the samples were immersed into the PTX/EA 
solution at high pressure, step 4 of procedure LPEA1 in Table 5-6. For an immersion time 
between 1 min and 1 h, the overall load decreased. For immersion times between 1 h and  
24 h, the PTX-load increased, as depicted in Table 5-10. By applying 24 h, the maximum 
PTX-loads of 1.056 µg/mm2 for NRLs and of 1.211 µg/mm2 for RLs were obtained.  
 
It is not totally clear why with increasing immersion time from 1 h to 24 h the PTX-
quantity in the coating increased. The PTX/EA solution should have fully penetrated the 
entire porous NRL in 2.3 µs, as was calculated earlier. In the calculation for the capillary 
driven penetration, straight cylindrical pores with a median pore diameter, dv50, of 76 nm  
were applied. In reality, the pores showed a pore size distribution with pore widths as small 
as 20 nm and as big as 120 nm. Additionally, pores were not straight, but exhibited a 
tortuosity and they were interconnected, as was seen in Chapter 4.5.2. The presence of 
smaller pores as well as a longer distance between the capillary meniscus and the capillary 
inlet caused by the tortuosity (parameter l in Equation (5-13)), can decrease the filling 
velocity. A longer immersion time might hence have triggered a “deeper” penetration and 
higher loads after 24 h of immersion compared to 1 h. The incoherence with the immersion 
time and the PTX-load of the samples loaded with immersion times below 1 h is not totally 
clear, but might be associated to different thicknesses of the PTX-burst-layer on top of the 
coating, as was demonstrated in Figure 5-18. The thickness of this layer is influenced by the 
withdrawal velocities, a factor which was not exactly controlled during the drug-loading.  
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Withdrawal velocity 
The withdrawal velocity in dip coating has an influence on the thickness of the 
deposited liquid layer on the substrate, as was depicted in the Equation of Landau-Levich, 
Equation (4-1) in Chapter 4.1. This equation was used to approximate, how much PTX was 
deposited on top of the TiO2-coating. Calculations of that amount were performed using the 
specifications of the PTX/DMSO and PTX/EA solutions, which were applied in the drug-
loading. The parameters in the calculation applying the PTX/DMSO solution were the 
dynamic viscosity of DMSO, ηDMSO, the liquid vapor surface tension of DMSO, γLV,DMSO, 
listed in Table 5-15, the density of DMSO, ρDMSO, of 1.100 g/cm3, the withdrawal velocity of 
1.0 ± 1 cm/s, the acceleration due to gravity of 9.81 m/s2 and the concentration of PTX in 
DMSO of 10 mg/ml. For PTX/EA the same parameters were applied, except that the values 
of ηEA and γLV,EA listed in Table 5-15 were applied, the density of EA was ρEA of  
0.897 g/cm3 and the concentration of PTX in EA was 103.61 mg/ml. The withdrawal 
velocity of the titania coatings from the drug/solvent solutions was not controlled in the 
present study, except for the samples produced with the method LPEA1 with immersion times 
of 5 h and 24 h and with the method LPEA2. For these samples, the pulling speed was 
adjusted to count 3 s to withdraw the plate of a length of 3 cm from the solution. Thus the 
resulting withdrawal velocity of ~ 1 cm/s was applied in the calculations.  
 
The amount of PTX in the liquid film on top of the TiO2-coating after withdrawal from 
the PTX/DMSO solution was calculated to be 0.112 µg/mm2 for 1 cm/s, Figure 5-26. This 
amount was bigger than the total load in the films, which was obtained in experiments. If the 
withdrawal velocity was as small as 0.1 cm/s, 0.024 µg/mm2 would have been deposited on 
the top of the NRLs, Figure 5-26. That the withdrawal velocity needs to be well controlled in 
the drug-loading procedure gets clearer if one uses the solution of a high concentration of 
PTX in EA. The amount of PTX in the burst-layer after withdrawal with 1 cm/s is  
0.530 µg/mm2, Figure 5-26. An increase of the withdrawal speed from 1 to 2 cm/s adds 59 %  
more PTX on top of the coating. To avoid variations in the drug-load in the PTX-burst-layer, 
always the same withdrawal velocity should be used. The thickness of the burst-layer can be 
reduced, if a lower withdrawal velocity is applied.  
 
However, the PTX-loads after 5 h and 24 h of immersion into the PTX/EA solution 
were reproducible for the NRLs and the RLs. PTX was accumulated in the drug reservoirs, in 
the pores of the structure surrounding the reservoirs and as a burst-layer, Figure 5-20. The 
therapeutical agent was preferentially localized at the edges of the reservoirs. This can be 
explained by the drying of the coating after drug-loading. During the drying, the solvent gets 
evaporated through the small pores of the porous structure surrounding the reservoirs. 
Capillary forces, as well as surface tensions directed the PTX/solvent solution towards the 
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edges of the reservoirs. 
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Figure 5-26 PTX-load in the liquid film on top of the TiO2-coating as a function of the withdrawal speed from 
the PTX/DMSO solution with 10 mg/ml or from the PTX/EA solution with a concentration of 104 mg/ml. 
 
5.6.2.3 Rinsing 
The rinsing of the PTX-loaded titania coatings, which was performed to remove the 
burst-layer, has shown that the PTX-morphology in the coatings can be changed by various 
concentrations of acetonitrile in UP-water. Amorphous PTX from EA_w730RL was 
transformed into the dihydrated crystalline form in, and on top of the coating. The crystals 
were long and needle-shaped, like depicted in Figure 5-22. The applied rinsing methods need 
future improvement to just dissolve PTX from the top of the surfaces. In the present study, 
PTX was not at all removed from the coating after rinsing in water for 3 s. The presence of 
PTX generated a hydrophobic character of the coating compared to the native coating 
without drug. This was shown by comparing the contact angles with water: 25.30 ° for the 
native RL and 66.74 ° for the drug-loaded RL, Table 4-11 and Table 5-12. This hindered the 
penetration of water. Mixtures of high concentrations of non-polar acetonitrile in water 
increased the PTX-solubility. Hence the entire drug was dissolved from the coating and not 
just from the burst-layer. When the coatings were immersed into bovine plasma for a drug-
release test, only the PTX-burst-layer was released after 4 d of testing. PTX is lipophilic and 
gets well dissolved in bovine plasma, which contains lipoproteins, cholesterol and fatty acids 
amongst other constituents, Table 5-17. But it is not recommended to use plasma as a rinsing 
agent, because it contains many other components, like proteins and ions, which can 
contaminate the coating.  
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Table 5-17 Main constituents and ionic concentrations of blood plasma [26]. 
major proteins and organic constituents of blood plasma
albumin 30-55 g/l
α-globulins 5-10 g/l
β-globulins 6-12 g/l
γ-globulins 6.6-15 g/l
α-lipoproteins 3.5-4.5 g/l
fibrinogen 1.7-4.3 g/l
total cholesterol 1.2-2.5 g/l
fatty acids 1.9-4.5 g/l
glucose 0.65-1.1 g/l
lactate 0.5 2.2 mM
urea 3-7 mM
ionic concentrations in blood plasma
Cl- 96-111 mM
HCO3- 16-31 mM
HPO42- 1-1.5 mM
SO42- 0.35-1 mM
H2PO42-
Na+ 131-155 mM
Mg2+ 0.7-1.9 mM
Ca2+ 1.9-3 mM
K+ 3.5-5.6 mM
 
Further studies are hence necessary to optimize the rinsing procedure. Another method 
to reduce the thickness of the PTX-burst-layer is to apply a reduced withdrawal velocity of 
the titania coatings from the PTX/solvent solution, like was pointed out earlier in this 
discussion.  
 
5.6.3 Factors influencing the in vitro release kinetics of Paclitaxel  
In the present study it has been observed that many factors can influence the drug 
release from the thin, nanostructured titania coatings. They belong to the three categories 
depicted in Table 5-18: the structure of the TiO2-coating, the drug’s properties and the 
parameters of the in vitro drug-release experiments. They will be discussed in the following. 
 
Table 5-18 Parameters influencing the PTX-release from the thin nanostructured TiO2-films. 
category parameter 
structure of the TiO2-coating pore diameter 
 pore tortuosity 
 pore interconnectivity 
 thickness of the nanoporous layer 
 size of the reservoirs 
features of the drug morphology 
 dissolution rate 
 size of drug particles 
drug-release experiment solubility in media 
 time intervals 
 temperature 
 agitation speed 
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5.6.3.1 Structures of the TiO2-coating and of paclitaxel 
The various polymorphs of PTX in the drug-delivering NRLs directed the release 
velocities of the therapeutical agent into water, Figure 5-14 and Figure 5-28. The highest 
cumulative release of PTX after 4 d of elution was recorded for amorphous PTX, lower ones 
for the anhydrous crystalline and dihydrated crystalline morphologies. The release was thus 
dominated by the dissolution of PTX rather than by its diffusion from the porous TiO2-
structure during the considered time interval. This gets clear if one considers the zero order 
release constants, k0, which depended on the PTX-morphology: amorphous > anhydrous 
crystalline > dihydrated crystalline, Table 5-9.  
 
The explanation of the dependence of the k0 on the PTX-morphology is the following. 
The drug molecules in the amorphous form of PTX are randomly arranged and not well 
ordered like in the case of the crystalline forms. Water can penetrate with less resistance than 
in the crystalline structures and dissolves the PTX-molecules. In the crystalline structures, 
the molecules are densely packed and ordered. The water penetration as well as the 
dissolution of the molecules from the crystal lattices is hindered, leading to a lower release 
constant. The higher release constant k0 of the anhydrous crystalline compared to the 
dihydrated crystalline forms of PTX is in addition related to their dissolution concentrations. 
The saturation concentration of the anhydrous crystalline PTX in water is 3 µg/ml, and for 
the dihydrated crystalline one 1 µg/ml [6]. At the beginning of the immersion into the water 
up to 10 h, more PTX got dissolved from the anhydrous crystalline form than from the 
dihydrated crystalline one, which has the lower saturation concentration. This shifted the 
release curve of the anhydrous crystalline form (ACET_w730NRL) to higher values 
compared to the dihydrated crystalline ones of WACET_w730NRL and WEA_w730NRL. 
In the proceeding elution, the anhydrous crystalline form got converted into the dihydrated 
crystalline one, which is the stable form in equilibrium with water [6]. Hence the release 
slowed down.  
 
A release test of amorphous PTX from a RL (EA_w730RL) into UP-water was 
performed during a longer period of time than 4 d to study the release kinetics. 11 % of the 
total PTX-load were continuously released up to 32 d. The zero-order model best fitted the 
data. From the performed release tests into water it was unclear, when the PTX-burst-layer 
was totally released from the coating, at what time the pharmaceutical got transported out of 
the pores or if both mechanisms took place simultaneously. The Korsmeyer-Peppas model 
predicted with a high correlation coefficient the diffusion dependence of the drug-release 
from the coating. The highest correlation coefficient of EA_w730NRL was obtained for the 
Higuchi model, Table 5-9. It describes the diffusion of a drug through a porous solid. A good 
fit to the zero order release kinetic was also determined in the release test of EA_w730RL up 
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to 32 d. It is described in literature, that this mechanism is observed for low-soluble drugs or 
drugs released from a reservoir system [15]. These two premises fit our system: PTX has a 
low solubility in water and the structured TiO2-coating can be characterised as a combination 
of a matrix system and a reservoir system. A matrix system, because the drug is partially 
dispersed in the porous TiO2-structure surrounding the reservoirs. And like described by 
Higuchi, the release depends then on the porosity ε of the solid structure and the tortuosity τ 
of the pores. In these systems, the concentration gradient of the drug changes with increasing 
release time. The RLs are also a reservoir system, because the drug is present in solid form in 
the reservoirs. And as described in Chapter 5.2 for the zero order release from reservoir 
systems, the release depends on the effective diffusivity of the drug through the surrounding 
membrane, thus the porous TiO2 surrounding the reservoirs. The combination of the burst-
layer, the matrix system and the reservoir system in the TiO2-drug-delivering coating 
represents a complex drug-delivery system. Hence it was not possible in the present 
feasibility study to identify the detailed mechanisms directing the drug flux out of the 
coating and to determine an effective diffusion coefficient. They should be analyzed in 
following studies, whereas the results of the structural characterization of the coating and the 
drug-load/release results from the present study should serve as a basis for understanding. In 
future drug-release studies, samples should be taken out of the release test at certain time 
points, dried and the cross sections observed by HRSEM. It should then be possible to 
detect, when the PTX-burst-layer was completely removed, when the PTX in the structure 
surrounding the reservoirs was eliminated and when the dissolution of PTX from the 
reservoirs takes place. This should be correlated to the shape of the release curves. To 
remove the PTX-burst-layer prior to analysis, and thus to focus just on the release from the 
porous TiO2, would be the ideal condition. 
 
By analyzing theoretically the possible transport mechanisms involved in the drug-
release from the TiO2-coatings, one can summarize structural factors influencing the release 
kinetics. To decrease the flux of drug out of the coating, the following changes of the 
structural parameters can be done.  
? A higher tortuosity factor of the pores in the ceramic structure surrounding the 
reservoirs should be applied (τ in Equations (5-4), (5-9)). It increases the diffusion path. 
? The higher the initial porosity of the system, e.g. the higher the density of the big 
reservoirs, the more drug can be loaded into the coating. Thus the density of the drug, the 
so-called drug size in Table 5-18, in the porous structure increases. The specific volume 
of the drug U in Equation (5-9) decreases and thus the release diminishes.  
? Shifting the ratio of molecule-to-pore diameter, χ, to a higher values will decrease the 
flux. That means the pore size distribution of the TiO2-structure surrounding the 
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reservoirs should be shifted to smaller pores. A median pore diameter, dv50, of 76 nm like 
applied in the present study, reveals a χ of 0.027. A new dv50 of 7.6 nm reveals a χ of 
0.275. Pore size effects on the apparent diffusion coefficient can then be quiet large and 
can slow down the drug-release. It is reported in literature that a χ larger than 0.1 greatly 
slows down the molecular flux [38]. One can compare these effects with the gaseous flow 
in porous materials. Three regimes with different diffusivities, depending on the pore 
diameter, are depicted in Figure 5-27. For macropores, collisions between the molecules 
occur much more frequently than collisions with the pore wall and molecular diffusion is 
the dominant transport mechanism. As the size of pores decreases, the number of 
collisions with the wall increases and Knudsen diffusion takes over. The mobility of the 
molecules starts to depend on the dimension of the pore, and the effective diffusion 
coefficient, Deff, reduces. At smaller pore sizes, when the pore diameter is similar to the 
molecule size, the molecules will constantly experience an interaction with the pore 
surface. Thus they will be in the configurational diffusion regime and Deff decreases 
further [39]. If investigations of the influence of the pore diameter on Deff should be 
deduced in future studies, one can precede as follows. One could think of using NRLs 
with various pore sizes. The pore sizes can be reduced by applying smaller primary TiO2-
nanoparticles. For instance to create pores of a width of 10 nm, the initial particles should 
exhibit a diameter of 5-10 nm. Another method to reduce the pore size is to increase the 
sintering temperature, whereas this is attended by a reduction in overall porosity. The 
produced NRLs should then be loaded with PTX by methods which were described in the 
present study and the PTX-burst-layer should be removed. The drug-loaded NRLs should 
be subjected to the release tests. The obtained release profiles should fit well the Higuchi 
and/or the zero order kinetics and should reveal Deff as a function of pore diameter, 
according to Figure 5-27. Thus one can determine pore sizes triggering a certain drug-
release and a critical pore size, which prevents diffusion at all. 
? Another option to decrease the PTX-flow from the coating is related to treating the 
system as a reservoir system. An increase in the thickness of the nanoporous TiO2-layer 
on top of the reservoirs, parameter Δx in Equation (5-2), increases the diffusion path of 
the molecules and hence retards the drug-release.  
? The change of amorphous PTX to the dihydrated polymorph decreases its dissolution 
and hence the PTX-release out of the coating into water. If this effect is still significant 
when the coating is exposed to plasma instead of water needs to be investigated further.  
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Figure 5-27 Relation between diffusivity and pore size for gaseous molecules. In the range of the highest 
diffusion coefficients, collisions between the molecules occur more frequently than with the wall (molecular 
diffusion). If the pore size gets smaller, the number of collisions with the walls increases (Knudsen diffusion). 
In the regime of the smallest diffusion coefficients, the molecules constantly interact with the pore’s surface. 
Adapted from [39]. 
 
5.6.3.2 Parameters of the drug-release experiments and relation to literature findings 
The obtained release profiles of the PTX-polymorphs from the TiO2-coatings into 
water were similar to the ones obtained by Kamath et al. [1]. He and co-workers examined 
formulations of PTX in non-degradable styrene-isobutylene-styrene copolymer matrices, 
Figure 5-28, for the commercially available TaxusTM stent. The total PTX-load in the 
polymers was 1 µg/mm2 and the release was performed into phosphate buffered saline 
(PBS), supplemented with Tween 20. Tween 20 as a surfactant was used to increase the 
aqueous solubility of PTX and to prevent drug loss through passive adsorption on the vial’s 
wall. The preparations of the eluates of PTX from the titania coatings for HPLC-analysis in 
the present study were also adjusted to detach PTX from the vial’s wall. Eluates were vortex 
mixed for 30 s prior to mixing them with acetonitrile and subjecting them to HPLC-analysis.  
 
The release profiles of PTX from the polymer matrices of the TaxusTM stent depend on 
the drug-concentration in the polymers. A high PTX-concentration triggers a fast release, a 
lower concentration a moderate release and the lowest drug-concentration a slow release, 
Figure 5-28. The slow release was characterized by releasing much less than 5 % of total 
drug-load within 10 d, the moderate by releasing about 5 % and the fast release by liberating 
70 % [1]. The slow release formulation is used in the commercially available TaxusTM stent. 
A certain quantity of therapeutical agent stays trapped in the polymers of each of the 
formulations [2]. 
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Figure 5-28 Cumulative PTX-release from different polymer matrices for the TaxusTM stent and of selected 
nanostructured titania coatings of the present study (graph modified from [1]). The release profiles of the 
polymer coatings were obtained in PBS supplemented with Tween 20 at 37 °C. The ones of the TiO2-coatings 
in water at 37 °C. 
 
Three representative release curves of PTX from the titania coatings recorded in the 
present study were added to the ones of the TaxusTM stent in Figure 5-28. Dihydrated 
crystalline PTX from WACET_w730NRL exhibited a moderate release when compared to 
the TaxusTM stent. The release of the amorphous PTX from EA_w730NRL and of anhydrous 
crystalline PTX from ACET_w730NRL were in between the moderate and fast release after 
4 d of testing. Similar release profiles from the PTX-loaded NRLs to the ones of Kamath et 
al. were thus obtained with the restriction that in the present study pure water was applied. 
The solubility of PTX in water was different to the one of PBS supplemented with Tween 
20. Different time intervals to renew the elution media also affect the drug-release profile 
and thus can restrict the comparison of the release kinetics between different studies. If 
diffusion is the driving force of drug-release, more frequent changes in the surrounding 
media create more frequently a higher concentration gradient between the drug-eluting 
matrix and the media. This can trigger a faster diffusion and thus a higher flux of the drug, 
except when always perfect sink conditions are applied. That means, that the concentration 
of drug in the release media should always be lower than 1/3 of the maximum solubility 
concentration.  
 
The last, but not negligible factor influencing the release profiles, and thus the 
comparison between studies performed by different research groups, is the agitation of the 
media during the release test. Depending on the way of agitation and the agitation speed, 
convection needs to be added to the pure diffusion and dissolution models mentioned in 
Chapter 5.2. Then two characteristic liquid layers exist at the surface of the drug-eluting 
matrix: a diffusion boundary layer and further distant to the surface a hydrodynamic 
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boundary layer [40]. The thickness of the diffusion layer thus depends on the velocity of the 
surrounding, moving release media. If one assumes a laminar flow of the media and the 
drug-dissolution from a rotating disk specimen-or vice versa if the media is rotating over the 
pharmaceutical formulation with an angular velocity ω-the thickness of the diffusion layer, 
h, is calculated by 
 
(5-16), 
 
with D the free diffusion coefficient of the drug, ν the kinematic viscosity of the media and 
dh the thickness of the hydrodynamic layer, which is derived by [40] 
 
(5-17). 
 
 
If thus the angular speed of the media on top of the matrices’ surface increases, the 
diffusion layer thickness h decreases, like is depicted in Figure 5-29. This augments the flux 
of medicament from the dosage form. This gets clearer if one inserts the diffusion layer 
thickness h in Equation (5-16) into the flux of the drug for the zero-order release kinetics in 
Equation (5-2) or into Equation (5-8) of the first order release constant.  
 
When further studying the development of the TaxusTM stent, one gets to know that the 
slow and moderate formulations displayed in Figure 5-28 were applied in clinical trials. 
Even if the moderate release-modification did not reveal a compromise in stent-safety, the 
slow release formulation was commercialized [1]. Thus it needs to be investigated in future 
studies, if a moderate release of PTX from the TiO2-coating is appropriate or if a slower 
release is preferential. Then the structural parameters of the titania film need to be modified 
as was described at the end of Chapter 5.6.3.1. 
 
The release kinetics of PTX into water were discussed up to now. They were 
performed to accomplish release profiles in a reasonable time and to compare the effective 
diffusion coefficients-which could finally not be deduced-with the theoretical ones and the 
ones from simulations in Table 5-14. But UP-water did not represent physiological fluids.  
 
One release experiment was hence performed with a selected drug-loaded RL and a 
TaxusTM stent into bovine plasma. The TaxusTM DES exhibited a continuous release without 
burst-effect up to 7 d, by which only 2 % of loaded drug was released. 46 % of the total 
drug-load in the titania RL was released within the first 4 d. After 4 d, no more PTX was 
liberated from the nanostructured coatings, Figure 5-24. More than 50 % of initially 
incorporated pharmaceutical hence stayed trapped in the coating. This could be verified by 
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electron micrography, Figure 5-25 (a). The quantity of released PTX from the coatings 
within the first days of elution corresponded to the amount of PTX present in the PTX-burst-
layer on top of the coating. 
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Figure 5-29 Influence of the angular velocity of agitation on the thickness of the diffusion layer at the release 
matrices’ surface.  
 
Since PTX is lipophilic, the applied plasma containing fatty acids, cf. Table 5-17, 
increased the drug’s solubility compared to the one in water. This caused more rapid drug 
dissolution from the burst-layer. That the major amount of PTX stayed in the TiO2-coating 
was generated by the built-up of a layer composed of plasma components on top of the 
coating, Figure 5-25 (b). It blocked the pores of the TiO2-structure surrounding the reservoirs 
and hence the diffusion of the pharmaceutical out of the coating. The composition of that 
layer was not analyzed. But it is described in literature that proteins and calcium phosphates 
tend to adhere on TiO2-surfaces [26, 41, 42, 43]. Immediately after implantation of a 
material, proteins adsorb on it surface. Fibrinogen and albumin represent adhesion proteins 
and are an essential component in the blood plasma, Table 5-17. Their presence on the 
implant’s surface can trigger the adhesion of other proteins and can strongly influence the 
adhesion of blood platelets and other cells [26].  
 
The calcification due to the deposition of calcium phosphate apatite is often observed 
on vascular implants. TiO2-and more preferentially crystalline anatase-has a tendency to 
reinforce apatite formation [41, 42]. The net charges of the titania surface in contact with an 
aqueous media depends on the pH of the media, which transforms the Ti-OH groups to the 
following [41]: 
? pH < 4: formation of [Ti-OH2]+ bonds creating a positive charged surface, 
? pH > 9: [Ti-O]- creates a negatively charged surface.  
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Between both pH-ranges, the acidic and basic groups coexist. At the isoelectric point of 
TiO2, at a pH of 5-6, the surface exhibits a net charge of 0. Thus at physiological conditions 
at pH 7.4 the surface is slightly negatively charged. The negative charge attracts cations like 
Ca2+ or Na+ and the positive charge attracts anions like H2PO4-. These ions are all 
components present in the blood plasma, Table 5-17, and their presence on the titania surface 
represents nucleation sites for the apatite formation. This happens more preferentially on 
anatase then on rutile when supersaturated calcium phosphate solutions are applied [41]. It is 
related to their different surface energies, cf. Chapter 4.6.3.  
 
It has to be pointed out that the main phase present in the applied TiO2-coatings was 
anatase. If the calcium phosphate precipitation on the titania films turns out to be a problem 
for their application in DESs, a higher sintering temperature can easily create rutile and thus 
decrease the calcification tendency of the coating. Lately it was reported by Osaka et al., that 
the presence of some transition metal ions, like Cr3+, Fe2+/Fe3+ were effective to depress the 
bioactivity of the anatase layer on stainless steels supports [44]. The nanostructured TiO2-
coating will be applied on 316L SS supports in a DES and not on silicon wafers. During the 
heat treatment, to densify the primary TiO2-nanoparticles in the coating, metal ions from the 
support might also migrate to the top of the films. Their presence might limit the apatite 
formation on top of the coatings [44]. On the contrary, the existence of the layer formed by 
plasma components can decrease the flux of the drug from the coating in such a way, that a 
sustained drug-release can be achieved. If the formation of that protein/calcium phosphate 
layer will have an influence on the drug-release under in vivo conditions, needs to be found 
out in future studies.  
 
5.7 Conclusions 
PTX was successfully loaded into the nanostructured TiO2-coatings. The load of the 
drug into a layer of 1.2 μm thickness and not containing reservoirs (NRL) can be varied from 
as small as 0.06 µg/mm2 to a maximum load of 1.06 µg/mm2. The PTX-loads depend on the 
parameters applied in the drug-loading procedures. The maximum PTX-load in a titania 
layer containing drug reservoirs (RL) was 1.21 µg/mm2 and higher than for the NRLs. PTX 
was accumulated in the drug reservoirs, in the porous structure surrounding the reservoirs 
and it was present as a burst-layer on top of the coating. The quantity of pharmaceutical 
agent loaded into the NRL or RL was comparable with the PTX-concentration in the 
commercially available TaxusTM stent [1, 29].  
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Different factors influencing the drug-load capacity of the titania coating were 
identified during the experiments. They were separated into the two categories (1) structure 
of the TiO2-coating and (2) process parameters used during the drug-loading. A higher 
porosity in the coating increases the PTX-load. The presence of the reservoirs in the RLs 
added 14.63 % more PTX into the porous film compared to the NRLs. Bigger reservoirs as 
well as a higher density of them will further increase the PTX-load, as was obtained from 
theoretical calculations. An increase of the thickness of the coating will also increase the 
space available to store PTX. But one has to be cautions to change the structure of the 
coating in needs of the drug-load capacity, because they are linked to the mechanical 
stability of the coating [45]. A solvent evaporation method was chosen to incorporate the 
pharmaceutical into the coating. This method has proven to be powerful to adapt the PTX-
loads for different needs. Different PTX-polymorphs could be created by the application of 
various solvents, in which PTX was dissolved. For instance the evaporation of ethyl acetate 
(EA) from PTX created amorphous PTX, the evaporation of acetone (ACET) the anhydrous 
crystalline and of an ACET/UP-water mixture the dihydrated crystalline morphologies. The 
increase of the number of dips into the PTX/solvent solution during drug-loading augmented 
the PTX-load. Various PTX-loads in the coatings could be achieved by applying different 
immersion times of the specimens into the PTX/solvent solutions. After 5 h of immersion, 
0.82 µg/mm2 for the NRL and 0.94 µg/mm2 for the RL were measured. After 24 h of 
immersion, 1.06 µg/mm2 for the NRL and 1.21 µg/mm2 for the RL were obtained. Besides 
PTX being present in the porous structure of the coating, it was detected on its top as a burst-
layer. The burst-layer was formed by the withdrawal of the specimens from the PTX/solvent 
solutions, which created a liquid layer on top of the coating. After evaporation of the solvent, 
a solid PTX-layer was present, which occupied 50 % of the total PTX-load in the coating. 
Because the withdrawal velocity of the specimens was not precisely controlled in the present 
feasibility study, it is recommended to do so in future studies. The thickness of the PTX-
burst-layer can be decreased by lowering the withdrawal velocity of the specimens from the 
PTX/solvent solution. Experiments to remove the PTX-burst-layer from the coating have 
shown that PTX an be removed from the coating, but the method needs further improvement.  
 
The drug-loaded RLs were subjected to drug-release experiments into either ultra-pure 
(UP)-water or bovine plasma. The obtained release profile into water fitted the moderate and 
sustained release formulations of PTX investigated for the TaxusTM drug-eluting stent (DES) 
[1, 2]. The detailed transport mechanisms involved in this nearly zero-order release from the 
RLs could not be identified, because during the tests PTX could have been released from the 
drug reservoirs, the porous structure surrounding the reservoirs and from the PTX-burst-
layer on top of the coating. It is suggested that in future studies the burst-layer should be 
removed before the release experiments are started.  
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The parameters influencing the drug-release were in this study evaluated 
experimentally and theoretically. They can be categorized into belonging to the structure of 
the coating, the features of PTX and the set-up of the release experiments. A decrease in the 
pore size of the structure surrounding the reservoirs, a tortuosity increase of them and an 
increase of the thickness of the nanoporous coating on top of the reservoirs can diminish the 
diffusion of PTX out of the coating. The pore sizes can thus take effect on the effective 
diffusivities of the drug from the coating. Smaller pores increase the interaction of the drug 
molecules with the pore walls and lower the molecular flux out of the coating [38]. A 
median pore diameter of an order of magnitude of 1 smaller than the one in the coatings 
under investigation would reveal a molecule-to-pore ratio of 0.208. Molecules would hence 
collide more frequent with the pore walls and thus decrease the diffusivity. Smaller pores in 
the coating can be formed by decreasing the diameter of the primary TiO2-nanoparticles to 
about 5-10 nm. If the drug particle size in the coating increases, which can be realized by 
completely filling the pores with PTX, a prolonged drug-release can be supported. The 
drug’s morphology can modify the drug-release, as was seen in the drug-release experiments 
of PTX into UP-water. The amorphous PTX was released faster from the NRL than the 
anhydrous and dihydrated crystalline forms. If this effect will be still significant when 
performing the elution in a physiological media like plasma, needs to be investigated further. 
 
In a release test of PTX-loaded RLs into bovine plasma, 46 % of the PTX-quantity 
loaded into the coating were released after 4 d of elution, the rest stayed trapped in the 
coating. The released amount was correlated to the quantity of PTX in the burst-layer on top 
of the coating. Hence ~ 0.6 μg/mm2 PTX were present in the porous structure of the RLs. If 
the drug-release from the RLs gets blocked by the deposition of a layer of plasma 
components on top of the coating, like was observed in the present study, under in vivo 
conditions needs to be further examined. The drug-release from the TaxusTM stent into 
bovine plasma for comparison was continuous up to 7 d, by which 2 % were released.  
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CHAPTER VI 
6 PRELIMINARY IN VITRO CYTOTOXICITY TESTS 
6.1 Background and Introduction 
Evaluating a material’s biocompatibility comprises complex testing. For a stent in 
particular, it has to be ensured that it resists the mechanical deformation accompanied by the 
stenting process and the dynamic movement of the coronary artery after implantation. The 
material-host responses need to be investigated prior to clinical trials. Those are for stents in 
vitro tests regarding cytocompatibility, hemocompatibility, as well as in vivo animal testing. 
Preliminary in vitro cytotoxicity tests of non-PTX-loaded, nanostructured TiO2-coatings 
have been performed in the present study and the results are presented in the following.  
 
Cytotoxicity in general means that a substance causes toxic effects at a cellular level, 
e.g. cell death, alterations in cell membrane permeability or enzymatic inhibition. A toxic 
material is defined as a material that releases a chemical in sufficient quantities to kill cells 
either directly or indirectly through inhibition of key metabolic pathways [1]. The titania 
coatings, which are not filled with PTX, should not exhibit cytotoxicity. They should be 
cytocompatible and should promote the fast adhesion and proliferation of endothelial cells 
(ECs). Long-term clinical outcomes of the implantation of stents have proven that the re-
endothelialization plays an important role in preventing late and very late stent thrombosis. 
Late stent thrombosis occurs later than 30 d, very late stent thrombosis later than 1 year after 
stenting. ECs are involved in the regulation of thrombosis and in the regulation of the 
proliferation of adjacent smooth muscle cells (SMC) [2, 3, 4]. Hence in vitro cell tests were 
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performed, in which the material was brought into direct contact with primary bovine ECs. 
The proliferation of the ECs was evaluated. Experiments were performed on the basis of the 
regulations described in the ISO 0993-5 for “Biological evaluation of medical devices-Part 
5: Tests for in vitro cytotoxicity” [5]. The use and interpretation of in vitro cell tests is often 
controversially discussed, because they do not deliver information about the situation in the 
more complex in vivo environment. At the implantation-site more than just one cell type is 
involved, the immune system is active and metabolites can be transported to specific organs 
and be metabolized. However, in vitro tests are the primary biocompatibility screening tests 
for a wide variety of materials. They minimize the use of animals in research, they are 
required by most regulatory agencies and are much less expensive than in vivo tests [1].  
 
The documentation of the preliminary cytotoxicity tests will be shown in chronological 
sequence. This will help to better understand, why certain process parameters of the titania 
coatings on stainless steel supports had to be changed during ongoing cell testing to create a 
better cytocompatibility. Also information obtained from the Thesis of A. Tourvieille de 
Labrouhe [6], which was performed in parallel to the present work, were taken into account 
for certain parameter changes. For a better overview, the used specimens and their 
specifications are summarized in Table 6-1. 
 
Table 6-1 Specimens applied in the cell tests. They differ in the support material and the sintering method. 
sintering method   
conventional HT1 HT2 
wafer 
“w” 
w730NRL, 
w730RL 
- - 
flat stainless steel 
“ss” 
ss730NRL 
ss730RL 
ss820NRL(H1), 
ss820(H1) 
ss730NRL(H2), 
ss730RL(H2) 
su
pp
or
t m
a
te
ria
l 
wire shapes stainless 
steel 
“ssWire” 
- ssWire820NRL 
(HT1), 
ssWire820 
- 
“conventional”: sintering as described in Chapter 4.2.5; “HT1”: sintering up to 450 °C in air, in the second 
cycle up to 820 °C in hydrogen/argon/oxygen; “H2”: two sintering cycles with the first one from room 
temperature up to 450 °C in air, the second one from room temperature to the maximum temperature 730 °C 
encapsulated under 300 mbar argon 
 
6.2 Materials and Methods 
6.2.1 Substrates applied in the cell testing 
The preliminary in vitro cytotoxicity tests were performed using titania coatings on 
either wafer or on 316L stainless steel (SS) supports. None of the samples were loaded with 
Paclitaxel (PTX). The cell tests were performed to just evaluate the cell responses to the 
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titania coatings in the non-reservoir layer (NRL) and the reservoir layer (RL) modifications.  
 
6.2.1.1 TiO2-coatings on silicon supports 
NRL- and RL-titania coatings on plate-shaped wafer supports, which were heat treated 
with the conventional method described in Chapter 4.2.5 and with the maximum sintering 
temperature of 730 °C (w730NRL and w730RL), were employed in the test CTSi1, Table 
6-2. The negative references, defined as a material not creating any cytotoxic response under 
the in vitro conditions [5], consisted of microscope glass cover slips (Menzel Gläser, 
Gerhard Menzel, Glasbearbeitungswerk GmbH & Co. KG) [7]. To fit the samples into the 24 
well culture dishes, they were cut with a diamond knife to exhibit an area of ~ 1 cm2. It was 
necessary to know the exact areas of these specimens to refer the determined cell number to 
them. The areas were hence measured like was described previously in Chapter 5.4.3: photos 
of the cut workpieces were taken by a light microscope (MZ8, Leica) equipped with a JVC 
TK C1380 CCD camera. The geometric surface area was subsequently determined 
employing the imaging software ImageJ (V 1.38x). The cell test of the titania coatings on 
wafers served to establish the methods for further cell testing.  
 
Table 6-2 Summary of in vitro cytotoxicity tests of the titania coatings on either wafer or steel supporting 
materials.  
cell test samples heat treatment shape 
conventional, cf. Chapter 4.2.5 CTSi1 w730NRL, w730RL, 
 cover slip (negative control) - 
flat 
HT1 (partially in Ar/H2 atmosphere) CTssWire ssWire820NRL(HT1),    
ssWire, ssWirePS, ssWireSIBS  
- 
wire 
CTssFlat1 ss730NRL, ss730RL  conventional, cf. Chapter 4.2.5 flat 
HT2 (partially encapsulated) 
 
CTssFlat2 
 
ss730NRL(HT2), ss730RL(HT2), 
ssFlat,  
cover slip (negative control) 
- 
flat 
 
6.2.1.2 TiO2-coatings on stainless steel wires 
In the cell test CTssWire, stainless steel wires (Heraeus Material S.A.) with a diameter 
similar to the one of stent’s struts of 300 µm and pre-treated with a special annealing by the 
company Meko GmbH, Germany, were applied. They were electropolished and cleaned 
according to the methods specified in Chapter 4.2.2 and in the thesis of A. Tourvieille de 
Labrouhe [6] prior to dip coating with TiO2.  
 
The titania coated wires in a NRL-modification and heat treated with a special 
sintering method with a maximum sintering temperature of 820 °C were termed 
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ssWire820NRL(HT1). They were prepared by dipping each wire into a TiO2-nanoparticle 
suspension and withdrawing it two times at 90 mm/min and one time at 250 mm/min to 
achieve a decisive coating thickness, cf. methods described in Chapter 4.2.3. They were 
subsequently heat treated with a method different to the conventional one applied before, to 
reduce the amount of precipitated iron oxide on the steel’s surface. Specimens were heated 
with a rate of 4.5 °C/min in a tubular furnace up to 450 °C and isothermally held for 60 min. 
The atmosphere was then changed from air to a combination of argon, hydrogen and air* to 
limit the oxidation of the steel’s surface, whereas the flow was kept constant at 0.342 l/min. 
A second heating step was conducted applying a rate of 4.5 °C/min to a maximum sintering 
temperature, Tmax, of 820 °C. The dwell time was 80 min before it was cooled to room 
atmosphere with 4.5 °C/min. Names of the samples heat treated with this method contain the 
abbreviation “HT1”.  
 
Besides the titania coated wires, native, not heat treated stainless steel wires were 
employed in the cell test, ssWire in Table 6-2. Two types of polymers were coated onto the 
native SS wires in order to test their application as negative controls in the cell tests on 
wires. They were termed ssWirePS and ssWireSIBS. The SS wires coated with polystyrene 
(PS), ssWirePS, were fabricated as follows. A solution of 26.73 %wt polystyrene (PS-storing 
tube, Semadeni) was prepared by dissolving PS in toluene (ACS reagent, purity  99.5 %,  
Sigma-Aldrich) in a glass bottle (Schott) and stirring it at 300 rpm (RCT classic, IKA®) at  
80 °C for 12 h. SS wires were after cleaning dipped into the PS/toluene solution and 
withdrawn with 250 mm/min (Precision dip coating system PL 3201, Speedline 
Technologies). After drying for 10 min at 37 °C in a climatic test cabinet (RUMED®), the 
dip coating was repeated twice. The samples were subsequently dried for 19 h at 60 °C to 
completely evaporate the solvent. The ssWireSIBS specimens were prepared accordingly, 
except that a solution of 10 %wt styrene-isobutylene-styrene (SIBS, Albemarle Europe 
SPRL Belgium) in toluene was used. SIBS is a non-degradable, thermoplastic elastomer, 
which is used in the drug-eluting TaxusTM stent by Boston Scientific Corp.  
 
6.2.1.3 TiO2-coatings on flat stainless steel supports 
Because the homogeneous cultivation of the cells on the wire substrates has been 
proven to be difficult, cf. Chapter 6.3.4, titania coatings on flat SS supports were 
investigated in the tests CTssFlat1 and CTssFlat2.  
 
 
 
* The exact composition of the atmosphere was not determined, because the oven’s tube exhibited a leakage. 
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CTssFlat1 
The titania coatings in the NRL- and RL-modifications were produced as was 
described in detail in Chapter 4.2.3. The conventional heat treatment was applied with a Tmax 
of 730 °C and the samples were termed ss730NRL and ss730RL. Specimens were not cut 
prior to the incubation with endothelial cells and held a rectangular shaped surface with the 
size of 1 x 5 cm.  
 
CTssFlat2 
The TiO2-coated specimens applied in the assay CTssFlat2 were dip coated as was 
described earlier for the NRLs and the RLs in Chapter 4.2.3. The heat treatment was 
performed with a new method, called HT2, to limit the build up of iron oxide on the steel’s 
surface and to obtain a good mechanical stability of the films (cf. Thesis A. Tourvieille [6]). 
The sintering was accomplished by applying two heating cycles. During the first cycle, 
specimens were mounted on an aluminum support in the tubular furnace and heated to  
450 °C with 4.5 °C/min. The time of the isothermal hold at this temperature was 60 min  
before cooling with 4.5 °C/min to room temperature. The flow of air was 0.342 l/min. The 
samples were afterwards encapsulated into a quartz glass tube (VQT SA, Switzerland) with 
an atmosphere of 300 mbar argon and no residual air (more details in Thesis A. Tourvieille 
[6]). A second sintering cycle was carried out by increasing the temperature with 4.5 °C/min  
up to 730 °C, keeping this Tmax constant for 80 min, before cooling to room atmosphere with 
the same rate. All samples with a rectangular surface of 1 x 5 cm were then cut into 
quadratic pieces with a surface area of 1 cm2 by electro erosion. The specimens were cleaned 
by rinsing them in acetone for 5 min and additionally in UP-water for 20 min. Native SS 
substrates, ssFlat, were also applied in the test. They were subjected to the same cutting and 
cleaning process like the titania coated samples. The negative references in this test were 
glass cover slips. 
 
6.2.2 Cells and cell viability testing 
6.2.2.1 Primary endothelial cells and incubation 
Primary bovine endothelial cells (ECs), which were isolated from a bovine aorta, were 
chosen in this test. Primary cells usually exhibit a higher specific sensitivity than some 
established cell lines [5, 8]. Prior to use, cells were de-frozen, the number of living and dead 
cells determined and the concentration of the cells in suspension adapted to 50000 cells/ml. 
The cell medium was Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen), 
supplemented with 10 % Fetal Bovine Serum (FBS, Invitrogen) and Penicillin, 
Streptomycin, Amphotericin (PSA, Invitrogen). All materials, which were to be tested, were 
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heat sterilized for 30 min at 121 °C prior to incubation (Dampfsterilisator HST 23/20, Zirbus 
GmbH). 
 
Samples with a cubic surface area of 1 cm2 of the tests CTSi1, CTssFlat2, as well as of 
CTssWire were each transferred into one well of the 24-wells tissue culture plastic plates 
(Zellkulturtest Platte 24, TPP). Cells were seeded at a concentration of 50000 cells per 
sample. After incubation at 37 °C, 5 % CO2 (Nuaire DHD Autoflow, CO2 Air-Jacked 
Incubator, Nuaire TM) in DMEM medium (DMEM, 10% FBS and PSA, Invitrogen) for 8 d,  
the analysis of the cytotoxicity was accomplished. This incubation period was chosen to 
ensure an adequate time for the formation of a cell monolayer, and in the view of future cell 
tests, in which paclitaxel (PTX) gets released from the titania films. The culture medium was 
completely replaced every 2 d of incubation. Samples of the test CTssFlat1 were incubated 
in a tissue culture dish (60 x 15 mm, Falcon), after 4 ml of the cell suspension were added. 
The test was stopped after only 2 d. 
 
6.2.2.2 Determination of the cell number 
By determining the number of living and dead cells present on the material, its toxicity 
can be estimated. Each substrate was after incubation for 8 d transferred into one well of the 
new 24 well plate and washed twice with fresh medium. 200 µl trypsin solution (Trypsin in 
ethylenediaminetetraacetic acid (EDTA) 0.05%, Invitrogen) was added and then stored in 
the incubator at 37 °C for 5 min. After trypsination and the incorporation of 400 µl medium 
to each sample, the cells were detached from the substrates and homogenated in the solution 
with a pipette. The solution composed of cells, media and trypsin was diluted with a trypane 
blue solution (Fluka) for 10 min. The dilution was adjusted to count 20 to 50 cells per 
quadrant in the hemocytometer (Neubauer Improved, 0.0025 mm2, Brand). Non-living cells 
were stained dark blue, because the color dye could migrate into the damaged cells. The 
living cells appeared transparent, because they excluded trypane blue [9]. 
 
6.2.2.3 Photometric determination of the cell viability 
The MTT-assay is a colorimetric method to measure the proliferation and viability of 
cells. In living cells, uptaken tetrazolium-salts like 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromid (MTT), which is a yellow, water-soluble salt, will be converted 
by the mitochondrial dehydrogenases to formazan, a dark blue, water insoluble substance, by 
reductive cleavage of the tetrazolium ring. This transformation will not take place in dead 
cells. The concentration of the formazan can be detected by a UV/VIS spectrophotometer in 
a cell suspension and correlates to the number of living cells and their cellular activity [9, 10].  
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A stock solution of MTT (Thiazolyl Blue Tetrazolium Bromide, TLC 98%, Sigma) in 
Phosphate Buffered Saline (Dulbecco’s PBS 1x, Gibco, Invitrogen) was prepared at a 
concentration of 5 mg/ml. The substrates under investigation were transferred into fresh 24 
well plates and washed two times with medium. 1 ml medium was added to each substrate 
and 160 µl of the MTT stock solution was incorporated. The well plates were stored in the 
incubator for 2 h. Afterwards the medium was removed and the samples were washed twice 
with fresh medium. 1 ml of a 39 mM isopropanol/hydrochloric acid solution was added to 
each substrate to destroy the cells, which were attached to them, and to release formazan. 
After incubating again for 15 min, 500 µl of the solution containing isopropanol, 
hydrochloric acid and formazan was each transferred into one well of a 48 well plastic 
culture plate and the absorbance measured at 540 nm with a microplate reader (Infinite 
M200, TECAN). 
 
6.2.2.4 Detection of the cell membrane permeability 
Glucose-6-phosphate (G-6-P) is produced in the cytoplasm of the cells. If the cell 
membrane is damaged, the G-6-P is released into the culture medium. In the resazurin essay 
the released G-6-P will be enzymatically transferred: the resazurin, which is blue and non-
fluorescent, is reduced with diaphorase to resorufin. Resorufin is pink and highly fluorescent 
and can be detected in fluorescence and photometric measurements. The greater the 
permeability of the cell membrane, and hence its damage, the higher is the amount of 
fluorescent resorufin in the media [11, 12, 13]. 
 
A stock solution of resazurin (Resazurin Sodium Salt, Sigma) in ultra pure water was 
prepared with a concentration of 1 mg/ml. After stirring for 5 min, the solution was filtered 
with a 0.45 µm cellulose acetate filter (Semadeni) to remove possible big agglomerates. 
After incubation, substrates with the attached cells were transferred into fresh 24 well plates 
and twice washed with fresh medium. 1 ml medium was then added to each, before 10 µl of 
the resazurin stock solution were incorporated. After 4 h of incubation at 37 °C, 500 µl of the 
solution, containing media, resazurin and resorufin, were each transferred into a well of a 
new 48 well plate. The concentration of resorufin was measured by fluorescence 
spectroscopy with a microplate reader. An excitation wavelength of 560 nm was applied and 
the emission of resorufin measured at 590 nm.  
 
6.2.2.5 Cell morphology by microscopy 
It is important to use visual methods to analyze the morphology, adhesion and growth 
of the cells on the substrates [5, 9]. In the present study, optical and electron microscopy 
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were the methods of choice. The electron microscopy combined with focused ion beam 
milling gave further insight into the adhesion of the cells onto the substrate by observing 
cross sections. 
 
Optical microscopy 
A staining of the adherent cells on the substrates was done before optical microscopy 
using Giemsa staining. After the substrates with attached cells were transferred from the 
incubation well plates into wells of a new culture dish, they were each rinsed two times with 
phosphate buffered saline (DPBS 1x, Gibco). A solution of 1 ml PBS in methanol of a 
concentration of 50/50 %vol was added. After 2 min the solution was taken out and 2 ml of 
pure methanol were given to each substrate and removed after 2 min. Furthermore 2 ml of 
anhydrous methanol was pipetted to each substrate and taken out after 10 min, to finish the 
dehydration of the cells. 1 ml of the Giemsa solution (Giemsa Stain, Modified Solution, 
Riedel-de-Haën) was added to each substrate, waited for 2 min and then it was removed.  
1 ml of a 5 x diluted Giemsa solution in water was each added. After 2 min the color dye 
solution was taken out and the substrates washed twice with ultra pure water. They were then 
fixed on a microscope slide and observed by light microscope (Olympus B071 with an Altra 
Soft Imaging System 20 camera and the software Analysis get it). 
 
Scanning electron microscopy 
Sample preparation for scanning electron microscopy (SEM) was performed in 
collaboration with the Center for Electron Microscopy, EPF Lausanne (CIME) and the 
Center of Electron Microscopy, Faculty of Biology and Medicine of the Université de 
Lausanne/Centre Hospitalier Universitaire Vaudois, Lausanne (CME, CHUV).  
 
Substrates with attached ECs were transferred from the incubation culture dishes into 
fresh 24 well plates and rinsed twice with 1 ml PBS-solution. 1 ml fixation solution, 
composed of 2.5 % glutaraldehyde and 2 % paraformaldehyde in 0.1 M PBS, was given to 
each sample and left for 30 min. Specimens were thereafter dehydrated by putting them 
sequentially for each 5 min in solutions of ethanol and water in different concentrations: 
50/50; 70/30; 90/10; 100 %vol. Samples were then dried with a critical point drying method 
(critical point dryer CPD 030, Baltec) at the CME, CHUV. The ethanol was thereby replaced 
by liquid CO2, which was then evaporated from the cells without damaging their 
morphology. Specimens were fixed on a holder for electron microscopy and sputter coated 
(MED 010, Baltec) with platinum to yield a coating thickness of 10 nm. The cells on the 
substrates were then observed with an XLS 30 scanning electron microscope (Philips). 
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Scanning electron microscopy combined with focused ion beam (FIB)  
The preparation of the samples for SEM-analysis, combined with focused ion beam 
(FIB) technique, was performed in collaboration with G. Knott, CIME, EPF Lausanne. The 
titania coated wires ssWire820NRL(HT1), to which cultured ECs adhered, were fixed with a 
solution of 2.5 % glutaraldehyde and 2 % paraformaldehyde in 0.1 M PBS for 4 hours. After 
fixation, the wires were washed thoroughly with cacodylate buffer (0.1 M), postfixed for  
40 min in 1.5% potassium ferrocyanide and 1% osmium tetroxide, then 1 hour in 1% 
osmium tetroxide alone, and finally stained further with 1% uranyl acetate for 40 minutes. 
They were dehydrated through increasing concentrations of ethanol and finally embedded in 
Durcupan ACM resin (Fluka, Switzerland). The resin was hardened for 24 hours at 65 °C.  
Resin blocks, with the samples uppermost, were trimmed to a size of approximately 5 x 5 
mm using a diamond wire saw. The upper surface of the block was then further trimmed 
with an ultramicrotome (Leica UCT) and a glass knife until the wire with the attached cells 
was not more than 20 μm distant from the surface. Specimens were then glued to SEM-stubs 
using carbon paint. The whole surfaces of the blocks were coated with a gold layer of 30 nm 
to avoid charging effects under the electron beam.  
 
Manipulation of the electron microscopes and image processing were performed by M. 
Cantoni, CIME, EPFL. A NVision 40 CrossBeam (Zeiss) was used for the milling and 
imaging of the titania coated wires embedded in the resin blocks. In the FIB, a masking layer 
of about 1 μm platinum was deposited locally with the ion beam on the area to be milled, in 
order to prevent a roughing on the milling front. Cross sections of the wires with cells were 
prepared every 20 nm using the FIB, generated by a gallium liquid metal ion source, at  
30 kV and a beam current of 700 nA. After each milling process, backscattered electron 
scanning images were recorded at accelerating voltages of 2 kV. The whole set of ~ 600 2D 
images were compiled to a 3D stack and processed using the software ImageJ. 
 
6.2.2.6 Statistics 
All data from the cell tests were statistically analyzed using analysis of variance, 
ANOVA, from the Statistical Design of Experiment provided by J. Lemaître, EPFL [14]. 
The number of replicas for each testing was 4, except for microscopy. 
 
6.2.3 Preliminary elution test for the corrosion tendency of the steel supports 
As will be seen in the results’ section of this chapter, iron oxide was built on the SS 
supports after particular heat-treatments. A preliminary test was thus performed to 
determine, if iron oxide was only precipitated on the steel’s surface, or if it was also build at 
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the interior of the steel samples. Therefore the following specimens were tested: native, non-
heat treated SS (native ss), SS heat treated with the method HT1 and then grinded to remove 
the oxide layer (ss820(HT1)_poli), heat treated SS and not grinded (ss820(HT1)_nonpoli) 
and a titania coated SS and heat treated with the method HT1 (ss820NRL(HT1)),  
Figure 6-1 (a). They were each placed into a tissue culture dish of a size of 60 x 15 mm 
(Falcon) and 4 ml deionized water with a conductance below 0.1 µS/cm was added to totally 
cover them. The culture dishes were closed to avoid water evaporation and left at room 
atmosphere. After 96 h, photos were taken (Cyber-shot, Sony) and the distribution of iron 
oxide around the samples evaluated visually. The same methods were applied to SS wires, 
which are depicted  in Figure 6-1 (b). The sample ssWire820(HT1)_poli was electropolished 
and not grinded like the flat analogue. 
 
native 
ssWire
ssWire820
(HT1)_poli
ssWire820
(HT1)_nonpoli
ssWire820
NRL(HT1)
(b)
native ss
ss820(H1)_
poli
ss820(HT1)_
nonpoli
ss820NRL
(HT1)
(a)
 
Figure 6-1 Samples used in the preliminary corrosion tests of the stainless steel supports: (a) rectangular and 
(b) wire steel samples. 
 
6.2.4 Methods for the surface characterization 
6.2.4.1 X-ray photoelectron spectroscopy 
To determine the elemental composition of the substrate’s surfaces after heat 
treatment, X-ray photoelectron spectroscopy (XPS)-measurements were carried out. The 
detailed analysis method is described in Chapter 4.4.1. Only the samples ss820NRL(HT1) 
and ssWire820NRL(HT1) were analyzed. The samples, which were heat treated with the 
method HT2, were further characterized by A. Tourvieille de Labrouhe [6]. 
 
6.2.4.2 Contact angle measurements 
The contact angles of the negative reference cover slip and the titania coated SS-
supports ss820NRL(HT2), ss820RL(HT2), were measured by the sessile drop method. This 
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method was described in detail in Chapter 4.4.2. 
 
6.2.4.3 Roughness determinations 
The roughnesses of the negative reference cover slip and the titania coated SS supports 
ss820NRL(HT2) and ss820RL(HT2) were measured using the mechanical profilometer 
Alpha Step 200 (TENCOR INSTRUMENTS). The procedure was explained in detail in 
Chapter 4.4.3.  
6.3 Results 
6.3.1 Cytocompatibility of the TiO2-coatings on silicon supports 
A smaller living cell density (LCD) was detected on the titania coated wafers with a 
NRL- and RL-modification as compared to the glass cover slip negative references, Figure 
6-2 (a). The lowest LCD of 2000 living cells per 1 mm2 substrate area was recorded for the 
RL w730RL. No significant differences of the cell’s viability on the different substrates were 
obtained, when considering the mitochondrial activity depicted in Figure 6-2 (b) and the cell 
membrane permeability displayed in Figure 6-2 (c). ECs were present as a monolayer on the 
RLs. Parts of the negative reference and the NRLs were covered by a monolayer, others by a 
multilayer of ECs, Figure 6-3. The cells on the RLs were slightly bigger than on the negative 
references and the NRLs.  
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Figure 6-2 (a) The living cell density, (b) the mitochondrial activity and (c) membrane permeability of the 
primary bovine endothelial cells after 8 d of incubation on the titania coated wafer supports of test CTSi1. 
Displayed are the adjusted mean values (columns), the non-adjusted mean values (Δ), the standard deviations  
(-) after ANOVA analysis with p < 0.05. 
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Figure 6-3 Optical micrographs of (a), (d) negative reference, (b), (e) titania reservoir layer on wafer support 
and (c), (f) titania non-reservoir layer on wafer support, all belonging to the cell test CTSi1. Samples were 
incubated for 8 d with primary bovine endothelial cells and stained by Giemsa staining method. 
 
6.3.2 Cytocompatibility of the TiO2-coatings on flat stainless steel after conventional 
sintering 
The SS supports with a rectangular surface and coated with a titania NRL or RL 
exhibited after 2 d of cultivation with the ECs a pink culture medium, which is indicative for 
an alkaline environment. In addition, brown precipitates near the samples were detected, 
Figure 6-4. They represent iron oxides, which got dissolved from the steel’s surface. After 
subjecting the samples to Giemsa staining, only a few ECs and cell debris were found on the 
titania surfaces, Figure 6-5. These results were the reason, why different heat treatments of 
the SS specimens had to be applied instead of the conventional sintering. The new methods 
were employed to limit the formation of iron oxides and hence cell death. 
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Figure 6-4 Iron oxide liberation from a titania non-reservoir layer on a flat SS support, sintered with the 
conventional heat treatment. After 2 d of cultivation with endothelial cells. The arrow indicates iron oxides. 
 
 
Figure 6-5 Optical micrographs of a titania non-reservoir layer on a flat SS support, sintered with the 
conventional heat treatment. After incubation for 2 d with the endothelial cells. Only a few endothelial cells 
(dark spots) were detected. 
 
6.3.3 Corrosion tendency of the specimens 
6.3.3.1 Elution test 
Non-coated SS samples, which were subjected to the heat treatment HT1 involving a 
partial sintering in argon/hydrogen/air atmosphere, showed a black color. Grinding of the 
sample to remove the black surface revealed the silver color of the SS, Figure 6-1. After 
immersion of the specimens for 96 h into water, the native SS and the grinded heat treated 
one, ss820(HT1)_poli, did not show the release of iron oxide, Figure 6-6. The non-grinded 
ss820_nonpoli and the titania coated ss820NRL(HT1) exhibited a brown coloration around 
them, which is representative for iron oxide. 
 
The findings of the wire samples were similar: the native SS, the grinded heat treated 
as well as the titania coated specimens did not show the release of iron oxide, Figure 6-7. 
Only ssWire820(HT1)_nonpoli exhibited the dissolution of iron oxides. From these two tests 
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it could be concluded that iron oxides were build on the steel’s surface during heat treatment. 
They were not formed in the bulk of the steel. Iron oxides precipitated because a residual 
amount of oxygen was present in the oven’s atmosphere. In future studies the heat treatment 
HT2, in which the specimens were encapsulated during the heat treatment at elevated 
temperatures, was applied. They did not exhibit the elution of iron oxides when they were 
immersed into water, as can be extracted from the Thesis of A. Tourvieille de Labrouhe [6]. 
For subsidiary information of the elemental composition of the specimens sintered with the 
sintering method HT1, X-ray photoelectron spectroscopy (XPS) measurements were 
realized. 
 
 
Figure 6-6 Samples from the preliminary corrosion test show for (a) native ss and (b) ss820(HT1)_poli no iron 
oxides, whereas for the samples (c) ss820(HT1)_nonpoli and (d) ss820NRL(HT1) iron oxides in the medium 
surrounding the specimens was detected. 
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Figure 6-7 Samples from the preliminary corrosion test show for (a) native ssWire, (b) ssWire820(HT1)_poli 
and (d) ssWire820NRL(HT1) no iron oxides. For (c) ssWire820(HT1)_nonpoli iron oxides in the medium 
surrounding the specimens were visible. 
 
6.3.3.2 Elemental composition 
The elements present in the titania coatings on SS supports and heat-treated with the 
method HT1 (ss820NRL(HT1)) were nickel oxide, iron oxide, chromium oxide and TiO2, 
Figure 6-8. If these oxides might also have existed as complex oxides combining Fe, Cr, Ni 
and O was not clear from the XPS data. A carbon peak was recorded in all spectra referred to 
being contamination. The findings for the titania NRL on SS wire (ssWire820NRL(HT1)) 
were similar, except that no Ni was found, Figure 6-9.  
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Figure 6-8 (a) XPS-spectrum of a titania coated stainless steel plate, which was sintered with the method HT1 
(ss820NRL(HT1)).(b)-(e) represent the peak-deconvolutions of Ni, Fe, Cr and Ti.  
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Figure 6-9 (a) XPS-spectrum of a titania coated stainless steel wire, which was sintered with the method HT1 
(ss820NRL(HT1)).(b)-(e) represent the peak-deconvolutions of Ni, Fe, Cr and Ti.  
 
 
6.3.4 Cytocompatibility of the TiO2-coatings on stainless steel wires after modified 
sintering  
Titania NRLs on SS wires and heat treated with the new method HT1 were subjected 
to an in vitro cell test. The ECs attached well on parts of the titania coated wires, as is 
depicted in Figure 6-10 and Figure 6-11. However, it was difficult to achieve a homogeneous 
cultivation of the ECs on the wires and hence a quantitative evaluation of the 
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cytocompatibility.  
 
In a first test, only 1 wire of each kind with a length of 1 cm was inserted into one of 
the 24 wells of the culture dish for cultivation. Cells attached on the NRLs, Figure 6-10 and 
Figure 6-11. The number of cells on the wires was too small to be counted with the 
hemocytometer-method. Even an up-concentration of the cells in the suspension, which was 
obtained after trypsination of the cells from the wire and centrifugation, did not reveal the 
cell number. Theoretically, if the whole wire would have been covered by cells with a 
diameter of 30 µm, a density of 1415 cells/mm2 should have been deduced. Hence it should 
have been possible to determine the living and dead cell numbers of this sample. By looking 
at the photos made by SEM in Figure 6-10, it gets obvious why the number of cells was 
lower than the theoretically expected one and hence non-detectable. The cells were only 
attached at the side of the wire, which was facing the top of the culture well during 
incubation. On the opposite side, which was facing the bottom of the plastic culture plate, 
almost no cells were present.  
 
 
Figure 6-10 SEM-micrograph of ssWire820NRL(HT1) showing the inhomogeneous attachment of the 
endothelial cells on a wire.  
 
This problem was addressed in following smaller tests, in which the wires in the 
culture well were rotated every 24 h. But cells were still only present on one side of the wire. 
The viability of the cells attached to the wire could not be evaluated by spectroscopic 
methods. The amount of metabolized MTT and resazurin was still below the detection limit. 
Small tests applying 10 wires placed in parallel into one well of the 24 well culture plate to 
increase the number of adherent cells and hence to increase the spectroscopic signals, failed. 
Only the cell morphology could be evaluated on the different types of specimens,  
Figure 6-11 and Figure 6-12. On the surface of the PS-coated native SS wires (ssWirePS) no 
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cells attached and only cell debris were observed. Thus the PS-coated wires could not be 
employed as negative controls in the present study. The surface of the wire, which was 
coated with the SIBS-polymer, was well covered with ECs. They were well spread on the 
surface. The cell density on the native SS support (ssWire) observed by optical microscopy 
was smaller than for the SIBS-wire and the titania coated wire (ssWire820NRL(HT1)). The 
shape of the ECs cultivated on the titania coated wire exhibited a more round shape than the 
ones on the native SS wire, Figure 6-11 (c, g, d, h). SEM further elucidated the shape of the 
cells on the titania coated wires ssWire820NRL(HT1) at higher magnification, Figure 6-12. 
One could see filopodia of the cells interacting with the surface, which is a good sign for the 
cell attraction by the substrate. The preparation of the samples on the polymer coated, as 
well as on the native steel wires, failed. 
 
 
Figure 6-11 Optical micrographs of (a), (e) a polystyrene coated SS wire, (b), (f) a SIBS coated SS wire, (c), 
(g) a native SS wire and (d), (h) a SS wire coated with a titania NRL and heat treated with the method HT1. 
After incubation with the primary endothelial cells for 8 d.  
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Figure 6-12 SEM-micrographs of a titania NRL on a SS wire, which was incubated for 8 d with endothelial 
cells. (a) to (d) show different magnifications.  
 
By applying focused ion beam (FIB) milling to cut cross sections of the NRL-coated 
SS wires exposed to the cell test, more insight into the attachment of the cells onto the TiO2-
coating could be deduced, Figure 6-13. The ECs were in contact with the coating only at 
certain points, whereas at others a distance between the coating and the specimen’s surface 
was observed. No additional substrates from the cell test were analyzed for comparison, 
because their preparation failed. In addition to the cell-substrate interaction, information 
about the substrates themselves could be gained by FIB. The thickness of the TiO2-coating 
could be measured to be 300 nm. The grains of the underlying SS wire were visible 
exhibiting different grey scales. Their sizes can hence be measured. This gives information 
of the influence of the heat-treatment on the SS composition. 
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Figure 6-13 Electron micrographs of a cross section of a titania coated stainless steel wire, which was 
incubated with endothelial cells for 8 d.  
 
6.3.5 Cytocompatibility of the TiO2-coatings on flat stainless steel after modified 
sintering 
Titania NRLs and RLs on flat SS supports, which were heat treated with the method 
HT2, were applied in this cell test. No significant differences of the living cell densities 
(LCD) as a function of substrate type was ascertained after ANOVA analysis of the data 
with an error risk of 5 %, Figure 6-14 (a). A high standard deviation was recorded for all of 
the samples. It was hence impossible to evaluate the cell test quantitatively, because the 
measured absorptions in the MTT assay (Figure 6-14 (b)) as well as the fluorescent signals 
in the resazurin test (Figure 6-14 (c)) are referenced to the adjusted mean values of the 
LCDs. The detected standard deviations in the LCDs propagated in the evaluation of the cell 
viability. This gets clearer if one compares the results of the MTT and resazurin tests. The 
MTT test and the resazurin assay are complementary tests. The lowest viability of the cells 
on ss730NRL(HT1) detected in the MTT experiment should lead to a high resorufin 
concentrations in the cell media. This was not the case: the membrane permeability did not 
show significant differences for all of the substrates.  
 
Even if the quantitative results of this test were not distinct and the assay needs to be 
repeated, essential information was gained regarding the cell attachment. All substrates 
under investigation were covered with widely spread, adherent ECs, like was observed in the 
optical micrographs in Figure 6-15 and the SEM-micrographs in Figure 6-16. On the 
negative reference and the native SS cells have build a multilayer coverage. The cells on the 
RLs and NRLs were present as a monolayer. Filopodia were expressed by the cells on all 
substrates. 
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Figure 6-14 (a) The living cell density, (b) the mitochondrial activity and (c) membrane permeability of the 
primary endothelial cells after 8 d of incubation on the substrates of test CTssFlat2. Displayed are the adjusted 
mean values (columns), the non-adjusted mean values (Δ) and the standard deviations (-) after ANOVA 
analysis with p < 0.05. 
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Figure 6-15 Optical micrographs of (a), (e) the cover slip negative reference, (b), (f) native stainless steel (SS), 
(c), (g) a titania RL on flat SS, (d), (h) a titania RL on flat SS, after incubation with endothelial cells for 8 d.  
 
 
Figure 6-16 SEM-micrographs of (a) the cover slip negative reference, (b) native stainless steel (SS), (c) a 
titania RL on flat SS, (d) a titania RL on flat SS, after incubation with endothelial cells for 8 d. 
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6.3.6 Roughnesses and contact angles 
The glass cover slip, which was applied as a negative reference in the cell tests, 
exhibited a smooth surface with a mean roughness, Ra, of 8.88 nm. The roughnesses of the 
NRLs on flat SS supports and heat treated with method HT2 (ss730NRL(HT2)) and of the 
equivalent RLs (ss730RL(HT2)) were 99.50 nm and 80.25 nm, respectively. The contact 
angle θc of the cover slip with water was measured to be 40.58 °. The titania coatings 
featured high standard deviations in the contact angles. They varied with the position on the 
substrates, at which the measurements were deduced. The middle of the quadratic surfaces of 
both sample-types exhibited a hydrophobic character with θc of 83.09 ° and 133.88 ° for the 
NRLs and RLs, respectively. At the border area, which is up to 3 mm distant from the 
sample’s edges, smaller contact angles were detected: 48.58 ° for NRLs and 63.57 for the 
RL. 
 
Table 6-3 Mean roughnesses Ra and contact angles θc with water of samples applied in the cell tests.  
sample cover slip ss730NRL(HT2) ss730RL(HT2) 
Ra (nm) 8.88 ± 4.96 99.50 ± 4.20  80.25 ± 25.44 
θc (°), water: middle / border* 40.58 ± 2.32 / 
- 
83.09 ± 10.72 /      
48.58 ± 8.75 
133.88 ± 6.94 /        
63.57 ± 14.62 
* the position of the measurement of the contact angle of a specimen of 1 cm2 surface area 
 
6.4 Discussion 
The cytocompatibility of the nanostructured titania coatings with primary endothelial 
cells (ECs) was evaluated. Non-reservoir layers (NRLs) and reservoir layers (RLs) were 
fabricated on either silicon wafer or 316 L stainless steel (SS) supports and tested. 
 
The well characterized titania coatings on wafer supports were sintered with the 
conventional heat treatment introduced in Chapter 4.2.5 and with the maximum sintering 
temperature of 730 °C. They were used to evaluate the influence of the topography of the 
NRLs and RLs on the cell proliferation and to establish the cell testing methods. A smaller 
living cell density (LCD) was detected on the surfaces of the TiO2-coated samples, as 
compared to the glass cover slip negative references, Figure 6-2. This behavior might be 
related to two issues. The higher LCD might have been caused by multilayer cell coverage of 
the negative reference and the monolayer coverage on the titania coatings. Secondly it might 
be related to the cell’s morphology. One could detect slightly bigger, more elongated ECs on 
the RLs compared to the NRLs and the negative reference in the micrographs of the cells on 
the surface. Bigger cells occupy a bigger area and hence fewer cells can attach to the surface. 
The different morphologies of the ECs were created by the reaction of the cells to the 
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material’s surface. On one side, the borosilicate glass cover-slip exhibited a different 
chemical composition at the surface than stoichiometric TiO2. It is known that TiO2 
promotes a good adhesion of osteoblasts in orthopedic and dental applications, and of ECs 
for stents [1, 15, 16]. The fast and good cell attachment on the TiO2-surfaces is supported by 
their hydrophilicity, because a hydrophilic surface enhances the cell attachment rather than a 
hydrophobic one [1]. The contact angles of the titania coated wafers with water were below 
20 ° (Table 4-11), the surfaces therefore hydrophilic. On the other side, the nanotopography 
of a surface can significantly change a cell’s shape and vitality. In the field of dental and 
orthopedic medicine, it is well demonstrated that the nanotopography, which spans length 
scales of 0-100 nm, can trigger protein adsorption followed by osteoblast adhesion [17, 18]. 
A study of Dalby et al. with ECs on polymer surfaces of different roughnesses revealed that 
after 1 week of incubation, the cells were more spread on the manufactured rough 
topographies than on chemically similar flat surfaces. Of all nanotopographies investigated 
in their study, islands of a size of 13 nm gave the largest cell response. The cells exhibited 
highly spread morphologies containing well-defined cytoskeletons. The effect of the surfaces 
with higher roughnesses was less distinct. The samples investigated in the present test fit into 
the same roughness interval. The cover slip negative reference had a mean roughness, Ra, of 
8.88 nm and the NRLs Ra of 16.70 nm (Table 6-3, Table 4-11). For the RLs, 25.30 nm was 
detected. Hence a good cell spreading on these types of surfaces could have been expected 
when compared to the findings by Dalby et al. Future testing with systematically varying the 
nanotopography of the TiO2-coating is necessary to study the ECs-adhesion on the titania 
coatings. ECs should adhere fast to the coating, proliferate and hence prevent thrombosis and 
restenosis. 
 
For the application of the coatings in a drug-eluting stents (DESs), SS supports instead 
of wafers will be applied. Titania NRLs and RLs on SS supports and heat treated with the 
conventional method and a maximum sintering temperature of 730 °C were subjected to a 
cell test. They were cytotoxic-only a few cells were present on the coating and iron oxides 
from the metal’s surface were released into the culture medium, Figure 6-4, Figure 6-5. The 
presence of small amounts of iron oxides on the top-surface of the titania films was detected 
by X-ray photoelectron spectroscopy (XPS) analysis, Figure 4-28. The elemental 
composition of the underlying steel’s surface could not be evaluated, because the escape 
depth of the photoelectrons was smaller than 10 nm and smaller than the thickness of the 
coating.  
 
The conventional heat treatment was then modified to avoid the iron oxide formation 
on the steel’s surface. Instead of using argon and oxygen in the high temperature region of 
the sintering cycle, a reducing atmosphere of argon, hydrogen and oxygen was applied. The 
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maximum sintering temperature was 820 °C and the method termed HT1. A preliminary 
corrosion test of SS-samples and NRL-coated SS, which were sintered with method HT1, in 
UP-water revealed the presence of iron oxides on top of the steel’s surface, Figure 6-6 and 
Figure 6-7, and not in the bulk of the SS. The formation and release of iron oxides can be 
explained by the following. The presence of a natural, thin metal oxide layer of the elements 
chromium and nickel creates a passivation of the native, low carbon, austenitic 316L SS. 
Hence it gets corrosion resistant against many aggressive media, e.g. body fluid. The 
formation and growth of this oxide layer can be provoked by a chemical treatment of the SS 
and by heating the SS in air atmosphere. [19, 20, 21; 22]. But the temperature of the heating 
in air is crucial to the performance of the SS. As described by Nomura et al. [20], the oxide 
films on SS, heated above 800 °C, were not protective against inner corrosion and iron oxide 
formation. Fine metal oxide particles, made of chromium oxides and nickel oxides, grew 
bigger on top of the coating with increasing oxidation time and heating temperature. The 
presence of these large oxide particles as well as a depletion of Cr and Ni in the underlying 
SS, destroyed the protective films of SS and iron oxides get released from SS. In the present 
study, they diffused from the steel’s surface through the porous titania coating into the 
surrounding medium. Their concentration in the culture medium was high enough to cause 
cell death. The mechanisms of the corrosion were in detail studied by A. Tourvieille de 
Labrouhe [6]. 
 
The presence of different metal oxides on top of the titania coated SS, heat treated with 
method HT1, were confirmed by XPS-analyses, Figure 6-8, Figure 6-9. The metal cations 
diffused into the coating from the SS due to the heat treatment with a maximum sintering 
temperature of 820 °C and were present on top of it. This was observed on both, flat SS 
coated with TiO2 ss820NRL(HT1) and wire shaped SS coated with TiO2 
ssWire820NRL(HT1). Iron oxides and chromium oxides were present, besides 
stoichiometric TiO2. The flat specimen showed additionally nickel oxide. The migration of 
Cr3+, Fe2+, Fe3+ from a 316 L stainless steel support through a 300 nm thick anatase layer 
after heating at 500 °C was recently also recorded by Shozui et al. [23].  
 
In the preliminary corrosion test, the NRL-coated wire (ssWire820NRL(HT1)) did not 
show the release of iron oxide. Hence it was subjected to a cytotoxicity test. Flat, spread and 
inter-connected ECs were present on one side of the titania coated wire as was observed by 
microscopy. The opposite side, which was facing the bottom of the culture dish during 
cultivation, did not contain cells. The reason lies in the nature of the ECs, which are adherent 
growing cells. Once the cell suspension was added to the wires in the well plate, cells 
attached to the top of them, not at the bottom. During the cultivation for 8 d, they did not 
migrate to completely cover the wire and preferentially proliferated on top. When looking at 
Preliminary in vitro cytotoxicity  tests  Chapter VI 
 
 
186 
the cross sections of the NRL-coated wires seeded with ECs obtained by FIB, one could 
observe that the cells were interacting with the substrate at some points, at others they were 
distant. Well pronounced filopodia were seen in the SEM-images, which indicate cell 
attraction by the substrate. Cells interact with biomaterials via so called focal adhesions, 
which comprise an assembly of intra- and extracellular proteins, coupled to each other by 
transmembrane integrins. The focal adhesions were seen in the SEM-micrographs of the 
FIB-cross sections. Cell-surface integrin receptors promote furthermore the cell attachment 
to substrates. These receptors transduce biochemical signals to the nucleus by activating the 
same intracellular pathways that are used by growth factor receptors. The more the cells 
spread, the higher their rate of proliferation [1]. A quantitative evaluation of the cell numbers 
on the wires and their viability could not be deduced. The number of cells attached to them 
was too small to get signals in the spectroscopic measurements of the cell viability. If the 
observed contacts between the cells on titania NRLs on wires were an indicator for a better 
cell spreading than on a positive reference, or less good compared to the negative reference 
could not be deduced. On the one hand, the elaborate preparation of the specimens failed. On 
the other hand, it was difficult to find an appropriate negative reference for the test with the 
SS wires. Only dead cell debris were present on the polystyrene (PS)-coated wires, whereas 
on the styrene-isobutylene-styrene (SIBS)-coated ones more cells were detected. SIBS is the 
polymer applied in the commercially available TaxusTM stent. Maybe in future studies the 
SIBS-coated stainless steel wires can be used as a negative reference, but it has to be 
checked if their usage fulfills the demanded regulations.  
 
In future studies it might be of interest to use the FIB-method to study the close contact 
between the cells and the titania coating. If process parameters of the coating, such as a 
change in sintering temperature to modify the pore size, porosity or phase of TiO2 will be 
applied, the cell response will certainly differ [1, 17]. How a pore size and shape can 
influence the cell attachment and where the focal adhesions of the cells are located in the 
highly porous coating might be accomplished with the help of FIB. Because by conventional 
SEM, one gets only a top view of the cells attached to the support and not of the region 
below the cell. To understand, how to trigger a fast, continuous re-endothelialization of the 
highly porous TiO2-coating is beneficial to its application in a DES. A fast re-
endothelialization is recommended for stents. Because ECs are involved in the regulation of 
thrombosis and in the proliferation of subjacent smooth muscle cells, when a stent is 
implanted into the coronary artery. An incomplete endothelialization of the stents struts is 
recognized as being a major cause of late stent thrombosis [2, 3, 4], which can lead to severe 
side effects in patients after 1 year of stenting. Besides the information of the cell-surface 
interaction in cross sections by FIB, one can get information about the coating’s thickness, 
the size of the steel’s grains and-if once cell testing will be performed on drug-loaded 
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coatings-the position of the drug in the coating. FIB might be a powerful tool for future 
investigations of the coating’s performance.  
 
The in vitro cell test on wires could not be optimized in the present feasibility study. A 
further cytotoxicity test was performed using flat SS supports and renouncing the effect of 
curvature existing on the wires on the cell attachment. In the last preliminary assay, 
specimens were prepared under well controlled sintering atmosphere with a so-called HT2-
method. The heating was performed in two cycles: a first one in air up to 450 °C to remove 
the binder and a second one from room temperature up to 730 °C. The samples were 
encapsulated in the second cycle in a quartz tube, in which reducing atmosphere of 300 mbar 
argon was present. This special atmosphere was applied to limit the iron oxide formation on 
the steel’s surface. The in such a way treated SS samples did not exhibit the release of iron 
oxide, as was deduced by A. Tourvieille [6]. Cells could be seeded on the native SS, on flat 
SS coated with NRLs or RLs. The optical micrographs of the negative references, the native 
SS and the two titania coatings showed all a good coverage with flat, spread ECs. On the 
negative reference and the SS, even multi-layered cell coverage was detected, Figure 6-16. A 
comparison of the viabilities of the different specimens by spectroscopic methods could not 
be deduced. A high standard deviation in the LCD, Figure 6-14, was detected. Applying the 
adjusted LCDs to calculate the signals form the spectroscopy data delivered the lowest 
viability of the NRL and the highest for the SS. The resazurin assay, as a complementary 
study, did not fit well with the MTT testing. Hence the errors in the LCD were assigned to 
the viability results and one could not perform a quantitative evaluation of the cytotoxicity. 
Factors, which might have caused the remarkable standard deviations, were identified. One 
might be related to inhomogeneities of the TiO2-coatings on the flat SS. It was found that the 
contact angles of the quadratic SS samples coated with NRLs and RLs with water varied on 
different positions of one specimen. Whereas in the middle of the 1 cm2 piece a contact 
angle θc of 83.09 ° for the NRL and of 133.88 ° for the RL was measured, the contact angles 
at the border area were 48.58 ° and 63.37 ° for NRLs and the RLs, respectively. The border 
area was the area of the specimen up to 3 mm distant to its edges. The different properties at 
the border area compared to the middle position were linked to varying thicknesses of the 
coating. They were created by the edge effect of the TiO2-suspension after dip coating, by 
which more suspension accumulated at the edges of the sample creating a thicker TiO2-
coating. A second factor causing the deviations of the LCDs was related to the cutting of the 
big rectangular specimens by electro erosion. Even after cleaning of the workpieces in 
acetone and water, some metal ions, which were released from the steel during cutting, 
might have been left in the porous structure of the TiO2-coating and promoted a certain cell 
response. However from this preliminary test it was shown that ECs grew on the NRLs and 
RLs on flat SS-supports, which were heat treated with the new method HT2. An analysis of 
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the elemental composition of the specimen’s surface and the analysis of the steel regarding 
corrosion can be found in the Thesis of A. Tourvieille in conjunction with the analysis of 
their mechanical stability. A future test is planned to proof the cytocompatibility of the 
nanostructured TiO2-coatings on stainless steel, which was indicated in the last preliminary 
cell test. The in vitro cell testing methods were established and the identified problems 
connected to the sample preparation will be accounted for in the following test. 
 
In the near future, further application-relevant in vitro testing might be of interest. One 
should study the hemocompatibility of the NRLs and RLs on SS, which were heat treated 
with the method HT2, to evaluate platelet adhesion and the tendency of thrombus formation. 
This is important for implants in contact with blood, such as stents. TiO2 is negatively 
charged when it is implanted. It should retard the attachment of blood components with a 
negative charge, e.g. platelets, and thus should help against thrombus formation, as is 
suggested by Liu et al. [24]. Another interesting study would be related to the study of the 
PTX-release from the coating. One can think of applying eluates of PTX from a titania RL 
into bovine plasma, like was discussed in Chapter 5, in a cell migration assay with SMCs 
[25]. It should help to evaluate the efficiency of the PTX-eluting titania coatings towards 
neointimal hyperplasia, which is characterized by an overproliferation of SMCs. 
 
6.5 Conclusion 
Several preliminary in vitro cytotoxicity tests were performed applying primary bovine 
endothelial cells (ECs) to different titania coated substrates. A first assay was accomplished 
with the coatings in the non-reservoir layer (NRL) and reservoir layer (RL) modifications on 
wafer supports, and sintered with the conventional heat treatment with a maximum sintering 
temperature, Tmax, of 730 °C. A good cytocompatibility of the ECs after 8 d of incubation in 
regard to their living cell density and their viability was detected. The established cell-test 
methods could be used for further assays, because in reality the coating will be applied to 
metal supports, such as stainless steel (SS). 
 
Surveys using the TiO2-coated SS supports prepared by the conventional heat 
treatment and with Tmax of 730 °C exhibited cytotoxicity after 2 d of incubation. Corrosion 
testing revealed that it was associated to the dissolution of iron oxides from the steel’s 
surface and their diffusion through the porous TiO2-structure to the ECs. It was hence 
necessary to change the sintering atmosphere of the TiO2-coated SS supports to reduce the 
iron oxide formation. Specimens were fabricated with a special sintering method termed 
HT1, in which a reducing atmosphere of argon, hydrogen and air during the high 
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temperature cycle of the sintering was applied. The ECs attached well to the titania coated 
wires and proliferated. However, the culturing conditions for the wire-shapes samples need 
to be optimized in future studies. The flat SS supports, which were heat treated with the 
method HT1, exhibited still the dissolution of iron oxides from the surface.  
 
A better controlled, reducing sintering atmosphere was hence applied to the coatings 
on flat SS in the so-called method HT2. Cells grew well on the titania coatings in the NRL- 
and RL-modifications. They exhibited a normal morphology with a flat, spread shape. Cells 
were interconnected and distributed all over the coating. However, the quantitative 
evaluation of the cell’s viability could not be deduced. A test to prove the cytocompatibility 
of the TiO2-coated SS supports heat-treated with the method HT2, which was indicated in 
the preliminary test, are under current investigation. 
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CHAPTER VII 
7 GENERAL CONCLUSION AND PERSPECTIVES 
The feasibility to use nanostructured titania (TiO2) films as drug-releasing coatings in 
drug-eluting stents (DESs) was studied. The characterization of the coatings on silicon wafer 
and stainless steel (SS) supports was accomplished in regard to their structure and chemical 
composition. A particular emphasis has been laid on the development of methods to load the 
titania coatings with the pharmaceutical agent paclitaxel (PTX) in therapeutical doses and to 
study its release. Preliminary in vitro cell tests were carried out to get information about the 
cytocompatibility of the non-drug-loaded coatings.  
 
The thin nanostructured TiO2-films were produced by dip coating the SS or silicon 
wafer supports with TiO2-nanopartiles and spherical polymer templates. A subsequent heat-
treatment burned the organic components to create a structured porosity in the coatings. It 
consisted of a titania porous structure enclosing ellipsoidal drug reservoirs, which had a 
diameter of 1 μm. The reservoirs have the functions to increase the porosity of the coating 
and to store a sufficient amount of medicament, which will be controlled-released through 
the surrounding porous structure. The structure of the porous coatings on SS could not be 
characterized completely. The coating adhered too strongly on the support to be detached 
from it, which would have been necessary for the analyses of the porosity or density. The 
TiO2-coatings fabricated on silicon wafer supports represented a good model to measure 
these parameters. The specifications of the coatings, which were heat-treated at a maximum 
sintering temperature, Tmax, of 730 °C and did not contain reservoirs (NRL), were 
determined. The pore size distribution (PSD) of the NRL, which is equivalent to the structure 
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surrounding the reservoirs in a reservoir layer (RL), exhibited a median pore width below 
100 nm and an open porosity of 50 %. The influence of the reservoir size and density on the 
overall porosity in the coatings could not be measured, but calculated. The RLs applied in the 
present study contained theoretically 3 % more pore volume compared to the NRL of the 
same thickness. The calculations showed that the total pore volume can be increased by 
creating thicker coatings with bigger reservoirs, or by increasing the reservoir density.  
 
It was shown that in our days it is still a challenge to measure the PSDs and porosities 
of thin films, which exhibit high pore volumes and pore widths of a few nanometers up to 
several micrometers. A large amount of film sample was required to perform one 
measurement by mercury intrusion porosimetry (MIP), which covers all pore sizes. Hence 
bulk, cylindrical samples with a NRL-structure were prepared by slip casting. A bimodal 
PSD and a porosity of 50 % was recorded by MIP. The influence of constrained sintering in 
the films was shown by comparing the results of the bulk specimens sintered at Tmax of 800 
°C with the ones of a NRL-coating, which was identically heat-treated. The densification 
was lower in the films. But the differences in densification due to constrained film sintering 
were not as pronounced in the start of the initial stage of sintering of the TiO2-nanoparticles, 
as in the intermediate or the final stage. Hence similar properties in regard to the specific 
surface area and porosity of the TiO2-bulks and the NRLs were detected when heat-treated at 
Tmax of 730 °C. The TiO2-films heat-treated at Tmax of 730 °C were composed of mainly 
anatase, the residual amount was rutile. Stoichiometric TiO2 was detected on the top of the 
coatings by X-ray photoelectron spectroscopy (XPS). The roughnesses of the porous NRLs 
and RLs depended on the roughnesses of the underlying support material: it was lower of the 
coatings on smooth silicon wafers compared to the coatings on SS. The TiO2-coatings on 
wafers featured a high hydrophilicity, whereas the films on SS featured a more hydrophobic 
character. The presence of the reservoirs did not significantly influence the wettability 
behavior of these two types of coatings. 
 
PTX was successfully loaded into the well characterized, nanostructured TiO2-
coatings. The load of the pharmacological agent into the NRLs could be varied from as small 
as 0.06 µg/mm2 to a maximum load of 1.06 µg/mm2, depending on the parameters of the 
drug-loading procedures. The maximum load of 1.21 µg/mm2 was obtained for the RLs, with 
PTX being accumulated in the drug reservoirs, in the surrounding porous ceramic structure 
and being present as a burst-layer on top of the coating. The drug quantity was comparable 
to the PTX-concentration in the commercially available TaxusTM stent.  
 
 
Different factors, which influence the drug-load in the films, could be identified. They 
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were related to the structure of the TiO2-coating and the process parameters applied in the 
drug-loading procedure. A higher porosity in the coating increases the PTX-load. The 
presence of the reservoirs in the RLs thus added 14 % more PTX into the porous film 
compared to the NRLs. Bigger reservoirs as well as a higher density of them will further 
increase the PTX-load, as was obtained from theoretical calculations. Film structures with a 
higher reservoir density can be realized in future studies by densely packing the spherical 
polymer template particles in a monolayer instead of using randomly arranged particles. A 
higher porosity or directed pores can be formed in the porous structure surrounding the 
reservoirs by employing a higher binder content or a filler in the TiO2-suspension. An 
increase of the thickness of the coating will also increase the space available to store PTX. 
But one should be cautious in manipulating any of the structural parameters of the coating, 
because they are linked to the mechanical stability. The critical film thickness in respect to 
the mechanical stability was evaluated in the studies performed by A. Tourvieille de 
Labrouhe*, in parallel to the present study.  
 
The amount of PTX in the coating depended furthermore on the parameters of the 
drug-loading process. The solvent evaporation method has proven to be powerful to adapt 
the PTX-loads for different needs. Various PTX-polymorphs could be created in the films 
depending on the used solvents. By varying the immersion times of the specimens into the 
PTX/solvent solution different drug-loads could be obtained in the NRLs and the RLs. 
Besides PTX being present in the porous structure of the coating, it was accumulated on the 
surface of the film as a burst-layer. The thickness of the PTX-burst-layer can theoretically be 
decreased by applying a lower withdrawal velocity to remove the samples from the 
PTX/solvent solution. This needs to be tested in future experiments. 
 
The PTX-loaded RLs were subjected to drug-release experiments into water. The 
obtained release profiles into water fitted well the release profiles reported for the 
commercially available TaxusTM stent. The factors influencing the PTX-release were 
evaluated. They can be categorized into belonging to the structure of the coating, to the 
features of PTX and to the release experiment. The diffusion of PTX out of the coating can 
theoretically be modulated by altering the structure of the porous ceramic surrounding the 
reservoirs. For instance a decrease in pore-width, an increase in the pore’s tortuosity and of 
the thickness of the nanoporous layer on top of the reservoirs can reduce the drug flux out of 
the coating. 
 
 
 
*A. Tourvieille de Labrouhe, “ Nanostructured ceramic coatings for deformable medical implants such as 
stents”, Thesis, Ecole Polytechnique Fédérale de Lausanne, 2009. 
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A 10 times smaller median pore size in the porous structure surrounding the reservoirs, 
compared to the one applied in the present study, will trigger molecule to pore-wall 
interactions. They slow down the diffusion and hence the drug flow. Smaller pores in the 
coating can be obtained by decreasing the size of the primary TiO2-nanoparticles in the 
TiO2-suspension from 21 nm to about 5–10 nm.  
 
The features of the drug can manipulate the drug-release. If the drug particle size in the 
coating increases, which can be realized by completely filling the pores with the drug, a 
prolonged drug-release can be supported. The drug-morphology can influence the drug-
release kinetics, as was shown in the present study. The amorphous form of PTX exhibited a 
higher release constant than the crystalline ones when immersed into water. A release test of 
PTX from RLs into bovine plasma revealed that almost half of the PTX-load was released 
after 1 d of testing. This was the amount of PTX in the burst-layer. After 4 d, no more drug 
was liberated and PTX stayed trapped in the pores of the coating. The release profile of PTX 
from the commercially available TaxusTM stent into bovine plasma was different. For that 
DES, a continuous release up to 7 d with a low burst-effect was recorded. The data fitted 
well the predicted release kinetics.  
 
That more than half of the amount of totally incorporated PTX remained in the thin RL 
in the release test into bovine plasma was caused by the formation of a layer composed of 
proteins and inorganics on top of the titania coating. It blocked small pores and thus the 
diffusion of PTX out of the coating into the medium. If the hindrance of the drug diffusion 
due to the presence of this layer will be as pronounced under in vivo conditions needs to be 
evaluated in future studies. As the case may be, applying higher sintering temperatures to 
increase the amount of rutile and to provoke the metal-ion diffusion into the top part of the 
coating can lower the tendency for protein adsorption and calcium phosphate precipitation.  
 
Several preliminary in vitro cytotoxicity tests were performed applying isolated, 
primary, bovine endothelial cells (ECs) to different non-PTX-loaded specimens. A first 
assay with NRLs and RLs on wafer supports resulted in cytocompatibility after 8 d of 
incubation. The TiO2-coated SS supports, heat treated in a protecting sintering atmosphere at 
elevated sintering temperatures, were covered by ECs. Cells exhibited a normal morphology 
with a flat, spread shape. A test to prove the cytocompatibility of the titania coatings on SS 
supports, which was indicated in this preliminary test, are under current investigation.  
 
Next tests to prove the feasibility to use the nanostructured titania coatings in DESs 
might be the following. The efficiency of the drug doses, which are released from the 
coatings, should be evaluated. The doses need to be high enough to inhibit smooth muscle 
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cell (SMC)-proliferation and migration when implanted as a DES in the coronary artery. 
This will contribute to prevent the re-blocking of the artery. If necessary, the coating’s 
structure can further be optimized to create the wanted medication. Following these testing it 
is conceivable to apply the drug-loaded titania coatings in animals to study its performance 
under in vivo conditions. 
 
In summary, it has been shown that the nanostructured TiO2-coatings with 
incorporated drug reservoirs have a high potential to be used as drug-eluting coatings on 
stent-implants. A technology platform comprising methods and understandings of the 
characterization, drug-loading, drug-release and the cytotoxicity tests of the TiO2-coatings 
was established. It provides a powerful tool to adapt the ceramic coatings for various 
applications despite in DESs. One can think of applying them in orthopedic or dental 
medical implants. The nanostructured coatings might then release antibiotics or growth 
factors besides triggering cell attachment due to the bioactive titania matrix and its 
nanotopography. 
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ABBREVIATIONS 
Abbreviation Meaning 
ACET  Acetone 
AcN  Acetonitrile 
AFM  Atomic Force Microscope 
ANOVA  ANalysis Of VAriance 
AP  Atmospheric Pressure drug-loading procedure 
Ar  Argon 
BET  Brunauer-Emmett-Teller (method to determine specific surface area) 
BJH  Barrett, Joyner, Halenda for determination of pore size distribution 
BMS  Bare Metal Stent 
BP  Biodegradable Polymer 
C  Carbon 
CAD  Coronary Artery Disease 
CCD  Charge Coupled Device 
CHUV  Centre Hospitalier Universitaire Vaudois 
CIME  Center for Electron Microscopy, EPF Lausanne 
CME  Center of Electron Microscopy, Université de Lausanne 
CoCr  Cobalt Chromium alloy 
Cr  Chromium 
Cu  Copper 
CVD  Chemical Vapor Deposition 
D2O  deuterated water; deuterium oxide 
DCM  DiChloroMethane 
DES  Drug-Eluting Stent 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO  DiMethyl SulfOxide 
DP  Durable Polymer 
DSC  Differential Scanning Calorimetry 
EA  Ethyl Acetate 
EC  Endothelial Cell 
EDTA  EthyleneDiamineTetraacetic Acid 
EP  Ellipsometric Porosimetry 
FBS  Fetal Bovine Serum 
FDA  US Food and Drug Administration 
FIB  Focused Ion Beam 
FT-IR  Fourier Transform InfraRed Spectroscopy 
G-6-P  Glucose-6-Phosphate 
H2O  Water 
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He  Helium 
HPLC  High Performance Liquid Chromatography 
HRSEM  High Resolution Scanning Electron Microscope 
HT1, HT2  special Heat Treatments 1, 2 
IR  InfraRed 
ISO  International Organization for Standardization 
IUPAC  International Union of Pure and Applied Chemistry 
LCD  Living Cell Density 
LP  Low Pressure drug-loading technique 
Mg  Magnesium 
MIP  Mercury Intrusion Porosimetry 
Mn  Manganese 
Mo  Molybdenum 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid 
Ni  Nickel 
NIST  National Institute of Standards and Technology 
NiTi  Nickel Titanium; Nitinol 
NRL  Non-Reservoir Layer 
NSP  Nitrogen Sorption Porosimetry 
OH  hydroxyl group 
P  Phosphorus 
PBS  Phosphate Buffered Saline 
PLGA  Poly-Lactic-Glycolic Acid 
PLLA  Poly-L-Lactic Acid 
PS  PolyStyrene 
PSA  Penicillin, Streptomycin, Amphotericin 
PSD  Pore Size Distribution 
PSI  Paul Scherrer Institute, Villigen 
PTCA  Percutaneous Transluminal Coronary Angioplasty 
PTX_K  Paclitaxel obtained from Knowshine (Shanghai) Pharmaceuticals Inc. 
PTX_S  Paclitaxel obtained from Sigma Aldrich 
PVA  PolyVinyl Chloride 
PVD  Physical Vapor Deposition 
RL  Reservoir Layer 
S  Sulfur 
SANS  Small Angle Neutron Scattering 
SEM  Scanning Electron Microscope 
Si  Silicon 
SIBS  polystyrene-b-IsoButylene-b-Styrene 
SiC  Silicon Carbide 
SiO2  Silicon Oxide 
SMC  Smooth Muscle Cell 
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SS  Stainless Steel 
TBME  Tert.-Butyl Methyl Ether 
TGA  ThermoGravimetric Analysis 
Ti  Titanium 
TiO2  Titanium oxide; titania 
TP1, TP2  Titania nanoparticle suspension 1, 2 
UP-water  UltraPure water 
XPS  X-ray Photoelectron Spectroscopy 
XRD  X-Ray Diffraction 
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SYMBOLS 
Symbol Unit Meaning 
Δ ° phase shift 
ΔG mJ/m2 difference of free energy of adhesion 
ΔH J/g heat of fusion 
ΔHv J/(mol·K) evaporation enthalpy 
Δp Pa pressure difference 
(ρ’/ρ)c - densification rate of the constrained film 
(ρ’/ρ)u - densification rate of the unconstrained film 
Aapparent m2 geometrical surface area 
Aeffective m2 effective surface area 
C g/ml concentration 
Ci g/ml initial drug concentration in the drug-release system 
Cs g/ml maximum solubility concentration 
Ct g/ml concentration at time t 
D m2/s diffusion coefficient 
dBET m grain diameter deduced from the specific surface area 
Deff m2/s effective diffusion coefficient 
dg m grain diameter 
dh m thickness of the hydrodynamic layer 
dmode m most frequent pore diameter 
dp m pore diameter 
DSE m2/s Stokes Einstein diffusion coefficient 
Dsim m2/s simulated diffusion coefficient 
dv50 m median pore diameter 
E eV energy of the emitted wave 
Ep eV parallel component of the energy of the emitted wave  
Es eV perpendicular component of the energy of the emitted wave  
f - roughness factor 
g m/s2 9.81, acceleration due to gravity 
H m thickness of deposited liquid film 
h, h1, h2 m thickness of the diffusion layer 
J mol/(m2·s) flux 
K″ - constant 
k0 g/(m2·s) zero order release constant 
k1 %/s first order release constant 
kB J/K 1.381·1023, Boltzman constant 
kh g(m2·s) Higuchi release constant 
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kKP %/s release constant depending on the release exponent 
l m distance between capillary inlet and capillary meniscus of fluid 
L m thickness of the porous coating 
M0 g initial amount of drug in the drug-eluting system 
Mis g initial amount of drug in solution 
Mt g amount of drug released at a certain time 
n - release exponent 
np - pore number density 
p0 Pa saturation vapor pressure 
p1 Pa 1.0133·105, atmospheric pressure 
p2 Pa saturation pressure 
pc Pa capillary pressure 
pe Pa equilibrium vapor pressure 
R J/(mol·K) 8.3145, ideal gas constant 
r1, r2 m radii of curvature 
Ra m average surface roughness 
Rg m radius of gyration 
rh m hydrodynamic radius 
rk m Kelvin radius 
rp m pore radius 
S m2 solid area accessible to drug dissolution 
SBET m2/g specific surface area 
t s time 
T1 °C boiling point at room temperature 
T2 °C room temperature 
tanψ - relative wave amplitude 
Tmax °C maximum sintering temperature 
U m3/g specific volume of drug in the porous structure 
v m/s withdrawal speed 
V ml volume of liquid dissolution media for drug-release 
Vm m3/mol molar volume 
vp m/s velocity through pore channels 
Vp m3 pore volume 
γ N/m surface tension 
γLV N/m liquid/vapor surface tension 
γSL N/m solid/liquid surface tension 
γSV N/m solid/vapor surface tension 
ε - porosity 
η Pa·s dynamic viscosity  
θc0 ° contact angle 
θc0 ° ideal contact angle 
λ m wavelength 
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ν m2/s kinematic viscosity 
νP - viscous poisson’s ratio 
ρ g/cm3 density 
ρArch g/cm3 Archimedes density 
ρs g/cm3 skeletal density 
σ Pa sintering stress 
τ - pore tortuosity 
χ - molecule-to-pore ratio 
ω rad/s angular velocity
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APPENDIX 
Particle size distribution 
 
Figure A-1 Particle size distribution of the titania particle suspension as obtained by differential disc centrifuge 
particle size analysis. 
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Ellipsometry porosimetry 
 
Figure A-2 Ellipsometric parameters tan(ψ) (upper image) and cos(Δ) (lower image) of the non-reservoir 
titania coating on stainless steel support. The measured data are represented by black dots, the mathematical fits 
in grey dots.  
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Figure A-3 Ellipsometric parameters tan(ψ) (upper image) and cos(Δ) (lower image) of the non-reservoir 
titania coating on wafer support. The measured data are represented by black dots, the mathematical fits in grey 
dots. 
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